| 1 |
Wang X, Wang X, Wen M, Li X. Bibliometric analysis of literature on prevention and treatment of gastric ulcer with natural medicines. Journal of Future Foods 2023;3:225-233. [DOI: 10.1016/j.jfutfo.2023.02.004] [Reference Citation Analysis]
|
| 2 |
Collin A, Mion F, Kefleyesus A, Beets C, Jaafari N, Boussageon R. Critical appraisal of international guidelines for the management of Helicobacter pylori infection in case of dyspepsia. Helicobacter 2023;28:e12952. [PMID: 36897573 DOI: 10.1111/hel.12952] [Reference Citation Analysis]
|
| 3 |
Guan JL, Han YY, Wang MR, Xia SH, Li JY, Zhang MY, Zhao K, Feng LN, Zhang Y, Dong RN, Liao JZ, Li PY. Impact of body size on efficacy of high-dose dual therapy for Helicobacter pylori eradication. Helicobacter 2023;28:e12953. [PMID: 36738099 DOI: 10.1111/hel.12953] [Reference Citation Analysis]
|
| 4 |
Gong Y, Zhai K, Sun L, He L, Wang H, Guo Y, Zhang J. RdxA Diversity and Mutations Associated with Metronidazole Resistance of Helicobacter pylori. Microbiol Spectr 2023;:e0390322. [PMID: 36943041 DOI: 10.1128/spectrum.03903-22] [Reference Citation Analysis]
|
| 5 |
Gong H, Xu H, Zhang D. Focusing on Helicobacter pylori infection in the elderly. Front Cell Infect Microbiol 2023;13. [DOI: 10.3389/fcimb.2023.1121947] [Reference Citation Analysis]
|
| 6 |
Ariño-Pérez I, Martínez-Domínguez SJ, Alfaro Almajano E, Carrera-Lasfuentes P, Lanas Á. Mistakes in the diagnosis and treatment of Helicobacter pylori infection in daily clinical practice. Helicobacter 2023;:e12957. [PMID: 36828666 DOI: 10.1111/hel.12957] [Reference Citation Analysis]
|
| 7 |
Karmakar BC, Paul S, Basak S, Ghosh M, Mukherjee P, Das R, Chaudhuri S, Dutta S, Mukhopadhyay AK. Development and evaluation of a simple PCR assay and nested PCR for rapid detection of clarithromycin-resistant Helicobacter pylori from culture and directly from the biopsy samples in India. Gut Pathog 2023;15:7. [PMID: 36782212 DOI: 10.1186/s13099-023-00530-7] [Reference Citation Analysis]
|
| 8 |
Peng X, Chen H, Wan Y, Su P, Yu J, Liu J, Lu Y, Zhang M, Yao J, Zhi M. Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study.. [DOI: 10.21203/rs.3.rs-2547217/v1] [Reference Citation Analysis]
|
| 9 |
Lu L, Wang Y, Ye J, Han Y, Lou G, Li Y, Yan H, Du Q. Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial. Helicobacter 2023;28:e12940. [PMID: 36458325 DOI: 10.1111/hel.12940] [Reference Citation Analysis]
|
| 10 |
Zheng SY, Zhu L, Wu LY, Liu HR, Ma XP, Li Q, Wu MD, Wang WJ, Li J, Wu HG. Helicobacter pylori-positive chronic atrophic gastritis and cellular senescence. Helicobacter 2023;28:e12944. [PMID: 36539375 DOI: 10.1111/hel.12944] [Reference Citation Analysis]
|
| 11 |
Ji YH, Shi YM, Hei QW, Sun JM, Yang XF, Wu T, Sun DL, Qi YX. Evaluation of guidelines for diagnosis and treatment of Helicobacter pylori infection. Helicobacter 2023;28:e12937. [PMID: 36408808 DOI: 10.1111/hel.12937] [Reference Citation Analysis]
|
| 12 |
Zhu Y, Lin C, Xu H, Xia Z, Yang W, Tang H, Hu X, Jiang T, Liu Z, Shen J. Establishment and Methodological Evaluation of a Method for Rapid Detection of Helicobacter pylori and Virulence Genes Based on CRISPR-Cas12a. Infect Drug Resist 2023;16:435-43. [PMID: 36721635 DOI: 10.2147/IDR.S398098] [Reference Citation Analysis]
|
| 13 |
Shah S, Cappell K, Sedgley R, Pelletier C, Jacob R, Bonafede M, Yadlapati R. Diagnosis and treatment patterns among patients with newly diagnosed Helicobacter pylori infection in the United States 2016-2019. Sci Rep 2023;13:1375. [PMID: 36697470 DOI: 10.1038/s41598-023-28200-3] [Reference Citation Analysis]
|
| 14 |
Zhang L, Huang H, Wang Z, Fang X, Hong H, Chen Y, Ren Q, Yao Y, Chen Z, Pan F, Li X, Chen M, Lin T. A study on the prevention of hemorrhage and perforation in patients with primary gastric diffuse large-B cell lymphoma during treatment with immunochemotherapy. Cancer Med 2023. [PMID: 36621835 DOI: 10.1002/cam4.5486] [Reference Citation Analysis]
|
| 15 |
Altebainawi AF, Alfaraj LA, Alharbi AA, Alkhuraisi FF, Alshammari TM. Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database. Ther Adv Drug Saf 2023;14:20420986231154075. [PMID: 36875514 DOI: 10.1177/20420986231154075] [Reference Citation Analysis]
|
| 16 |
Aslan A, Karapinar HS, Kilicel F, Boyacıoğlu T, Pekin C, Toprak ŞS, Cihan M, Yilmaz BS. Trace element levels in serum and gastric mucosa in patients with Helicobacter pylori positive and negative gastritis. J Trace Elem Med Biol 2023;75:127108. [PMID: 36435152 DOI: 10.1016/j.jtemb.2022.127108] [Reference Citation Analysis]
|
| 17 |
Burgermeister E, Ebert MP. Microbiome in Gastric Cancer. Microbiome in Gastrointestinal Cancer 2023. [DOI: 10.1007/978-981-19-4492-5_4] [Reference Citation Analysis]
|
| 18 |
Radić M, Kaliterna DM, Bonacin D, Vergles JM, Radić J, Fabijanić D, Kovačić V. Beneficial effects of Helicobacter pylori eradication in systemic sclerosis patients. Wien Klin Wochenschr 2022. [PMID: 36583748 DOI: 10.1007/s00508-022-02142-8] [Reference Citation Analysis]
|
| 19 |
Marginean CM, Cioboata R, Olteanu M, Vasile CM, Popescu M, Popescu AIS, Bondari S, Pirscoveanu D, Marginean IC, Iacob GA, Popescu MD, Stanciu M, Mitrut P. The Importance of Accurate Early Diagnosis and Eradication in Helicobacter pylori Infection: Pictorial Summary Review in Children and Adults. Antibiotics (Basel) 2022;12. [PMID: 36671261 DOI: 10.3390/antibiotics12010060] [Reference Citation Analysis]
|
| 20 |
Çağlar R. Helicobacter pylori Eradikasyonunda Kullanılan Kombine Tedavilerin Etkinliklerinin Karşılaştırılması. SABD 2022. [DOI: 10.33631/sabd.1210607] [Reference Citation Analysis]
|
| 21 |
Wang YZ, Chen J, Pei SQ, Wang C, Han G, Kan LD, Li LC. Treatment strategies and pharmacist-led medication management for Helicobacter pylori infection. Drug Dev Res 2022. [PMID: 36567647 DOI: 10.1002/ddr.22025] [Reference Citation Analysis]
|
| 22 |
Vu TB, Tran TNQ, Tran TQA, Vu DL, Hoang VT. Antibiotic Resistance of Helicobacter pylori in Patients with Peptic Ulcer. Medicina (Kaunas) 2022;59. [PMID: 36676631 DOI: 10.3390/medicina59010006] [Reference Citation Analysis]
|
| 23 |
Zhang Y, Wang C, Zhang L, Yu J, Yuan W, Li L. Vitamin D(3) eradicates Helicobacter pylori by inducing VDR-CAMP signaling. Front Microbiol 2022;13:1033201. [PMID: 36569092 DOI: 10.3389/fmicb.2022.1033201] [Reference Citation Analysis]
|
| 24 |
Pezhman Alavinejad, Eskandar Hajiani, Abazar Parsi, Azam Satari, Mohammad Javad Rezaei, Morteza Nayebi, Ahmad Hormati, Omid Eslami, Mohammed Hussien Ahmed, Quang Trung Tran, Masoud Arshadzadeh, Siamak Baghaei, Samira Mohammadi, Seyed Jalal Hashemi, Alireza Sedaghat. Effect of Helicobacter pylori eradication on metabolic profile: an international, multicenter, case-control study. BMC Gastroenterol 2022;22:507. [PMID: 36482315 DOI: 10.1186/s12876-022-02604-3] [Reference Citation Analysis]
|
| 25 |
Mansour-ghanaei F, Masihipour B, Fathalipour M, Hassanipour S, Sokhanvar H, Mansour-ghanaei A, Asgharnezhad M, Joukar F. The Efficacy, Safety, and Tolerability of Levofloxacin Quadruple Therapy for Helicobacter pylori Eradication: A Randomized, Double-Blind Clinical Trial. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-7. [DOI: 10.1155/2022/9794901] [Reference Citation Analysis]
|
| 26 |
Dargenio VN, Castellaneta S, Panico S, Papagni ME, Dargenio C, Schettini F, Francavilla R, Cristofori F. Probiotics and gastrointestinal diseases. Minerva Pediatr (Torino) 2022;74:703-23. [PMID: 36315413 DOI: 10.23736/S2724-5276.22.07031-8] [Reference Citation Analysis]
|
| 27 |
Hirashita Y, Fukuda M, Kodama M, Tsukamoto Y, Okimoto T, Mizukami K, Kawahara Y, Wada Y, Ozaka S, Togo K, Kinoshita K, Fuchino T, Fukuda K, Okamoto K, Ogawa R, Matsunari O, Honda K, Murakami K. Potential association of eEF1A dimethylation at lysine 55 in the basal area of Helicobacter pylori-eradicated gastric mucosa with the risk of gastric cancer: a retrospective observational study. BMC Gastroenterol 2022;22:490. [PMID: 36437464 DOI: 10.1186/s12876-022-02521-5] [Reference Citation Analysis]
|
| 28 |
Liang B, Yuan Y, Peng XJ, Liu XL, Hu XK, Xing DM. Current and future perspectives for Helicobacter pylori treatment and management: From antibiotics to probiotics. Front Cell Infect Microbiol 2022;12:1042070. [PMID: 36506013 DOI: 10.3389/fcimb.2022.1042070] [Reference Citation Analysis]
|
| 29 |
Yu C, Qiu J, Xiong M, Ou C, Zeng M, Song H. Trends in Helicobacter pylori-related gastric ulcer research from 2012 to 2022: A bibliometric and visual analysis. Front Med (Lausanne) 2022;9:1027534. [PMID: 36507534 DOI: 10.3389/fmed.2022.1027534] [Reference Citation Analysis]
|
| 30 |
Bornschein J, Pritchard DM, Malfertheiner P. Letter to the editor: Helicobacter pylori eradication - the proof is not in the symptoms. Gut 2022:gutjnl-2022-329057. [PMID: 36379692 DOI: 10.1136/gutjnl-2022-329057] [Reference Citation Analysis]
|
| 31 |
Anisimova E, Gorokhova I, Karimullina G, Yarullina D. Alarming Antibiotic Resistance of Lactobacilli Isolated from Probiotic Preparations and Dietary Supplements. Antibiotics 2022;11:1557. [DOI: 10.3390/antibiotics11111557] [Reference Citation Analysis]
|
| 32 |
Cheng H, Yang Y, Yang H, Tsai Y, Chang W, Wu C, Kuo H, Yu Y, Yang E, Cheng W, Chen W, Sheu B. Evolution of the Correa's cascade steps: A long-term endoscopic surveillance among non-ulcer dyspepsia and gastric ulcer after H. pylori eradication. Journal of the Formosan Medical Association 2022. [DOI: 10.1016/j.jfma.2022.11.008] [Reference Citation Analysis]
|
| 33 |
Telaku S, Telaku M, Behluli E, Isjanovski V, Alidema F. Impact of Lactobacillus Reuteri and Three Other Probiotics in Helicobacter Pylori Eradication. Open Access Maced J Med Sci 2022;10:2215-2219. [DOI: 10.3889/oamjms.2022.10733] [Reference Citation Analysis]
|
| 34 |
Tseng Y, Liou J, Cheng W, Hsu J, Hsu T, Wu M, Wong C. Combating multidrug-resistant Helicobacter pylori with moenomycin A in combination with clarithromycin or metronidazole. Front Chem 2022;10:897578. [DOI: 10.3389/fchem.2022.897578] [Reference Citation Analysis]
|
| 35 |
Metwally M, Ragab R, Abdel Hamid HS, Emara N, Elkholy H. Helicobacter pylori Antibiotic Resistance in Egypt: A Single-Center Study. Infect Drug Resist 2022;15:5905-13. [PMID: 36312439 DOI: 10.2147/IDR.S386082] [Reference Citation Analysis]
|
| 36 |
Krolevets TS, Livzan MA, Mozgovoy SI. Hyperplasia of enterochromaffin-like (ECL) cells as a precursor of neuroendocrine gastric tumors in autoimmune gastritis. jour 2022. [DOI: 10.31146/1682-8658-ecg-205-9-147-152] [Reference Citation Analysis]
|
| 37 |
Nikbazm R, Rahimi Z, Moradi Y, Alipour M, Shidfar F. The effect of cranberry supplementation on Helicobacter pylori eradication in H. pylori positive subjects: a systematic review and meta-analysis of randomised controlled trials. Br J Nutr 2022;128:1090-9. [PMID: 34670631 DOI: 10.1017/S0007114521004256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 38 |
Ermolenko EI, Molostova AS, Baryshnikova NV, Svarval AV, Gladyshev NS, Kashchenko VA, Suvorov AN. The clinical effectiveness of probiotics and autoprobiotics in treatment of <i>Helicobacter pylori</i>-associated dyspepsia. Russian Journal of Infection and Immunity 2022;12:726-734. [DOI: 10.15789/2220-7619-tce-1927] [Reference Citation Analysis]
|
| 39 |
Mărginean CD, Mărginean CO, Meliț LE. Helicobacter pylori-Related Extraintestinal Manifestations—Myth or Reality. Children 2022;9:1352. [DOI: 10.3390/children9091352] [Reference Citation Analysis]
|
| 40 |
Teufel A, Quante M, Kandulski A, Hirth M, Zhan T, Eckardt M, Thieme R, Schulte N, Belle S, Wiest I, Reißfelder C, Riemann JF, Schlitt HJ, Gockel I, Malfertheiner P, Ebert MP. Prävention gastrointestinaler Tumoren. Gastroenterologie up2date 2022;18:261-276. [DOI: 10.1055/a-1785-7315] [Reference Citation Analysis]
|
| 41 |
Gareayaghi N, Kocazeybek B. Detection of A2143G, A2142C, and A2142G Point Mutations with Real-Time PCR in Stool Specimens from Children Infected with Helicobacter pylori. Diagnostics 2022;12:2119. [DOI: 10.3390/diagnostics12092119] [Reference Citation Analysis]
|
| 42 |
Karbalaei M, Keikha M. Statistical proof of Helicobacter pylori eradication in preventing metachronous gastric cancer after endoscopic resection in an East Asian population. World J Gastrointest Surg 2022; 14(8): 867-873 [DOI: 10.4240/wjgs.v14.i8.867] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 43 |
Tempera PJ, Michael M, Tageldin O, Hasak S. Gastric Cancer Due to Chronic H. pylori Infection: What We Know and Where We Are Going. Diseases 2022;10:57. [DOI: 10.3390/diseases10030057] [Reference Citation Analysis]
|
| 44 |
Hou X, Wang J, Du Q, Tian D, Hu N, Liu D, Zhou F, Xie L, Gu L, Kudou K, Zhang S. Efficacy and safety of vonoprazan-based quadruple therapy for the eradication of Helicobacter pylori in patients with peptic ulcers: a pooled analysis of two randomized, double-blind, double-dummy, phase 3 trials.. [DOI: 10.21203/rs.3.rs-1837897/v1] [Reference Citation Analysis]
|
| 45 |
Durak S, Coşar AM, Fidan S. Gastrik intestinal metaplazi sıklığı ve Helikobakter Pilori ile ilişkisinin belirlenmesi. Med Records 2022. [DOI: 10.37990/medr.1158426] [Reference Citation Analysis]
|
| 46 |
Isomoto H, Sakaguchi T, Inamine T, Takeshita S, Fukuda D, Ohnita K, Kanda T, Matsushima K, Honda T, Sugihara T, Hirayama T, Nakao K, Tsukamoto K. SNP rs2920280 in PSCA Is Associated with Susceptibility to Gastric Mucosal Atrophy and Is a Promising Biomarker in Japanese Individuals with Helicobacter pylori Infection. Diagnostics 2022;12:1988. [DOI: 10.3390/diagnostics12081988] [Reference Citation Analysis]
|
| 47 |
Yvonne L. Latour, Johanna C. Sierra, Kara M. McNamara, Thaddeus M. Smith, Paula B. Luis, Claus Schneider, Alberto G. Delgado, Daniel P. Barry, Margaret M. Allaman, M. Wade Calcutt, Kevin L. Schey, M. Blanca Piazuelo, Alain P. Gobert, Keith T. Wilson. Ornithine Decarboxylase in Gastric Epithelial Cells Promotes the Immunopathogenesis of Helicobacter pylori Infection. J Immunol 2022;209. [PMID: 35896340 DOI: 10.4049/jimmunol.2100795] [Reference Citation Analysis]
|
| 48 |
Eyoum Bille BB, Kouitcheu Mabeku LB. Relationship between active Helicobacter pylori infection and anemia, iron deficiency, iron deficiency anemia: A cross‐sectional study in a sub‐Saharan setting. JGH Open 2022;6:554-568. [DOI: 10.1002/jgh3.12787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 49 |
Yang J, Yang H, Dai Y, Jiang Y, Long Y, Zeng J, Ma X. Evidence construction of Chinese herbal formulae for the treatment of H. pylori positive peptic ulcer: A Bayesian network Meta-analysis. Phytomedicine 2022;105:154327. [PMID: 35905565 DOI: 10.1016/j.phymed.2022.154327] [Reference Citation Analysis]
|
| 50 |
Garrido-treviño L, López-martínez M, Flores-hinojosa J, Tijerina-rodríguez L, Bosques-padilla F. Tratamiento empírico vs tratamiento basado en susceptibilidad para erradicar H.pylori: ¿es posible cambiar este paradigma usando métodos moleculares modernos? Revista de Gastroenterología de México 2022;87:330-341. [DOI: 10.1016/j.rgmx.2022.01.007] [Reference Citation Analysis]
|
| 51 |
Garrido-treviño L, López-martínez M, Flores-hinojosa J, Tijerina-rodríguez L, Bosques-padilla F. Empiric treatment vs susceptibility-guided treatment for eradicating H. pylori: Is it possible to change that paradigm using modern molecular methods? Revista de Gastroenterología de México (English Edition) 2022;87:330-341. [DOI: 10.1016/j.rgmxen.2022.06.003] [Reference Citation Analysis]
|
| 52 |
Goldberg L, Amrick TJ. Successful Eradication of Helicobacter pylori with 5-Day Concomitant Treatment. GastroHep 2022;2022:1-4. [DOI: 10.1155/2022/1211329] [Reference Citation Analysis]
|
| 53 |
Parra-Sepúlveda C, Sánchez-Alonzo K, Olivares-Muñoz J, Gutiérrez-Zamorano C, Smith CT, Carvajal RI, Sáez-Carrillo K, González C, García-Cancino A. Consumption of a Gelatin Supplemented with the Probiotic Strain Limosilactobacillus fermentum UCO-979C Prevents Helicobacter pylori Infection in a Young Adult Population Achieved. Foods 2022;11. [PMID: 35741866 DOI: 10.3390/foods11121668] [Reference Citation Analysis]
|
| 54 |
Li C, Yue J, Ding Z, Zhang Q, Xu Y, Wei Q, Wang J, Ning X, Zeng H, Cao J. Prevalence and predictors of Helicobacter pylori infection in asymptomatic individuals: a hospital-based cross-sectional study in Shenzhen, China. Postgrad Med 2022. [PMID: 35653281 DOI: 10.1080/00325481.2022.2085950] [Reference Citation Analysis]
|
| 55 |
Song Z, Chen Y, Lu H, Zeng Z, Wang W, Liu X, Zhang G, Du Q, Xia X, Li C, Jiang S, Wu T, Li P, He S, Zhu Y, Zhang G, Xu J, Li Y, Huo L, Lan C, Miao Y, Jiang H, Chen P, Shi L, Tuo B, Zhang D, Jiang K, Wang J, Yao P, Huang X, Yang S, Wang X, Zhou L. Diagnosis and treatment of Helicobacter pylori infection by physicians in China: A nationwide cross-sectional study. Helicobacter 2022;27:e12889. [PMID: 35363917 DOI: 10.1111/hel.12889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 56 |
Nemr N, Kishk RM, Salem A, Abdalla MO, Abd El-Fadeal NM, Soliman NM. Genotypic detection of metronidazole and clarithromycin resistance in dyspeptic patients with helicobacter pylori. Environ Sci Pollut Res Int 2022;29:41467-74. [PMID: 35088259 DOI: 10.1007/s11356-021-18198-4] [Reference Citation Analysis]
|
| 57 |
Jiang F, Guo CG, Cheung KS, Li B, Law SYK, Leung WK. Age of eradication and failure rates of clarithromycin-containing triple therapy for Helicobacter pylori: A 15-year population-based study. Helicobacter 2022;27:e12893. [PMID: 35411663 DOI: 10.1111/hel.12893] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 58 |
Aanniz T, Bakri W, El Mazouri S, Wakrim H, Kandoussi I, Belyamani L, Ouadghiri M, Ibrahimi A. Biofilm and Quorum Sensing in Helicobacter pylori. Bacterial Biofilms [Working Title] 2022. [DOI: 10.5772/intechopen.104568] [Reference Citation Analysis]
|
| 59 |
Kansal D, Kumar A, Gupta S, Sood A, Bodh S. Raised liver enzyme in a patient receiving Helicobacter pylori triple regimen: A case report. IJCAAP 2022;7:106-107. [DOI: 10.18231/j.ijcaap.2022.020] [Reference Citation Analysis]
|
| 60 |
Fei Y, Fang R, Xiao L, Zhang Y, Fan K, Jiang Y, Lei S, Xu R, Yang D, Ye Y, Xiang S, Wang P, Zhou C, Tang T. The development of a colorimetric biosensing assay for the detection of Helicobacter pylori in feces. Anal Biochem 2022;:114737. [PMID: 35595119 DOI: 10.1016/j.ab.2022.114737] [Reference Citation Analysis]
|
| 61 |
Dai B, Xiang A, Qu D, Chen G, Wang L, Wang W, Zhai D, Wang L, Lu Z. Rapid and Sensitive Assay of Helicobacter pylori With One-Tube RPA-CRISPR/Cas12 by Portable Array Detector for Visible Analysis of Thermostatic Nucleic Acid Amplification. Front Microbiol 2022;13:858247. [DOI: 10.3389/fmicb.2022.858247] [Reference Citation Analysis]
|
| 62 |
Graham DY, Liou JM. Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antimicrobial Stewardship. Clin Gastroenterol Hepatol 2022;20:973-983.e1. [PMID: 33775895 DOI: 10.1016/j.cgh.2021.03.026] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 22.0] [Reference Citation Analysis]
|
| 63 |
Gisbert JP, Alcedo J, Amador J, Bujanda L, Calvet X, Castro-fernández M, Fernández-salazar L, Gené E, Lanas Á, Lucendo A, Molina-infante J, Nyssen OP, Pérez-aisa A, Puig I. V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterología y Hepatología (English Edition) 2022;45:392-417. [DOI: 10.1016/j.gastre.2021.07.001] [Reference Citation Analysis]
|
| 64 |
Zerbib F, Berger A. Reflujo gastroesofágico. EMC - Tratado de Medicina 2022;26:1-9. [DOI: 10.1016/s1636-5410(22)46448-8] [Reference Citation Analysis]
|
| 65 |
Zerbib F, Berger A. Reflusso gastroesofageo. EMC - AKOS - Trattato di Medicina 2022;24:1-9. [DOI: 10.1016/s1634-7358(22)46545-4] [Reference Citation Analysis]
|
| 66 |
López-valverde N, Macedo de Sousa B, López-valverde A, Suárez A, Rodríguez C, Aragoneses JM. Possible Association of Periodontal Diseases With Helicobacter pylori Gastric Infection: A Systematic Review and Meta-Analysis. Front Med 2022;9:822194. [DOI: 10.3389/fmed.2022.822194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 67 |
Wang R, Song C, Gao A, Liu Q, Guan W, Mei J, Ma L, Cui D. Antibody-conjugated liposomes loaded with indocyanine green for oral targeted photoacoustic imaging-guided sonodynamic therapy of Helicobacter pylori infection. Acta Biomater 2022;143:418-27. [PMID: 35219867 DOI: 10.1016/j.actbio.2022.02.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 68 |
Xu M, Zhou J, Heng D, Su X, Onakpa MM, Bai Y, Duan JA, Che CT, Bi H, Zhao M. Quinone Derivatives as Promising Anti-Helicobacter pylori Agents from Aerial Parts of Mitracarpus hirtus. J Nat Prod 2022. [PMID: 35412828 DOI: 10.1021/acs.jnatprod.1c01163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 69 |
Ansari S, Yamaoka Y. Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance. Clin Microbiol Rev 2022;:e0025821. [PMID: 35404105 DOI: 10.1128/cmr.00258-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 70 |
Wang L, Cao ZM, Zhang LL, Dai XC, Liu ZJ, Zeng YX, Li XY, Wu QJ, Lv WL. Helicobacter Pylori and Autoimmune Diseases: Involving Multiple Systems. Front Immunol 2022;13:833424. [PMID: 35222423 DOI: 10.3389/fimmu.2022.833424] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 71 |
Liu Y, Wang S, Yang F, Chi W, Ding L, Liu T, Zhu F, Ji D, Zhou J, Fang Y, Zhang J, Xiang P, Zhang Y, Zhao H. Antimicrobial resistance patterns and genetic elements associated with the antibiotic resistance of Helicobacter pylori strains from Shanghai. Gut Pathog 2022;14:14. [PMID: 35354484 DOI: 10.1186/s13099-022-00488-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 72 |
Guo Z, Tian S, Wang W, Zhang Y, Li J, Lin R. Correlation Analysis Among Genotype Resistance, Phenotype Resistance, and Eradication Effect After Resistance-Guided Quadruple Therapies in Refractory Helicobacter pylori Infections. Front Microbiol 2022;13:861626. [PMID: 35330762 DOI: 10.3389/fmicb.2022.861626] [Reference Citation Analysis]
|
| 73 |
Basso L, Gallo G, Biacchi D, Carati MV, Cavallaro G, Esposito L, Giuliani A, Izzo L, Izzo P, Lamazza A, Polistena A, Tarallo M, Micarelli A, Fiori E. Role of New Anatomy, Biliopancreatic Reflux, and Helicobacter Pylori Status in Postgastrectomy Stump Cancer. J Clin Med 2022;11:1498. [PMID: 35329824 DOI: 10.3390/jcm11061498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 74 |
Shakir SM, Otiso J, Keller G, Heule HV, Osborn LJ, Cole N, Schuetz AN, Richter SS, Couturier MR, Lainhart W. Multicenter Evaluation of a Gradient Diffusion Method for Antimicrobial Susceptibility Testing of Helicobacter pylori. Microbiol Spectr. [DOI: 10.1128/spectrum.02111-21] [Reference Citation Analysis]
|
| 75 |
Guan JL, Hu YL, An P, He Q, Long H, Zhou L, Chen ZF, Xiong JG, Wu SS, Ding XW, Luo HS, Li PY. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial. Pharmacotherapy 2022;42:224-32. [PMID: 35075679 DOI: 10.1002/phar.2662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 76 |
Mahajan PS, Abdulmajeed H, Aljafari A, Kolleri JJ, Dawdi SA, Mohammed H. A Cautionary Tale: Unveiling Valentino’s Syndrome. Cureus 2022. [DOI: 10.7759/cureus.22667] [Reference Citation Analysis]
|
| 77 |
Dargenio VN, Cristofori F, Dargenio C, Giordano P, Indrio F, Celano G, Francavilla R. Use of Limosilactobacillus reuteri DSM 17938 in paediatric gastrointestinal disorders: an updated review. Benef Microbes 2022;:1-22. [PMID: 35212258 DOI: 10.3920/BM2021.0151] [Reference Citation Analysis]
|
| 78 |
Pichon M, Freche B, Burucoa C. New Strategy for the Detection and Treatment of Helicobacter pylori Infections in Primary Care Guided by a Non-Invasive PCR in Stool: Protocol of the French HepyPrim Study. J Clin Med 2022;11:1151. [PMID: 35268242 DOI: 10.3390/jcm11051151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 79 |
Zhang T, Zhang B, Tian W, Ma X, Wang F, Wang P, Wei Y, Liu L, Tang X. A Bibliometric Analysis of Atrophic Gastritis From 2011 to 2021. Front Med 2022;9:843395. [DOI: 10.3389/fmed.2022.843395] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 80 |
Lopes-de-Campos D, Leal Seabra C, Pinto RM, Adam Słowiński M, Sarmento B, Nunes C, Cristina L Martins M, Reis S. Targeting and Killing the Ever-Challenging Ulcer Bug. Int J Pharm 2022;:121582. [PMID: 35176334 DOI: 10.1016/j.ijpharm.2022.121582] [Reference Citation Analysis]
|
| 81 |
Murata M, Sugimoto M, Miyamoto S, Kawai T. Long-term improvement in constipation-related symptoms after Helicobacter pylori eradication therapy. Helicobacter 2022;27:e12863. [PMID: 34791741 DOI: 10.1111/hel.12863] [Reference Citation Analysis]
|
| 82 |
Brincat A, Hofmann M. Automated extraction of genes associated with antibiotic resistance from the biomedical literature. Database 2022;2022. [DOI: 10.1093/database/baab077] [Reference Citation Analysis]
|
| 83 |
Quach DT, Aoki R, Iga A, Le QD, Kawamura T, Yamashita K, Tanaka S, Yoshihara M, Hiyama T. Diagnostic Accuracy of H. pylori Status by Conventional Endoscopy: Time-Trend Change After Eradication and Impact of Endoscopic Image Quality. Front Med 2022;8:830730. [DOI: 10.3389/fmed.2021.830730] [Reference Citation Analysis]
|
| 84 |
Naseem F, Shah SU, Rashid SA, Farid A, Almehmadi M, Alghamdi S. Metronidazole Based Floating Bioadhesive Drug Delivery System for Potential Eradication of H. pylori: Preparation and In Vitro Characterization. Polymers (Basel) 2022;14:519. [PMID: 35160508 DOI: 10.3390/polym14030519] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 85 |
Lu Y, Liu H, Yang K, Mao Y, Meng L, Yang L, Ouyang G, Liu W. A comprehensive update: gastrointestinal microflora, gastric cancer and gastric premalignant condition, and intervention by traditional Chinese medicine. J Zhejiang Univ Sci B 2022;23:1-18. [PMID: 35029085 DOI: 10.1631/jzus.B2100182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 86 |
Ibrahim N, El Said H, Choukair A. Zinc carnosine-based modified bismuth quadruple therapy vs standard triple therapy for Helicobacter pylori eradication: A randomized controlled study. World J Clin Cases 2022; 10(1): 227-235 [DOI: 10.12998/wjcc.v10.i1.227] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 87 |
Sharndama HC, Mba IE. Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms. Braz J Microbiol 2022. [PMID: 34988937 DOI: 10.1007/s42770-021-00675-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 88 |
Haumaier F, Schneider-Fuchs A, Backert S, Vieth M, Sterlacci W, Wöhrl BM. Rapid Detection of Quinolone Resistance Mutations in gyrA of Helicobacter pylori by Real-Time PCR. Pathogens 2022;11:59. [PMID: 35056007 DOI: 10.3390/pathogens11010059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 89 |
Dabbebi H, Elloumi H, Kechiche C, Hammemi E, Cheikh I, Jmaa A. Effect of Helicobacter pylori eradication therapy on the response of MALT-Gastric lymphoma. Tunis Med 2022;100:37-43. [PMID: 35822330] [Reference Citation Analysis]
|
| 90 |
Howden CW, Sheldon KL, Almenoff JS, Chey WD. Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data. Dig Dis Sci 2022;67:4382-6. [PMID: 34862940 DOI: 10.1007/s10620-021-07323-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 91 |
Alfadhli A, Alboraie M, Afifi M, Dangi A. A randomized clinical trial comparing triple therapy versus non-bismuth based quadruple therapy for the eradication of Helicobacter Pylori in Kuwait. J Global Infect Dis 2022;14:99. [DOI: 10.4103/jgid.jgid_13_22] [Reference Citation Analysis]
|
| 92 |
Mišak Z, Hojsak I. Helicobacter Pylori Gastritis and Peptic Ulcer Disease. Textbook of Pediatric Gastroenterology, Hepatology and Nutrition 2022. [DOI: 10.1007/978-3-030-80068-0_12] [Reference Citation Analysis]
|
| 93 |
Lohse AW, Huber S. Magen/Darm- und Lebererkrankungen. Arzneiverordnungs-Report 2022 2022. [DOI: 10.1007/978-3-662-66303-5_12] [Reference Citation Analysis]
|
| 94 |
Retnakumar R, Nath AN, Nair GB, Chattopadhyay S. Gastrointestinal microbiome in the context of Helicobacter pylori infection in stomach and gastroduodenal diseases. Progress in Molecular Biology and Translational Science 2022. [DOI: 10.1016/bs.pmbts.2022.07.001] [Reference Citation Analysis]
|
| 95 |
Popovych T, Kizim Y, Kizim Y, Obernikhina N, Voroshylova N. METAL-INDUCED PROTEIN DENATURATION: REGULARITIES, PATHOLOGICAL MANIFESTATIONS, AND IN VITRO MODELING. USMYJ 2021;127:48-54. [DOI: 10.32345/usmyj.4(127).2021.48-54] [Reference Citation Analysis]
|
| 96 |
Kiselev HY, Gorlenko CL, El-taravi YA, Porubayeva EE, Budanova EV. Modern knowledge on pathogenesis, diagnosis and treatment of helicobacter infection. jour 2021. [DOI: 10.31146/1682-8658-ecg-193-9-15-26] [Reference Citation Analysis]
|
| 97 |
Kao JY, Almenoff JS, Portenier DD, Sheldon KL. Helicobacter pylori eradication by low‐dose rifabutin triple therapy (RHB‐105) is unaffected by high body mass index. GastroHep 2021;3:426-434. [DOI: 10.1002/ygh2.494] [Reference Citation Analysis]
|
| 98 |
Kuang S, Xu J, Chen M, Zhang Y, Shi F, Lu X. The influence of pretreatment with PPI on Helicobacter pylori eradication: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e27944. [PMID: 34964772 DOI: 10.1097/MD.0000000000027944] [Reference Citation Analysis]
|
| 99 |
Namyalo E, Nyakarahuka L, Afayoa M, Baziira J, Tamale A, Atuhaire GC, Kungu JM. Prevalence of Helicobacter pylori among Patients with Gastrointestinal Tract (GIT) Symptoms: A Retrospective Study at Selected Africa Air Rescue (AAR) Clinics in Kampala, Uganda, from 2015 to 2019. J Trop Med 2021;2021:9935142. [PMID: 34790241 DOI: 10.1155/2021/9935142] [Reference Citation Analysis]
|
| 100 |
Sergeeva AV, Shkarin VV, Kovalishena OV. The role of <i>Helicobacter pylori</i> in complex human comorbidity. Russian Journal of Infection and Immunity 2021;12:21-32. [DOI: 10.15789/2220-7619-tro-1667] [Reference Citation Analysis]
|
| 101 |
Cai HL, Tong YL. Association of serum pepsinogen with degree of gastric mucosal atrophy in an asymptomatic population. World J Clin Cases 2021; 9(31): 9431-9439 [PMID: 34877278 DOI: 10.12998/wjcc.v9.i31.9431] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 102 |
Ma Win TM, Htun M, Phyu Myint WP, Aung MM, Ni N. High‐dose dual therapy and CYP2C19 polymorphism in Helicobacter pylori eradication. GastroHep 2021;3:379-383. [DOI: 10.1002/ygh2.484] [Reference Citation Analysis]
|
| 103 |
Nyi KN, Soe AM, Htut ZM. Molecular detection of genotypic clarithromycin‐resistant strains and its effect on the eradication rate of concomitant therapy in Helicobacter pylori infection. GastroHep 2021;3:372-378. [DOI: 10.1002/ygh2.476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 104 |
Haq MMU, Furqan M, Zia A, Khalil A, Kalwar HA. The efficacy of levofloxacin‐based sequential regimen to eradicate Helicobacter pylori infection. GastroHep 2021;3:384-387. [DOI: 10.1002/ygh2.482] [Reference Citation Analysis]
|
| 105 |
Aung WP, Aye TT, Aye KS, Kyaw AMM. Levofloxacin‐based Helicobacter pylori eradication in chronic dyspepsia. GastroHep 2021;3:394-400. [DOI: 10.1002/ygh2.478] [Reference Citation Analysis]
|
| 106 |
Aye TT, Win TM, Tun MN. The status of Helicobacter pylori infection related extraintestinal diseases in Myanmar. GastroHep 2021;3:344-351. [DOI: 10.1002/ygh2.472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 107 |
Ihtesham A, Maqbool S, Nadeem M, Bilawal Abbas Janjua M, Sundus O, Bakht Naqqash A, Inayat Mohamed W, Turab Haider S, Ahmad M, Ahmad Talha Mustafa M, Osama Mehboob H. Helicobacter pylori induced Immune Thrombocytopenic Purpura and perspective role of Helicobacter pylori eradication therapy for treating Immune Thrombocytopenic Purpura. AIMS Microbiol 2021;7:284-303. [PMID: 34708173 DOI: 10.3934/microbiol.2021018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 108 |
Xia X, Zhang L, Xu C, Hong H, Liu Z. Helicobacter pylori Infection and Endothelial Dysfunction. Helicobacter pylori - From First Isolation to 2021 2021. [DOI: 10.5772/intechopen.97260] [Reference Citation Analysis]
|
| 109 |
Keikha M, Karbalaei M. Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections. BMC Gastroenterol 2021;21:388. [PMID: 34670526 DOI: 10.1186/s12876-021-01977-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 110 |
Bakulina NV, Tikhonov SV, Lishchuk NB. Chronic gastritis and functional dyspepsia. Unity and struggle of two opposites. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-15-164-174] [Reference Citation Analysis]
|
| 111 |
Khan S, Sharaf M, Ahmed I, Khan TU, Shabana S, Arif M, Kazmi SSUH, Liu C. Potential utility of nano-based treatment approaches to address the risk of Helicobacter pylori. Expert Rev Anti Infect Ther 2021;:1-18. [PMID: 34658307 DOI: 10.1080/14787210.2022.1990041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 112 |
Gisbert JP, Alcedo J, Amador J, Bujanda L, Calvet X, Castro-Fernández M, Fernández-Salazar L, Gené E, Lanas Á, Lucendo AJ, Molina-Infante J, Nyssen OP, Pérez-Aisa A, Puig I. V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2021:S0210-5705(21)00229-6. [PMID: 34629204 DOI: 10.1016/j.gastrohep.2021.07.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 113 |
Liu F, Yu J, Zhang YX, Li F, Liu Q, Zhou Y, Huang S, Fang H, Xiao Z, Liao L, Xu J, Wu XY, Wu F. High-throughput tandem-microwell assay for ammonia repositions FDA-Approved drugs to inhibit Helicobacter pylori urease. FASEB J 2021;35:e21967. [PMID: 34613630 DOI: 10.1096/fj.202100465RR] [Reference Citation Analysis]
|
| 114 |
Chen LW, Chien CH, Lin CL, Chien RN. Increased Glycated Hemoglobin but Decreased Cholesterol after a Loss of Helicobacter pylori Infection: A Community-Based Longitudinal Metabolic Parameters Follow-Up Study. J Pers Med 2021;11:997. [PMID: 34683138 DOI: 10.3390/jpm11100997] [Reference Citation Analysis]
|
| 115 |
Chen LW, Chang LC, Hua CC, Liu CJ, Chou TS, Lin CL, Chien RN. The Application of High-Dose Proton Pump Inhibitor Induction Treatment before Dual Therapy for Helicobacter pylori Eradication: An Open-Label Random Trial. J Clin Med 2021;10:4352. [PMID: 34640370 DOI: 10.3390/jcm10194352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 116 |
El Shahawy MS, Shady ZM, Gaafar A. Influence of adding vitamin D3 to standard clarithromycin-based triple therapy on the eradication rates of Helicobacter pylori infection. Arab J Gastroenterol 2021;22:209-14. [PMID: 34521593 DOI: 10.1016/j.ajg.2021.08.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 117 |
Abdelghany A, El-Desouky MA, Shemis M. Synthesis and characterization of amoxicillin-loaded polymeric nanocapsules as a drug delivery system targeting Helicobacter pylori. Arab J Gastroenterol 2021:S1687-1979(21)00044-7. [PMID: 34509390 DOI: 10.1016/j.ajg.2021.06.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 118 |
Anis S, Farooqi SR, Niaz SK. Characterization of Domain V Mutations in Clinical Isolates of Helicobacter pylori in Pakistan and Their Effect on Clarithromycin MIC. Infect Drug Resist 2021;14:3393-403. [PMID: 34466005 DOI: 10.2147/IDR.S306878] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 119 |
Cha B, Bang BW, Shin JB, Ko EJ, Ko W, Kwon KS, Shin YW, Suh YJ, Kim H. Bismuth containing quadruple therapy versus tailored therapy as first-line treatments for Helicobacter pylori infection in a high clarithromycin resistance area. Scand J Gastroenterol 2021;56:1017-22. [PMID: 34369255 DOI: 10.1080/00365521.2021.1948606] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 120 |
Wang Y, Guo X, Zhou S, Wang L, Fang Y, Xing L, Zhao Y, Zhang LP, Qiu H, Zeng J, Gu Y. Selective photodynamic inactivation of Helicobacter pylori by a cationic benzylidene cyclopentanone photosensitizer - an in vitro and ex vivo study. J Photochem Photobiol B 2021;223:112287. [PMID: 34454316 DOI: 10.1016/j.jphotobiol.2021.112287] [Reference Citation Analysis]
|
| 121 |
Abengozar R, Sharma A, Sharma R. Gastric cancer: lessons learned from high-incidence geographic regions. J Gastrointest Oncol 2021;12:S350-60. [PMID: 34422399 DOI: 10.21037/jgo-2019-gi-05] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 122 |
Pennelli G, Grillo F, Galuppini F, Ingravallo G, Pilozzi E, Rugge M, Fiocca R, Fassan M, Mastracci L. Gastritis: update on etiological features and histological practical approach. Pathologica 2020;112:153-65. [PMID: 33179619 DOI: 10.32074/1591-951X-163] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 123 |
Kunovsky L, Dite P, Jabandziev P, Dolina J, Vaculova J, Blaho M, Bojkova M, Dvorackova J, Uvirova M, Kala Z, Trna J. Helicobacter pylori infection and other bacteria in pancreatic cancer and autoimmune pancreatitis. World J Gastrointest Oncol 2021; 13(8): 835-844 [PMID: 34457189 DOI: 10.4251/wjgo.v13.i8.835] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 124 |
Santos EC, Gomes RB, Fernandes PV, Ferreira MA, Abdelhay ESFW. The protein-protein interaction network of intestinal gastric cancer patients reveals hub proteins with potential prognostic value. Cancer Biomark 2021. [PMID: 34366321 DOI: 10.3233/CBM-203225] [Reference Citation Analysis]
|
| 125 |
Yang H, Hu B. Diagnosis of Helicobacter pylori Infection and Recent Advances. Diagnostics (Basel) 2021;11:1305. [PMID: 34441240 DOI: 10.3390/diagnostics11081305] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 126 |
Bricker-Ford R. Novel "High-dose Quad" Salvage Therapy Approach for Helicobacter pylori Infection: A Case Report. J Pharm Pract 2021;:8971900211033143. [PMID: 34269127 DOI: 10.1177/08971900211033143] [Reference Citation Analysis]
|
| 127 |
Liao W, Chen C, Wen T, Zhao Q. Probiotics for the Prevention of Antibiotic-associated Diarrhea in Adults: A Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Gastroenterol 2021;55:469-80. [PMID: 33234881 DOI: 10.1097/MCG.0000000000001464] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 128 |
Fathy El Sayed A, Magd Eldin Mohammad Sadek A, Ahmed Ragab Abdelhamid W. Comparison between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Trial. Middle East J Dig Dis 2021;13:223-9. [PMID: 36606218 DOI: 10.34172/mejdd.2021.229] [Reference Citation Analysis]
|
| 129 |
Akar M, Aydın F, Kayman T, Abay S, Karakaya E. Detection of Helicobacter pylori by invasive tests in adult dyspeptic patients and antibacterial resistance to six antibiotics, including rifampicin in Turkey. Is clarithromycin resistance rate decreasing? Turk J Med Sci 2021;51:1445-64. [PMID: 33631868 DOI: 10.3906/sag-2101-69] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 130 |
Cortés P, Nelson AD, Bi Y, Stancampiano FF, Murray LP, Pujalte GGA, Gomez V, Harris DM. Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review. J Prim Care Community Health 2021;12:21501327211014087. [PMID: 33949229 DOI: 10.1177/21501327211014087] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 131 |
Milivojevic V, Rankovic I, Krstic MN, Milosavljevic T. Dyspepsia Challenge in Primary Care Gastroenterology. Dig Dis 2022;40:270-5. [PMID: 34126614 DOI: 10.1159/000517668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 132 |
Pozdeeva AO, Pozdeev OK, Gulyaev PE, Valeeva YV, Savinova AN. Current development of <i>Helicobacter pylori</i> eradication protocols. Russian Journal of Infection and Immunity 2021;11:1037-1049. [DOI: 10.15789/2220-7619-cdo-1679] [Reference Citation Analysis]
|
| 133 |
Parihar V, McNamara D. Endoscopic Detection of Helicobacter pylori by the Rapid Urease Test. Methods Mol Biol 2021;2283:37-43. [PMID: 33765307 DOI: 10.1007/978-1-0716-1302-3_5] [Reference Citation Analysis]
|
| 134 |
Perkovic N, Mestrovic A, Bozic J, Ivelja MP, Vukovic J, Kardum G, Sundov Z, Tonkic M, Puljiz Z, Vukojevic K, Tonkic A. Randomized Clinical Trial Comparing Concomitant and Tailored Therapy for Eradication of Helicobacter pylori Infection. J Pers Med 2021;11:534. [PMID: 34207870 DOI: 10.3390/jpm11060534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 135 |
Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointesinal Research. Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Korean J Intern Med 2021;36:807-38. [PMID: 34092054 DOI: 10.3904/kjim.2020.701] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 136 |
Shahraki MS, Pouramini A, Heydari Y, Shahabi Shahmiri S. Does Bariatric Surgery Change the Recurrence of Helicobacter pylori Infection? Obes Surg 2021;31:4210-2. [PMID: 34089440 DOI: 10.1007/s11695-021-05507-6] [Reference Citation Analysis]
|
| 137 |
Kim YJ, Chung WC, Kim DB. Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection. Helicobacter 2021;26:e12792. [PMID: 33650225 DOI: 10.1111/hel.12792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 138 |
Saleh RO, Ahmed NS, Ewais EA, Mahmood AS, Sofy AR. Frequency infections of Helicobacter pylori and Epstein - Barr virus in Iraqi patients with chronic gastritis and their serum level of P16. Gene Reports 2021;23:101165. [DOI: 10.1016/j.genrep.2021.101165] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 139 |
Van den Poel B, Gils S, Micalessi I, Carton S, Christiaens P, Cuyle PJ, Moons V, Van Olmen G, Smismans A, Bourgain C, Bossuyt P, Frans J. Molecular detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies: a prospective evaluation of RIDA®GENE Helicobacter pylori assay. Acta Clin Belg 2021;76:177-83. [PMID: 31662122 DOI: 10.1080/17843286.2019.1685741] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 140 |
Yang C, Liu L, Majaw JK, Liang L, Chen Y. Efficacy of Lactobacillus reuteri supplementation therapy for Helicobacter pylori eradication: A meta-analysis of randomised controlled trials. Medicine in Microecology 2021;8:100036. [DOI: 10.1016/j.medmic.2021.100036] [Reference Citation Analysis]
|
| 141 |
Schubert JP, Gehlert J, Rayner CK, Roberts-Thomson IC, Costello S, Mangoni AA, Bryant RV. Antibiotic resistance of Helicobacter pylori in Australia and New Zealand: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:1450-6. [PMID: 33217029 DOI: 10.1111/jgh.15352] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 142 |
Fernández-esparrach G, Marín-gabriel JC, Díez Redondo P, Núñez H, Rodríguez de Santiago E, Rosón P, Calvet X, Cuatrecasas M, Cubiella J, Moreira L, Pardo López ML, Pérez Aisa Á, Sanz Anquela JM. Quality in diagnostic upper gastrointestinal endoscopy for the detection and surveillance of gastric cancer precursor lesions: Position paper of AEG, SEED and SEAP. Gastroenterología y Hepatología (English Edition) 2021;44:448-464. [DOI: 10.1016/j.gastre.2021.05.001] [Reference Citation Analysis]
|
| 143 |
Nkuize M, Vanderpas J, Buset M, Gomez-Galdon M, Delforge M, Miendje-Deyi VY, Muls V, De Wit S. Primary antibiotic resistance of Helicobacter pylori isolates is twofold more frequent in HIV-positive than HIV-negative individuals: A descriptive observational study. Microbiologyopen 2021;10:e1184. [PMID: 34180600 DOI: 10.1002/mbo3.1184] [Reference Citation Analysis]
|
| 144 |
Polozova EI, Skvortsov VV, Trokhina IE, Nefedov NS. Features of the course of gastric ulcer in different age groups. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-5-38-44] [Reference Citation Analysis]
|
| 145 |
Nelson A, Bi Y, Harris D. Helicobacter Pylori: a comprehensive review for primary care providers. Rom J Intern Med 2021;59:112-8. [PMID: 33565305 DOI: 10.2478/rjim-2020-0043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 146 |
Marabotto E, Pellegatta G, Sheijani AD, Ziola S, Zentilin P, De Marzo MG, Giannini EG, Ghisa M, Barberio B, Scarpa M, Angriman I, Fassan M, Savarino V, Savarino E. Prevention Strategies for Esophageal Cancer-An Expert Review. Cancers (Basel) 2021;13:2183. [PMID: 34062788 DOI: 10.3390/cancers13092183] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 147 |
Li M, Dan W, Zhang H, Yun Y, He Q. Xiao Chai Hu Tang for Peptic Ulcers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med 2021;2021:6693677. [PMID: 34012475 DOI: 10.1155/2021/6693677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 148 |
Cen S, Jia J, Ge Y, Ma Y, Li X, Wei J, Bai Y, Wu X, Song J, Bi H, Wu B. A new antibacterial 3,5-dimethylorsellinic acid-based meroterpene from the marine fungus Aspergillus sp. CSYZ-1. Fitoterapia 2021;152:104908. [PMID: 33892126 DOI: 10.1016/j.fitote.2021.104908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 149 |
Mannion A, Dzink-Fox J, Shen Z, Piazuelo MB, Wilson KT, Correa P, Peek RM Jr, Camargo MC, Fox JG. Helicobacter pylori Antimicrobial Resistance and Gene Variants in High- and Low-Gastric-Cancer-Risk Populations. J Clin Microbiol 2021;59:e03203-20. [PMID: 33692136 DOI: 10.1128/JCM.03203-20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 150 |
Muheim L, Signorell A, Markun S, Chmiel C, Neuner-Jehle S, Blozik E, Ursprung P, Rosemann T, Senn O. Potentially inappropriate proton-pump inhibitor prescription in the general population: a claims-based retrospective time trend analysis. Therap Adv Gastroenterol 2021;14:1756284821998928. [PMID: 33948109 DOI: 10.1177/1756284821998928] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 151 |
Ozturk T, Sengul D, Sengul I. Helicobacter pylori and association between its positivity and anatomotopographic settlement in the stomach with the host age range. Ann Afr Med 2021;20:1-8. [PMID: 33727504 DOI: 10.4103/aam.aam_69_19] [Reference Citation Analysis]
|
| 152 |
Katsurahara M, Imoto I, Umeda Y, Miura H, Tsuboi J, Yamada R, Yasuma T, Nakamura M, Hamada Y, Inoue H, Tanaka K, Horiki N, Gabazza EC, Takei Y. Increased Reflux Esophagitis after Helicobacter pylori Eradication Therapy in Cases Undergoing Endoscopic Submucosal Dissection for Early Gastric Cancer. Cancers (Basel) 2021;13:1779. [PMID: 33917861 DOI: 10.3390/cancers13081779] [Reference Citation Analysis]
|
| 153 |
Spiteri JA, Zahra G, Schembri J, Pisani A, Borg E, Spiteri N, Bianco EZ, Caruana P, Gauci J, Muscat M, Barbara C, Ellul P. Identification of antibiotic resistance patterns in Helicobacter pylori strains isolated from gastric biopsies using real-time PCR and genotypic analysis. Ann Gastroenterol 2021;34:501-9. [PMID: 34276188 DOI: 10.20524/aog.2021.0624] [Reference Citation Analysis]
|
| 154 |
Pak K, Junga Z, Mertz A, Singla M. The Patterns and Associated Cost of Serologic Testing for Helicobacter pylori in the U.S. Military Health System. Mil Med 2020;185:e1417-9. [PMID: 32633752 DOI: 10.1093/milmed/usaa141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 155 |
Durán C, Ciucci S, Palladini A, Ijaz UZ, Zippo AG, Sterbini FP, Masucci L, Cammarota G, Ianiro G, Spuul P, Schroeder M, Grill SW, Parsons BN, Pritchard DM, Posteraro B, Sanguinetti M, Gasbarrini G, Gasbarrini A, Cannistraci CV. Nonlinear machine learning pattern recognition and bacteria-metabolite multilayer network analysis of perturbed gastric microbiome. Nat Commun 2021;12:1926. [PMID: 33771992 DOI: 10.1038/s41467-021-22135-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 156 |
Nkuize M, Vanderpas J, Buset M, Delforge M, Cadière GB, De Wit S. Failure to eradicate Helicobacter pylori infection is more frequent among HIV-positive patients. HIV Med 2021;22:547-56. [PMID: 33765332 DOI: 10.1111/hiv.13083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 157 |
Saito H, Nishikawa Y, Masuzawa Y, Tsubokura M, Mizuno Y. Helicobacter pylori Infection Mass Screening for Children and Adolescents: a Systematic Review of Observational Studies. J Gastrointest Cancer 2021;52:489-97. [PMID: 33761050 DOI: 10.1007/s12029-021-00630-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 158 |
Snir Y, Leibovitzh H, Leibovici-Weissman Y, Vilkin A, Cohen AD, Shochat T, Niv Y, Dotan I, Feldhamer I, Boltin D, Levi Z. Dose-dependent association of proton pump inhibitors use with gastric intestinal metaplasia among Helicobacter pylori-positive patients. United European Gastroenterol J 2021;9:343-53. [PMID: 32962566 DOI: 10.1177/2050640620951403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 159 |
Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020. Gut Liver. 2021;15:168-195. [PMID: 33468712 DOI: 10.5009/gnl20288] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 160 |
Lansdorp-Vogelaar I, Meester RGS, Laszkowska M, Escudero FA, Ward ZJ, Yeh JM. Cost-effectiveness of prevention and early detection of gastric cancer in Western countries. Best Pract Res Clin Gastroenterol 2021;50-51:101735. [PMID: 33975689 DOI: 10.1016/j.bpg.2021.101735] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 161 |
Çakir Güney B, Düzenli T, Önal Y, Kaplan M, Tanoğlu A. Favorable effects of close telephone follow-up on Helicobacter pylori eradication success. Anatolian Current Medical Journal 2021;3:10-14. [DOI: 10.38053/acmj.865053] [Reference Citation Analysis]
|
| 162 |
Fernández-Esparrach G, Marín-Gabriel JC, Díez Redondo P, Núñez H, Rodríguez de Santiago E, Rosón P, Calvet X, Cuatrecasas M, Cubiella J, Moreira L, Pardo López ML, Pérez Aisa Á, Sanz Anquela JM; en representación de la Asociación Española de Gastroenterología, la Sociedad Española de Endoscopia Digestiva y la Sociedad Española de Anatomía Patológica. Quality in diagnostic upper gastrointestinal endoscopy for the detection and surveillance of gastric cancer precursor lesions: Position paper of AEG, SEED and SEAP. Gastroenterol Hepatol 2021;44:448-64. [PMID: 33609597 DOI: 10.1016/j.gastrohep.2021.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 163 |
Galal AMF, Mohamed HS, Abdel-Aziz MM, Hanna AG. Development, synthesis, and biological evaluation of sulfonyl-α-l-amino acids as potential anti-Helicobacter pylori and IMPDH inhibitors. Arch Pharm (Weinheim) 2021;354:e2000385. [PMID: 33576040 DOI: 10.1002/ardp.202000385] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 164 |
Mi M, Wu F, Zhu J, Liu F, Cui G, Wen X, Hu Y, Deng Z, Wu X, Zhang Z, Qi T, Chen Z. Heterogeneity of Helicobacter pylori Strains Isolated from Patients with Gastric Disorders in Guiyang, China. Infect Drug Resist 2021;14:535-45. [PMID: 33603417 DOI: 10.2147/IDR.S287631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 165 |
Molaoa SZ. Prevalence of Helicobacter pylori infection and the incidence of the associated malignant and peptic ulcer disease (PUD) at Nelson Mandela Academic Hospital: a retrospective analysis. J Drug Assess 2021;10:57-61. [PMID: 34104536 DOI: 10.1080/21556660.2020.1854560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 166 |
Albasha AM, Elnosh MM, Osman EH, Zeinalabdin DM, Fadl AAM, Ali MA, Altayb HN. Helicobacter pylori 23S rRNA gene A2142G, A2143G, T2182C, and C2195T mutations associated with clarithromycin resistance detected in Sudanese patients. BMC Microbiol 2021;21:38. [PMID: 33535966 DOI: 10.1186/s12866-021-02096-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 167 |
Pih GY, Choi KD, Gong EJ, Na HK, Ahn JY, Lee JH, Jung KW, Kim DH, Song HJ, Lee GH, Jung HY. Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection. Helicobacter 2021;26:e12759. [PMID: 33113240 DOI: 10.1111/hel.12759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 168 |
Yun J, Wu Z, Qi G, Han T, Zhang D. The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection. Expert Rev Gastroenterol Hepatol 2021;15:149-57. [PMID: 32960107 DOI: 10.1080/17474124.2021.1826306] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 169 |
Kim JH. Efficacy and Safety of DWJ1252 Compared With Gasmotin Treatment: Once Met 3 Times Tablets. J Neurogastroenterol Motil 2021;27:3-4. [PMID: 33380550 DOI: 10.5056/jnm20260] [Reference Citation Analysis]
|
| 170 |
Hebel-Gerber S, García-Cancino A, Urbina A, Simirgiotis MJ, Echeverría J, Bustamante-Salazar L, Sáez-Carrillo K, Alarcón J, Pastene-Navarrete E. Chilean Rhubarb, Gunnera tinctoria (Molina) Mirb. (Gunneraceae): UHPLC-ESI-Orbitrap-MS Profiling of Aqueous Extract and its Anti-Helicobacter pylori Activity. Front Pharmacol 2020;11:583961. [PMID: 33708110 DOI: 10.3389/fphar.2020.583961] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 171 |
Parreira P, Martins MCL. The biophysics of bacterial infections: Adhesion events in the light of force spectroscopy. Cell Surf 2021;7:100048. [PMID: 33665520 DOI: 10.1016/j.tcsw.2021.100048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 172 |
Gong RJ, Xu CX, Li H, Liu XM. Polymerase chain reaction-based tests for detecting Helicobacter pylori clarithromycin resistance in stool samples: A meta-analysis. World J Clin Cases 2021; 9(1): 133-147 [PMID: 33511178 DOI: 10.12998/wjcc.v9.i1.133] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 173 |
Zullo A, Bruzzese V, Pellegrino G, Scolieri P, Stefanantoni K, Angelelli C, Riccieri V. Helicobacter pylori and Upper Endoscopy in Systemic Sclerosis: A Cross-sectional Study in the Real World. J Clin Rheumatol 2021;27:40-1. [PMID: 33347033 DOI: 10.1097/RHU.0000000000001502] [Reference Citation Analysis]
|
| 174 |
Nyssen OP, Bordin D, Tepes B, Pérez-Aisa Á, Vaira D, Caldas M, Bujanda L, Castro-Fernandez M, Lerang F, Leja M, Rodrigo L, Rokkas T, Kupcinskas L, Pérez-Lasala J, Jonaitis L, Shvets O, Gasbarrini A, Simsek H, Axon ATR, Buzás G, Machado JC, Niv Y, Boyanova L, Goldis A, Lamy V, Tonkic A, Przytulski K, Beglinger C, Venerito M, Bytzer P, Capelle L, Milosavljević T, Milivojevic V, Veijola L, Molina-Infante J, Vologzhanina L, Fadeenko G, Ariño I, Fiorini G, Garre A, Garrido J, F Pérez C, Puig I, Heluwaert F, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut 2021;70:40-54. [PMID: 32958544 DOI: 10.1136/gutjnl-2020-321372] [Cited by in Crossref: 83] [Cited by in F6Publishing: 83] [Article Influence: 41.5] [Reference Citation Analysis]
|
| 175 |
Xu M, Zhou J, Zeng L, Xu J, Onakpa MM, Duan J, Che C, Bi H, Zhao M. Pimarane-derived diterpenoids with anti- Helicobacter pylori activity from the tuber of Icacina trichantha. Org Chem Front 2021;8:3014-22. [DOI: 10.1039/d1qo00374g] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 176 |
Lohse AW, Huber S. Magen-Darm-Mittel und Lebertherapeutika. Arzneiverordnungs-Report 2021 2021. [DOI: 10.1007/978-3-662-63825-5_32] [Reference Citation Analysis]
|
| 177 |
Wang J, Dong F, Su H, Zhu L, Shao S, Wu J, Liu H. H. pylori is related to NAFLD but only in female: A Cross-sectional Study. Int J Med Sci 2021;18:2303-11. [PMID: 33967606 DOI: 10.7150/ijms.50748] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 178 |
Kamarchuk G, Pospelov A, Savytskyi A, Gudimenko V, Vakula V, Herus A, Harbuz D, Kamarchuk L, Pereira MF. On the Prospect of Application of Point-Contact Sensors to Solving the Global Security Problems: An Analytical Review. Terahertz (THz), Mid Infrared (MIR) and Near Infrared (NIR) Technologies for Protection of Critical Infrastructures Against Explosives and CBRN 2021. [DOI: 10.1007/978-94-024-2082-1_15] [Reference Citation Analysis]
|
| 179 |
Cubiella J, Pérez Aisa Á, Cuatrecasas M, Díez Redondo P, Fernández Esparrach G, Marín-gabriel JC, Moreira L, Núñez H, Pardo López ML, Rodríguez de Santiago E, Rosón P, Sanz Anquela JM, Calvet X. Gastric cancer screening in low incidence populations: Position statement of AEG, SEED and SEAP. Gastroenterología y Hepatología (English Edition) 2021;44:67-86. [DOI: 10.1016/j.gastre.2020.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 180 |
Gonciarz W, Lechowicz Ł, Urbaniak M, Kaca W, Chmiela M. Use of Fourier-Transform Infrared Spectroscopy (FT-IR) for Monitoring Experimental Helicobacter pylori Infection and Related Inflammatory Response in Guinea Pig Model. Int J Mol Sci 2020;22:E281. [PMID: 33396581 DOI: 10.3390/ijms22010281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 181 |
Sun YY, Jing DD. Relationship between Helicobacter pylori infection and gastrointestinal microecology. Shijie Huaren Xiaohua Zazhi 2020; 28(24): 1261-1265 [DOI: 10.11569/wcjd.v28.i24.1261] [Reference Citation Analysis]
|
| 182 |
Vörhendi N, Soós A, Anne Engh M, Tinusz B, Szakács Z, Pécsi D, Mikó A, Sarlós P, Hegyi P, Eröss B. Accuracy of the Helicobacter pylori diagnostic tests in patients with peptic ulcer bleeding: a systematic review and network meta-analysis. Therap Adv Gastroenterol 2020;13:1756284820965324. [PMID: 33403002 DOI: 10.1177/1756284820965324] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 183 |
Kharel S, Bist A, Shrestha S, Homagain S. Helicobacter pylori healthy South Asians. JGH Open 2020;4:1037-46. [PMID: 33319035 DOI: 10.1002/jgh3.12426] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 184 |
Sampaio PS, Calado CRC. Potential of FTIR-Spectroscopy for Drugs Screening against Helicobacter pylori. Antibiotics (Basel) 2020;9:E897. [PMID: 33322665 DOI: 10.3390/antibiotics9120897] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 185 |
Klein S, Gildenblat J, Ihle MA, Merkelbach-Bruse S, Noh KW, Peifer M, Quaas A, Büttner R. Deep learning for sensitive detection of Helicobacter Pylori in gastric biopsies. BMC Gastroenterol 2020;20:417. [PMID: 33308189 DOI: 10.1186/s12876-020-01494-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 186 |
Meriem Z, Elmekkaoui A, Bouqfar M, Zazour A, Khannoussi W, Kharrasse G, Abda N, Ismaili Z. Non-Bismuth Quadruple Therapy, Sequential Therapy or High-Dose Esomeprazole and Amoxicillin Dual Therapy for First-Line Helicobacter pylori Eradication: A Prospective Randomized Study. Cureus 2020. [DOI: 10.7759/cureus.11837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 187 |
Elsaghier AM, Abdel Aal FH, Abu Faddan NH, Farghaly HS, Hassan MA, Sherif MF. Serum level of some micronutrients in children infected with Helicobacter pylori. Egypt Pediatric Association Gaz 2020;68:4. [DOI: 10.1186/s43054-020-0017-3] [Reference Citation Analysis]
|
| 188 |
Song Z, Zhou L, Xue Y, Suo B, Tian X, Niu Z. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial. Helicobacter 2020;25:e12762. [PMID: 33040439 DOI: 10.1111/hel.12762] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 189 |
Salehi N, Attaran B, Zare-Mirakabad F, Ghadiri B, Esmaeili M, Shakaram M, Tashakoripour M, Eshagh Hosseini M, Mohammadi M. The outward shift of clarithromycin binding to the ribosome in mutant Helicobacter pylori strains. Helicobacter 2020;25:e12731. [PMID: 32794288 DOI: 10.1111/hel.12731] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 190 |
Alavifard H, Mirzaei N, Yadegar A, Baghaei K, Smith SM, Sadeghi A, Zali MR. Investigation of Clarithromycin Resistance-Associated Mutations and Virulence Genotypes of Helicobacter pylori Isolated from Iranian Population: A Cross-Sectional Study. Curr Microbiol 2021;78:244-54. [PMID: 33251569 DOI: 10.1007/s00284-020-02295-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 191 |
Guo B, Cao NW, Zhou HY, Chu XJ, Li BZ. Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis. Microb Pathog 2021;152:104661. [PMID: 33249167 DOI: 10.1016/j.micpath.2020.104661] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 192 |
Hu Y, Zhu Y, Lu NH. Recent progress in Helicobacter pylori treatment. Chin Med J (Engl). 2020;133:335-343. [PMID: 31929363 DOI: 10.1097/cm9.0000000000000618] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 193 |
Ahn JY. Prevention of Peptic Ulcer Associated with Aspirin and Antiplatelet Agent. Korean J Gastroenterol 2020;76:238-41. [PMID: 33234770 DOI: 10.4166/kjg.2020.140] [Reference Citation Analysis]
|
| 194 |
Plitzko G, Schmutz G, Kröll D, Nett PC, Borbély Y. Ulcer Disease in the Excluded Segments after Roux-en-Y Gastric Bypass: a Current Review of the Literature. Obes Surg 2021;31:1280-9. [PMID: 33230760 DOI: 10.1007/s11695-020-05123-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 195 |
Rahman MM, Kibria MG, Sultana N, Akhter M, Begum H, Haque MA, Haque R, Sarker SA, Ahmed F, Hasan M. Seroprevalence of Helicobacter pylori and its association with metabolic syndrome in a rural community of Bangladesh. JGH Open 2021;5:64-72. [PMID: 33490615 DOI: 10.1002/jgh3.12448] [Reference Citation Analysis]
|
| 196 |
Rao W, Xie M, Zang YJ, Zhi KQ. Chronic atrophic gastritis and Helicobacter pylori infection status in liver transplant recipients. Transpl Infect Dis 2021;23:e13513. [PMID: 33207018 DOI: 10.1111/tid.13513] [Reference Citation Analysis]
|
| 197 |
Zahid R, Akram M, Riaz M, Munir N, Shehzad M. Phytotherapeutic modalities for the management of Helicobacter pylori associated peptic ulcer. Eur J Inflamm 2020;18:205873922096830. [DOI: 10.1177/2058739220968308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 198 |
Lee HA, Kim JY, Kim J, Nam B, Kim O. Anti-Helicobacter pylori activity of acomplex mixture of Lactobacillus paracasei HP7 including the extract of Perilla frutescens var. acuta and Glycyrrhiza glabra. Lab Anim Res 2020;36:40. [PMID: 33134159 DOI: 10.1186/s42826-020-00073-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 199 |
Zaman A, Shamsuzzaman S, Bhuiyan F, Hasan MR, Saito T. <p>Observation of Changes in <em>Helicobacter pylori</em> Antigen and Antibody Positivity According to Non-Invasive Tests Before and After <em>Helicobacter pylori</em> Eradication Therapy in Symptomatic Patients</p>. IJGM 2020;Volume 13:1093-1103. [DOI: 10.2147/ijgm.s273368] [Reference Citation Analysis]
|
| 200 |
Cubiella J, Pérez Aisa Á, Cuatrecasas M, Díez Redondo P, Fernández Esparrach G, Marín-Gabriel JC, Moreira L, Núñez H, Pardo López ML, Rodríguez de Santiago E, Rosón P, Sanz Anquela JM, Calvet X; en representación de la Asociación Española de Gastroenterología, la Sociedad Española de Endoscopia Digestiva y la Sociedad Española de Anatomía Patológica. Gastric cancer screening in low incidence populations: Position statement of AEG, SEED and SEAP. Gastroenterol Hepatol 2021;44:67-86. [PMID: 33252332 DOI: 10.1016/j.gastrohep.2020.08.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 201 |
Zhou A, Li L, Zhao G, Min L, Liu S, Zhu S, Guo Q, Liu C, Zhang S, Li P. Vitamin D3 Inhibits Helicobacter pylori Infection by Activating the VitD3/VDR-CAMP Pathway in Mice. Front Cell Infect Microbiol 2020;10:566730. [PMID: 33194806 DOI: 10.3389/fcimb.2020.566730] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 202 |
Coates MM, Kintu A, Gupta N, Wroe EB, Adler AJ, Kwan GF, Park PH, Rajbhandari R, Byrne AL, Casey DC, Bukhman G. Burden of non-communicable diseases from infectious causes in 2017: a modelling study. Lancet Glob Health 2020;8:e1489-98. [PMID: 33098769 DOI: 10.1016/S2214-109X(20)30358-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 203 |
Açar S. Helikobakter Pylori Eradikasyonunda Modifiye Hibrit Tedavi Etkinliği. Zeynep Kamil Tıp Bülteni 2020. [DOI: 10.16948/zktipb.773921] [Reference Citation Analysis]
|
| 204 |
Fisher L, Fisher A, Smith PN. Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review). J Clin Med 2020;9:E3253. [PMID: 33053671 DOI: 10.3390/jcm9103253] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 205 |
Kalfus IN, Graham DY, Riff DS, Panas RM. Rifabutin-Containing Triple Therapy (RHB-105) for Eradication of Helicobacter pylori: Randomized ERADICATE Hp Trial. Antibiotics (Basel) 2020;9:E685. [PMID: 33050205 DOI: 10.3390/antibiotics9100685] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 206 |
Graham DY. Transitioning of Helicobacter pylori Therapy from Trial and Error to Antimicrobial Stewardship. Antibiotics (Basel) 2020;9:E671. [PMID: 33023041 DOI: 10.3390/antibiotics9100671] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 207 |
Liu W, Li J, Zhang D, Chen B, Wang X, Zhang X, Xue L. Trefoil factor 1 and gastrokine 2 inhibit Helicobacter pylori-induced proliferation and inflammation in gastric cardia and distal carcinogenesis. Oncol Lett 2020;20:318. [PMID: 33133254 DOI: 10.3892/ol.2020.12181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 208 |
Tang C, Zhu Y, Yang X, Xu B, Ye C, Yang Y, Zhong J, Zhao Q, Yu L. Upper gastrointestinal mucosal injury associated with ticagrelor plus aspirin, ticagrelor alone, or aspirin alone at 1-year after coronary artery bypass grafting. J Gastroenterol Hepatol 2020;35:1720-30. [PMID: 32154936 DOI: 10.1111/jgh.15030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 209 |
Tang Y, Tang G, Pan L, Zhu H, Zhou S, Wei Z. Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China. Sci Rep 2020;10:15403. [PMID: 32958842 DOI: 10.1038/s41598-020-72400-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 210 |
Zou Q, Zhang H, Meng F, He L, Zhang J, Xiao D. Proteomic and transcriptomic studies of BGC823 cells stimulated with Helicobacter pylori isolates from gastric MALT lymphoma. PLoS One 2020;15:e0238379. [PMID: 32915799 DOI: 10.1371/journal.pone.0238379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 211 |
Choi YI, Chung J. Helicobacter pylori Eradication in Patients Undergoing Gastrectomy: Diagnosis and Therapy. Korean J Helicobacter Up Gastrointest Res 2020;20:204-9. [DOI: 10.7704/kjhugr.2019.0037] [Reference Citation Analysis]
|
| 212 |
Saxena A, Mukhopadhyay AK, Nandi SP. Helicobacter pylori: Perturbation and restoration of gut microbiome. J Biosci 2020;45. [DOI: 10.1007/s12038-020-00078-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 213 |
Kim YM, Lee KH, Kim JH, Park SY, Song YG, Jeon SY, Park H. Is Only Clarithromycin Susceptibility Important for the Successful Eradication of Helicobacter pylori? Antibiotics (Basel) 2020;9:E589. [PMID: 32916937 DOI: 10.3390/antibiotics9090589] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 214 |
Abdulkhakov SR, Bordin DS, Abdulkhakov RA, Safina DD, Gizdatullina AR, Gimadieva LZ, Safina GM, Ziyatdinov AI, Maturina AM, Nyssen OP, Megraud F, O'Morain C, Perez-Gisbert J. [European Registry on the management of Helicobacter pylori infection: features of diagnosis and treatment in Kazan]. Ter Arkh 2020;92:52-9. [PMID: 33346462 DOI: 10.26442/00403660.2020.08.000758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 215 |
Wang JW, Dong FX, Su H, Zhu L, Shao S, Liu H. H. Pylori is related to osteoporosis but only in premenopausal female: a cross-sectional study. BMC Musculoskelet Disord 2020;21:559. [PMID: 32811503 DOI: 10.1186/s12891-020-03586-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 216 |
Gurbuz BC, Inceman HN, Aydemir M, Celtik C, Gerenli N, Zemheri E. Prevalence of Helicobacter pylori among children in a training and research hospital clinic in Istanbul and comparison with Updated Sydney Classification Criteria. North Clin Istanb 2020;7:499-505. [PMID: 33163887 DOI: 10.14744/nci.2020.70037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 217 |
Lok CH, Zhu D, Wang J, Ren YT, Jiang X, Li SJ, Zhao XY. Phenotype and Molecular Detection of Clarithromycin and Levofloxacin Resistance in Helicobacter pylori Clinical Isolates in Beijing. Infect Drug Resist 2020;13:2145-53. [PMID: 32753910 DOI: 10.2147/IDR.S249370] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 218 |
Maksimov ML, Kiseleva NM, Semenikhin DG, Romanov BK. Adverse reactions with the use of non-steroidal anti-inflammatory drugs. Vrač skoroj pomoŝi (Emergency Doctor) 2020. [DOI: 10.33920/med-02-2008-02] [Reference Citation Analysis]
|
| 219 |
Horie R, Handa O, Ando T, Ose T, Murakami T, Suzuki N, Sendo R, Imamoto E, Itoh Y. Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan. Helicobacter 2020;25:e12698. [PMID: 32368846 DOI: 10.1111/hel.12698] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 220 |
Alihosseini S, Ghotaslou R, Heravi FS, Ahmadian Z, Leylabadlo HE. Management of antibiotic-resistant Helicobacter pylori infection: current perspective in Iran. J Chemother 2020;32:273-85. [PMID: 32657237 DOI: 10.1080/1120009X.2020.1790889] [Reference Citation Analysis]
|
| 221 |
Kuo CJ, Lin CY, Le PH, Chang PY, Lai CH, Lin WR, Chang ML, Hsu JT, Cheng HT, Tseng CN, Lin CJ, Su MY, Hsieh SY, Chiu CT. Rescue therapy with rifabutin regimen for refractory Helicobacter pylori infection with dual drug-resistant strains. BMC Gastroenterol 2020;20:218. [PMID: 32650737 DOI: 10.1186/s12876-020-01370-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 222 |
Liu Q, Zhang Y, Xu C, Chen B, Xu H, Cao Y, Guo T, Gao Y, Zhou Z, Zhou X, Xu X, He J. Dentists Are at a Higher Risk for Oral Helicobacter pylori Infection. Biomed Res Int 2020;2020:3945189. [PMID: 32695813 DOI: 10.1155/2020/3945189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 223 |
Mattar R, Marques SB, Ribeiro IB, Visconti TAC, Funari M, DE Moura EGH. DIAGNOSTIC ACCURACY OF GASTROPANEL® FOR ATROPHIC GASTRITIS IN BRAZILIAN SUBJECTS AND THE EFFECT OF PROTON PUMP INHIBITORS. Arq Gastroenterol 2020;57:154-60. [PMID: 32609157 DOI: 10.1590/S0004-2803.202000000-29] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 224 |
Holtmann G, Schrenk D, Madisch A, Allescher HD, Ulrich-Merzenich G, Mearin F, Larrey D, Malfertheiner P. Use of Evidence-Based Herbal Medicines for Patients with Functional Gastrointestinal Disorders: A Conceptional Framework for Risk-Benefit Assessment and Regulatory Approaches. Dig Dis 2020;38:269-79. [PMID: 31770769 DOI: 10.1159/000504570] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 225 |
Etçioğlu E, Aydin A. Birinci Basamakta Dispepsi Şikayeti Olan Erişkin Hastaya Klinik Yaklaşım. Sakarya Medical Journal 2020. [DOI: 10.31832/smj.747308] [Reference Citation Analysis]
|
| 226 |
Dang NQH, Ha TMT, Nguyen ST, Le NDK, Nguyen TMT, Nguyen TH, Pham TTH, Tran VH. High rates of clarithromycin and levofloxacin resistance of Helicobacter pylori in patients with chronic gastritis in the south east area of Vietnam. J Glob Antimicrob Resist 2020;22:620-4. [PMID: 32590188 DOI: 10.1016/j.jgar.2020.06.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 227 |
Beer A, Hudler H, Hader M, Kundi M, Hudler S, Täuber V, Schachner H, Gruber S, Hirschl AM, Kain R, Makristathis A. Apparent intracellular Helicobacter pylori detected by immunohistochemistry - the missing link in eradication failure. Clin Infect Dis 2020:ciaa839. [PMID: 32569354 DOI: 10.1093/cid/ciaa839] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 228 |
Kasmi H, Doukani K, Ali A, Tabak S, Bouhenni H. Epidemiological Profile of Helicobacter pylori Infection in Patients with Digestive Symptoms in Algeria. J Epidemiol Glob Health 2020;10:293-7. [PMID: 32959615 DOI: 10.2991/jegh.k.200527.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 229 |
Na'amnih W, Ben Tov A, Bdair-Amsha A, Cohen S, Tsamir J, Chodick G, Muhsen K. Physicians' adherence to management guidelines for H. pylori infection and gastroesophageal reflux disease: a cross-sectional study. Isr J Health Policy Res 2020;9:28. [PMID: 32527326 DOI: 10.1186/s13584-020-00389-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 230 |
Kim BJ. Natural Course of Atrophic Gastritis and Intestinal Metaplasia. Korean J Helicobacter Up Gastrointest Res 2020;20:101-106. [DOI: 10.7704/kjhugr.2020.0024] [Reference Citation Analysis]
|
| 231 |
Kim J, Kim Y, Chung WC. Proton Pump Inhibitor Switching Strategy after Failure of Standard Triple Therapy for Helicobacter pylori Infection. Korean J Helicobacter Up Gastrointest Res 2020;20:146-52. [DOI: 10.7704/kjhugr.2019.0036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 232 |
Sayed IM, Sahan AZ, Venkova T, Chakraborty A, Mukhopadhyay D, Bimczok D, Beswick EJ, Reyes VE, Pinchuk I, Sahoo D, Ghosh P, Hazra TK, Das S. Helicobacter pylori infection downregulates the DNA glycosylase NEIL2, resulting in increased genome damage and inflammation in gastric epithelial cells. J Biol Chem 2020;295:11082-98. [PMID: 32518160 DOI: 10.1074/jbc.RA119.009981] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 233 |
Mahant S, Sharma AK, Gehlot V, Mukhopadhyay AK, Chhawchharia A, Dutta S, Agarwal A, Som A, Das K, Das R. Geographically distinct North-East Indian Helicobacter pylori strains are highly sensitive to clarithromycin but are levofloxacin resistant. Indian J Med Microbiol 2019;37:337-44. [PMID: 32003330 DOI: 10.4103/ijmm.IJMM_19_158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 234 |
Kasahun GG, Demoz GT, Desta DM. Primary Resistance Pattern of Helicobacter pylori to Antibiotics in Adult Population: A Systematic Review. Infect Drug Resist 2020;13:1567-73. [PMID: 32547126 DOI: 10.2147/IDR.S250200] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 235 |
Turan G, Kocaöz S. Helicobacter Pylori Infection Prevalence and Histopathologic Findings in Laparoscopic Sleeve Gastrectomy. Obes Surg 2019;29:3674-9. [PMID: 31290105 DOI: 10.1007/s11695-019-04052-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 236 |
Butorova LI, Ardatskaya MD, Osadchuk MA, Kadnikova NG, Lukianova EI, Plavnik RG, Sayutina EV, Topchiy TB, Tuayeva EM. [Comparison of clinical-metabolic efficacy of pre- and probiotics in the conducted optimized protocols of eradication therapy of Helicobacter pylori infection]. Ter Arkh 2020;92:64-9. [PMID: 32598700 DOI: 10.26442/00403660.2020.04.000647] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 237 |
Wang M, Kong WJ, Zhang JZ, Lu JJ, Hui WJ, Liu WD, Kang XJ, Gao F. Association of Helicobacter pylori infection with colorectal polyps and malignancy in China. World J Gastrointest Oncol 2020;12:582-91. [PMID: 32461789 DOI: 10.4251/wjgo.v12.i5.582] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 238 |
Saracino IM, Pavoni M, Saccomanno L, Fiorini G, Pesci V, Foschi C, Piccirilli G, Bernardini G, Holton J, Figura N, Lazzarotto T, Borghi C, Vaira B. Antimicrobial Efficacy of Five Probiotic Strains Against Helicobacter pylori. Antibiotics (Basel) 2020;9:E244. [PMID: 32403331 DOI: 10.3390/antibiotics9050244] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 239 |
Sierra JC, Piazuelo MB, Luis PB, Barry DP, Allaman MM, Asim M, Sebrell TA, Finley JL, Rose KL, Hill S, Holshouser SL, Casero RA, Cleveland JL, Woster PM, Schey KL, Bimczok D, Schneider C, Gobert AP, Wilson KT. Spermine oxidase mediates Helicobacter pylori-induced gastric inflammation, DNA damage, and carcinogenic signaling. Oncogene 2020;39:4465-74. [PMID: 32350444 DOI: 10.1038/s41388-020-1304-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 240 |
Şenocak Taşçı E, Akbaş T. The Relationship between the Sydney Classification and the First-Line Treatment Efficacy in Helicobacter-Associated Gastritis. Med Princ Pract 2020;29:551-7. [PMID: 32344409 DOI: 10.1159/000508248] [Reference Citation Analysis]
|
| 241 |
Na HK, Lee JH, Park SJ, Park HJ, Kim SO, Ahn JY, Kim DH, Jung KW, Choi KD, Song HJ, Lee GH, Jung HY. Effect of Helicobacter pylori eradication on reflux esophagitis and GERD symptoms after endoscopic resection of gastric neoplasm: a single-center prospective study. BMC Gastroenterol 2020;20:123. [PMID: 32316932 DOI: 10.1186/s12876-020-01276-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 242 |
Sugimoto M, Murata M, Yamaoka Y. Chemoprevention of gastric cancer development after Helicobacter pylori eradication therapy in an East Asian population: Meta-analysis. World J Gastroenterol 2020; 26(15): 1820-1840 [PMID: 32351296 DOI: 10.3748/wjg.v26.i15.1820] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 243 |
Liu A, Wang Y, Song Y, Du Y. Treatment with compound Lactobacillus acidophilus followed by a tetracycline- and furazolidone-containing quadruple regimen as a rescue therapy for Helicobacter pylori infection. Saudi J Gastroenterol 2020;26:78-83. [PMID: 32295932 DOI: 10.4103/sjg.SJG_589_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 244 |
İspiroğlu M, Gişi K, Kantarçeken B. Proton Pompa İnhibitörlerinin Uzun Dönem Kullanımındaki Etkileri. Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi 2020. [DOI: 10.17517/ksutfd.690248] [Reference Citation Analysis]
|
| 245 |
Lee WY, Oh E, Cui M, Kim CO, Lim Y, Kim H, Park H, Yoon S, Park MS, Hong T. Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects. Transl Clin Pharmacol 2020;28:55-65. [PMID: 32274381 DOI: 10.12793/tcp.2020.28.e5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 246 |
Di Pierro F, Bertuccioli A, Saponara M, Ivaldi L. Impact of a two-bacterial-strain formula, containing Bifidobacterium animalis lactis BB-12 and Enterococcus faecium L3, administered before and after therapy for Helicobacter pylori eradication. Minerva Gastroenterol Dietol 2020;66:117-23. [PMID: 32272820 DOI: 10.23736/S1121-421X.19.02651-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 247 |
Liu Y, Cai Y, Chen S, Gou Y, Wang Q, Zhang M, Wang Y, Hong H, Zhang K. Analysis of Risk Factors of Gastric Low-Grade Intraepithelial Neoplasia in Asymptomatic Subjects Undergoing Physical Examination. Gastroenterol Res Pract 2020;2020:7907195. [PMID: 32256566 DOI: 10.1155/2020/7907195] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 248 |
Kim YA, Cho YJ, Kwak SG. The Association between Helicobacter pylori Infection and Irritable Bowel Syndrome: A Meta-Analysis. Int J Environ Res Public Health 2020;17:E2524. [PMID: 32272678 DOI: 10.3390/ijerph17072524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 249 |
Smirnova OV, Sinyakov AA. Influence of <i>Helicobacter pylori</i> on cytokine regulation in chronic atrophic gastritis. Russian Journal of Infection and Immunity 2020;10:187-192. [DOI: 10.15789/2220-7619-ioh-1167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 250 |
Boyanova L, Markovska R, Medeiros J, Gergova G, Mitov I. Delafloxacin against Helicobacter pylori, a potential option for improving eradication success? Diagnostic Microbiology and Infectious Disease 2020;96:114980. [DOI: 10.1016/j.diagmicrobio.2019.114980] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 251 |
Ciucci S, Durán C, Palladini A, Ijaz UZ, Sterbini FP, Masucci L, Cammarota G, Ianiro G, Spuul P, Schroeder M, Grill SW, Parsons BN, Pritchard DM, Posteraro B, Sanguinetti M, Gasbarrini G, Gasbarrini A, Cannistraci CV. Machine learning pattern recognition and differential network analysis of gastric microbiome in the presence of proton pump inhibitor treatment or Helicobacter pylori infection.. [DOI: 10.1101/2020.03.24.005587] [Reference Citation Analysis]
|
| 252 |
Liu C, Cheng L, Ji L, Li F, Zhan Y, Wu B, Ke Y, Chen P, Hua F, Yuan L, Min Z, Sun L, Chen H, Cheng Y. Intestinal microbiota dysbiosis play a role in pathogenesis of patients with primary immune thrombocytopenia. Thromb Res 2020;190:11-9. [PMID: 32272276 DOI: 10.1016/j.thromres.2020.03.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 253 |
Wang R, Bai D, Xiang W, Zhang YF, Ba KY, Chen XZ; SIGES research group. Helicobacter pylori prevalence in the Southwest of China: A protocol for systematic review. Medicine (Baltimore) 2020;99:e19369. [PMID: 32176059 DOI: 10.1097/MD.0000000000019369] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 254 |
Yang T, Hu R, Tang X, Shen Y, Tay A, Pi X, Wang G, Debowski AW, Stubbs KA, Benghezal M, Marshall BJ, Li H, Tang H. Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections. Precision Clinical Medicine 2020;3:127-35. [DOI: 10.1093/pcmedi/pbaa010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 255 |
Ndiaye NF, Idohou-dossou N, Bürkli S, Diouf A, Loucoubar C, Guiro AT, Zimmermann MB, Wade S, Moretti D. Polyphenol-rich tea decreases iron absorption from fortified wheat bread in Senegalese mother–child pairs and bioavailability of ferrous fumarate is sharply lower in children. Eur J Clin Nutr 2020;74:1221-8. [DOI: 10.1038/s41430-020-0601-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 256 |
Xia X, Zhang L, Chi J, Li H, Liu X, Hu T, Li R, Guo Y, Zhang X, Wang H, Cai J, Li Y, Liu D, Cui Y, Zheng X, Flaker GC, Liao D, Hao H, Liu Z, Xu C. Helicobacter pylori Infection Impairs Endothelial Function Through an Exosome-Mediated Mechanism. J Am Heart Assoc 2020;9:e014120. [PMID: 32174233 DOI: 10.1161/JAHA.119.014120] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 257 |
Wang R, Chen XZ. Prevalence of atrophic gastritis in southwest China and predictive strength of serum gastrin-17: A cross-sectional study (SIGES). Sci Rep 2020;10:4523. [PMID: 32161305 DOI: 10.1038/s41598-020-61472-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 258 |
Lim SH, Kim N, Kim SE, Baik GH, Lee JY, Park KS, Shin JE, Song HJ, Myung D, Choi SC, Kim HJ. A Comparison of Accuracy between IMMULITE2000® and GENEDIA® for Helicobacter pylori Infection. Korean J Helicobacter Up Gastrointest Res 2020;20:54-62. [DOI: 10.7704/kjhugr.2019.0014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 259 |
Cárdenas PA, Garcés D, Prado-Vivar B, Flores N, Fornasini M, Cohen H, Salvador I, Cargua O, Baldeón ME. Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome. Eur J Clin Microbiol Infect Dis 2020;39:1365-72. [PMID: 32125555 DOI: 10.1007/s10096-020-03854-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 260 |
Rahimi F, Talebi Bezmin Abadi A. Tracking the Virulent Helicobacter pylori Strains Instead of Its Pan-Screening to Prevent Gastric Cancer. BioNanoSci 2020;10:315-317. [DOI: 10.1007/s12668-019-00678-0] [Reference Citation Analysis]
|
| 261 |
Endall R, Thompson M, Parameswaran V, Burgess J. The Relationship of Gastrinoma in MEN 1 to Helicobacter pylori infection. J Clin Endocrinol Metab 2020;105:dgaa004. [PMID: 31919513 DOI: 10.1210/clinem/dgaa004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 262 |
Sung J. Peptic ulcer disease. Oxford Textbook of Medicine 2020. [DOI: 10.1093/med/9780198746690.003.0295] [Reference Citation Analysis]
|
| 263 |
Zhao B, Zhang J, Mei D, Luo R, Lu H, Xu H, Huang B. Does Helicobacter pylori Eradication Reduce the Incidence of Metachronous Gastric Cancer After Curative Endoscopic Resection of Early Gastric Cancer: A Systematic Review and Meta-Analysis. J Clin Gastroenterol 2020;54:235-41. [PMID: 30829904 DOI: 10.1097/MCG.0000000000001195] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 264 |
Park JU, Cho JS, Kim JS, Kim HK, Jo YH, Rahman MAA, Lee YI. Synergistic Effect of Rubus crataegifolius and Ulmus macrocarpa Against Helicobacter pylori Clinical Isolates and Gastritis. Front Pharmacol 2020;11:4. [PMID: 32153392 DOI: 10.3389/fphar.2020.00004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 265 |
Khien VV, Thang DM, Hai TM, Duat NQ, Khanh PH, Ha DT, Binh TT, Dung HDQ, Trang TTH, Yamaoka Y. Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives from Vietnam. Gut Liver 2019;13:483-97. [PMID: 31009957 DOI: 10.5009/gnl18137] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 266 |
Kim BJ, Lee H, Lee YC, Jeon SW, Kim GH, Kim HS, Sung JK, Lee DH, Kim HU, Park MI, Choi IJ, Yoon SM, Kim SW, Baik GH, Lee JY, Kim JI, Kim SG, Kim J, Lee J, Kim JG, Kim JJ; Korean College of Helicobacter Upper Gastrointestinal Research. Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for Helicobacter pylori Infection: A Nationwide Randomized Trial in Korea. Gut Liver. 2019;13:531-540. [PMID: 31505907 DOI: 10.5009/gnl19136] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 267 |
Kim TH, Park JM, Cheung DY, Oh JH. Comparison of 7- and 14-Day Eradication Therapy for Helicobacter pylori with First- and Second-Line Regimen: Randomized Clinical Trial. J Korean Med Sci 2020;35:e33. [PMID: 32030921 DOI: 10.3346/jkms.2020.35.e33] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 268 |
Zhang H, Zhang X, Liu J, Sun L, Shen Y, Zhou C, Zhang H, Xie L, Chen J, Liu Y, Wang Y. Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors. Pharmacological Research 2020;152:104606. [DOI: 10.1016/j.phrs.2019.104606] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 269 |
Oh JH, Kwon JG, Jung HK, Tae CH, Song KH, Kang SJ, Kim SE, Jung K, Kim JS, Park JK, Bang KB, Baeg MK, Shin JE, Shin CM, Lee JY, Lim HC; Functional Dyspepsia Research Group and Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Functional Dyspepsia in Korea. J Neurogastroenterol Motil 2020;26:29-50. [PMID: 31917913 DOI: 10.5056/jnm19209] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 270 |
Topi S, Santacroce L, Bottalico L, Ballini A, Inchingolo AD, Dipalma G, Charitos IA, Inchingolo F. Gastric Cancer in History: A Perspective Interdisciplinary Study. Cancers (Basel) 2020;12:E264. [PMID: 31978985 DOI: 10.3390/cancers12020264] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 271 |
Parra-Sepúlveda C, Merino JS, Sáez-Carrillo K, González C, García-Cancino A. ANTIBIOTIC RESISTANCE SURVEILLANCE OF HELICOBACTER PYLORI AT THE BIOBÍO REGION (CHILE) IN A DECADE. Arq Gastroenterol 2019;56:361-6. [PMID: 31721972 DOI: 10.1590/S0004-2803.201900000-72] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 272 |
Sezgin O, Aydın MK, Özdemir AA, Kanık AE. Standard triple therapy in Helicobacter pylori eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies. Turk J Gastroenterol 2019;30:420-35. [PMID: 31060997 DOI: 10.5152/tjg.2019.18693] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 273 |
Tarasconi A, Coccolini F, Biffl WL, Tomasoni M, Ansaloni L, Picetti E, Molfino S, Shelat V, Cimbanassi S, Weber DG, Abu-Zidan FM, Campanile FC, Di Saverio S, Baiocchi GL, Casella C, Kelly MD, Kirkpatrick AW, Leppaniemi A, Moore EE, Peitzman A, Fraga GP, Ceresoli M, Maier RV, Wani I, Pattonieri V, Perrone G, Velmahos G, Sugrue M, Sartelli M, Kluger Y, Catena F. Perforated and bleeding peptic ulcer: WSES guidelines. World J Emerg Surg 2020;15:3. [PMID: 31921329 DOI: 10.1186/s13017-019-0283-9] [Cited by in Crossref: 97] [Cited by in F6Publishing: 101] [Article Influence: 32.3] [Reference Citation Analysis]
|
| 274 |
Pan J, Shi Z, Lin D, Yang N, Meng F, Lin L, Jin Z, Zhou Q, Wu J, Zhang J, Li Y. Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial. Front Med 2020;14:43-50. [PMID: 31907860 DOI: 10.1007/s11684-019-0706-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 275 |
Lentze MJ, Koletzko S. Krankheiten von Magen und Duodenum bei Kindern und Jugendlichen. Pädiatrie 2020. [DOI: 10.1007/978-3-642-54671-6_147-2] [Reference Citation Analysis]
|
| 276 |
Leja M, Dumpis U. What Would the Screen-and-Treat Strategy for Helicobacter pylori Mean in Terms of Antibiotic Consumption? Dig Dis Sci 2020;65:1632-42. [PMID: 31659615 DOI: 10.1007/s10620-019-05893-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 277 |
Kamarchuk GV, Pospelov АP, Kamarchuk LV, Savytskyi AV, Harbuz DA, Vakula VL. Point-Contact Sensors as an Innovative Tool in Defense Against Chemical Agents, Environment and Health Risks: A Review. Functional Nanostructures and Sensors for CBRN Defence and Environmental Safety and Security 2020. [DOI: 10.1007/978-94-024-1909-2_18] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 278 |
Lohse AW, Huber S. Magen-Darm-Mittel und Lebertherapeutika. Arzneiverordnungs-Report 2020 2020. [DOI: 10.1007/978-3-662-62168-4_31] [Reference Citation Analysis]
|
| 279 |
De Marchi D, Panozzo MP, Antico A, Tozzoli R. Valutazione di un nuovo metodo immunometrico per la misura dei marcatori biochimico/sierologici di gastrite atrofica. Riv Ital Med Lab 2020;15. [DOI: 10.23736/s1825-859x.19.00036-7] [Reference Citation Analysis]
|
| 280 |
Offermanns S. Pharmaka mit Wirkung auf die Magenfunktion. Pharmakologie und Toxikologie 2020. [DOI: 10.1007/978-3-662-58304-3_45] [Reference Citation Analysis]
|
| 281 |
张 鹏. Research Progress on the Relationship between Helicobacter pylori Virulence Protein Typing and Gastric Mucosal Lesions. ACM 2020;10:92-96. [DOI: 10.12677/acm.2020.102015] [Reference Citation Analysis]
|
| 282 |
McNicholl AG, Bordin DS, Lucendo A, Fadeenko G, Fernandez MC, Voynovan I, Zakharova NV, Sarsenbaeva AS, Bujanda L, Perez-Aisa Á, Vologzhanina L, Zaytsev O, Ilchishina T, Coba C, Lasala JP, Alekseenko S, Modolell I, Molina-Infante J, Ruiz-Zorrilla Lopez R, Alonso-Galan H, Moreno NF, Hinojosa J, Santaella I, Varela P, Gonzalez-Cordero PL, Barrio J, Dominguez-Jimenez JL, Nuñez O, Alcedo J, Nyssen OP, Caldas M, Donday MG, Shvetz O, Megraud F, O'Morain C, Gisbert JP. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. Clin Gastroenterol Hepatol 2020;18:89-98. [PMID: 30978536 DOI: 10.1016/j.cgh.2019.03.048] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 283 |
Lonjid T, Sambuu T, Tumurbat N, Banzragch U, Dondov G, Badamjav T, Davaa B, Tudev BE, Batsaikhan B. Incidence of Stomach and Esophageal Cancers in Mongolia: Data from 2009 to 2018. Euroasian J Hepatogastroenterol 2020;10:16-21. [PMID: 32742967 DOI: 10.5005/jp-journals-10018-1313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 284 |
Barinova AS, Naletov AV, Naletov SV, Masyuta DI, Perederiy EA. Influence of parental compliance on the effectiveness of treatment of chronic gastroduodenal pathology in children. RRP 2019;5:69-74. [DOI: 10.3897/rrpharmacology.5.48560] [Reference Citation Analysis]
|
| 285 |
Sticlaru L, Stăniceanu F, Cioplea M, Nichita L, Bastian A, Micu G, Popp C. Dangerous Liaison: Helicobacter pylori, Ganglionitis, and Myenteric Gastric Neurons: A Histopathological Study. Anal Cell Pathol (Amst) 2019;2019:3085181. [PMID: 32082967 DOI: 10.1155/2019/3085181] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 286 |
Lassalle M, Le Tri T, Bardou M, Biour M, Kirchgesner J, Rouby F, Dumarcet N, Zureik M, Dray-Spira R. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol 2020;76:449-57. [PMID: 31838548 DOI: 10.1007/s00228-019-02810-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 287 |
Bao C, Wang K, Ding Y, Kong J. Association Between Anti-bacterial Drug Use and Digestive System Neoplasms: A Systematic Review and Meta-analysis. Front Oncol 2019;9:1298. [PMID: 31828038 DOI: 10.3389/fonc.2019.01298] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 288 |
Ilianov Iliev H, Dimitrova Kovacheva-slavova M, Asenov Angelov T, Yankov Valkov H, Bedran A, Georgiev Vladimirov B. Gastric Microbiota: Between Health and Disease. Gastrointestinal Stomas 2019. [DOI: 10.5772/intechopen.86926] [Reference Citation Analysis]
|
| 289 |
Ahn JY. Effectiveness of Helicobacter pylori Eradication before Endoscopic Resection. Korean J Helicobacter Up Gastrointest Res 2019;19:215-219. [DOI: 10.7704/kjhugr.2019.0016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 290 |
Kim Y, Chung WC. Eradication Therapy for Helicobacter pylori with Diagnostic Test for Clarithromycin Resistance. Korean J Helicobacter Up Gastrointest Res 2019;19:225-30. [DOI: 10.7704/kjhugr.2019.0019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 291 |
Gong J, Li L, Zuo X, Li Y. Change of the duodenal mucosa-associated microbiota is related to intestinal metaplasia. BMC Microbiol 2019;19:275. [PMID: 31815623 DOI: 10.1186/s12866-019-1666-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 292 |
Parreira P, Monteiro C, Graça V, Gomes J, Maia S, Gomes P, Gonçalves IC, Martins MCL. Surface Grafted MSI-78A Antimicrobial Peptide has High Potential for Gastric Infection Management. Sci Rep 2019;9:18212. [PMID: 31796755 DOI: 10.1038/s41598-019-53918-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 293 |
Kim YJ, Chung WC, Cho IH, Kim J, Kim S. Prognostic effect of different etiologies in patients with gastric cardia cancer. Medicine (Baltimore) 2019;98:e18397. [PMID: 31852158 DOI: 10.1097/MD.0000000000018397] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 294 |
Kokoska L, Kloucek P, Leuner O, Novy P. Plant-Derived Products as Antibacterial and Antifungal Agents in Human Health Care. Curr Med Chem 2019;26:5501-41. [PMID: 30182844 DOI: 10.2174/0929867325666180831144344] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 16.8] [Reference Citation Analysis]
|
| 295 |
Fialho A, Fialho A, Nassri A, Muenyi V, Malespin M, Shen B, De Melo SW. Helicobacter pylori is Associated with Less Fistulizing, Stricturing, and Active Colitis in Crohn's Disease Patients. Cureus. 2019;11:e6226. [PMID: 31890426 DOI: 10.7759/cureus.6226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 296 |
Tang DM, Chascsa DM, Chou JY, Ho N, Auh S, Wank SA, Koh C, Kumar S. Helicobacter pyloriinfection is strongly associated with metabolic syndrome, and weakly associated with non‐alcoholic fatty liver disease, in a US Hispanic population. GastroHep 2019;1:325-331. [DOI: 10.1002/ygh2.375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 297 |
Majima A, Dohi O, Takayama S, Hirose R, Inoue K, Yoshida N, Kamada K, Uchiyama K, Ishikawa T, Takagi T, Handa O, Konishi H, Naito Y, Itoh Y. Linked color imaging identifies important risk factors associated with gastric cancer after successful eradication of Helicobacter pylori. Gastrointest Endosc 2019;90:763-9. [PMID: 31299258 DOI: 10.1016/j.gie.2019.06.043] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 298 |
Khani S, Talebi Bezmin Abadi A, Mohabati Mobarez A. Clarithromycin-Susceptible But Virulent Helicobacter pylori Strains Infecting Iranian Patients' Stomachs. Infect Drug Resist 2019;12:3415-20. [PMID: 31802920 DOI: 10.2147/IDR.S223602] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 299 |
Zou J, Xiao Y, Cheng Y, Ren X, Li S, Gang D. Investigation of Helicobacter pylori Infection and Its Related Factors in the Tianjin Binhai Area, China. Jundishapur J Microbiol 2019;12. [DOI: 10.5812/jjm.94845] [Reference Citation Analysis]
|
| 300 |
Miranda AC, Caldato C, Said MN, Levy CS, Teixeira CEC, Quaresma JAS. GENDER, AGE, ENDOSCOPIC FINDINGS, UREASE AND HELICOBACTER PYLORI : ALL UNCORRELATED WITHIN A SAMPLE OF A HIGH GASTRIC CANCER PREVALENCE POPULATION IN AMAZON. Arq Gastroenterol 2019;56:264-9. [PMID: 31633723 DOI: 10.1590/S0004-2803.201900000-50] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 301 |
Kouitcheu Mabeku LB, Eyoum Bille B, Tepap Zemnou C, Tali Nguefack LD, Leundji H. Broad spectrum resistance in Helicobacter pylori isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR isolates. BMC Infect Dis. 2019;19:880. [PMID: 31640588 DOI: 10.1186/s12879-019-4536-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 302 |
de Brito BB, da Silva FAF, Soares AS, Pereira VA, Santos MLC, Sampaio MM, Neves PHM, de Melo FF. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol 2019; 25(37): 5578-5589 [PMID: 31602159 DOI: 10.3748/wjg.v25.i37.5578] [Cited by in CrossRef: 91] [Cited by in F6Publishing: 95] [Article Influence: 22.8] [Reference Citation Analysis]
|
| 303 |
Morilla AM, Álvarez-argüelles ME, Duque JM, Armesto E, Villar H, Melón S. Primary antimicrobial resistance rates and prevalence of Helicobacter pylori infection in the north of Spain. A 13-year retrospective study. Gastroenterología y Hepatología (English Edition) 2019;42:476-485. [DOI: 10.1016/j.gastre.2019.05.003] [Reference Citation Analysis]
|
| 304 |
Ciccaglione AF, Cellini L, Marzio L. Pylera® plus ranitidine vs Pylera® plus esomeprazole in first-line treatment of Helicobacter pylori infection: Two pilot studies. Helicobacter 2019;24:e12606. [PMID: 31168941 DOI: 10.1111/hel.12606] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 305 |
Nahm JH, Kim WK, Kwon Y, Kim H. Detection of Helicobacter pylori with clarithromycin resistance-associated mutations using peptide nucleic acid probe-based melting point analysis. Helicobacter 2019;24:e12634. [PMID: 31304664 DOI: 10.1111/hel.12634] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 306 |
McNicholl AG, O'Morain CA, Megraud F, Gisbert JP; As Scientific Committee of the Hp-Eureg on Behalf of the National Coordinators. Protocol of the European Registry on the management of Helicobacter pylori infection (Hp-EuReg). Helicobacter 2019;24:e12630. [PMID: 31282060 DOI: 10.1111/hel.12630] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 307 |
Hanafiah A, Binmaeil H, Raja Ali RA, Mohamed Rose I, Lopes BS. Molecular characterization and prevalence of antibiotic resistance in Helicobacter pylori isolates in Kuala Lumpur, Malaysia. Infect Drug Resist. 2019;12:3051-3061. [PMID: 31632095 DOI: 10.2147/idr.s219069] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 308 |
Mendoza E, Duque X, Hernández Franco JI, Reyes Maldonado E, Morán S, Martínez G, Salinas Rodríguez A, Martínez H. Association between Active H. pylori Infection and Iron Deficiency Assessed by Serum Hepcidin Levels in School-Age Children. Nutrients 2019;11:E2141. [PMID: 31500264 DOI: 10.3390/nu11092141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 309 |
Wu L, Wang Z, Sun G, Peng L, Lu Z, Yan B, Huang K, Yang Y. Effects of anti-H. pylori triple therapy and a probiotic complex on intestinal microbiota in duodenal ulcer. Sci Rep 2019;9:12874. [PMID: 31492912 DOI: 10.1038/s41598-019-49415-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 310 |
Yatheendranathan GD, Ankaiya S, Kumar JL. Comparative Study between Two Triple-therapy Regimens in Treating Helicobacter pylori: Related Peptic Ulcer Disease. SBV Journal of Basic, Clinical and Applied Health Science 2019;2:108-111. [DOI: 10.5005/jp-journals-10082-02222] [Reference Citation Analysis]
|
| 311 |
Karatay E, Gül Utku Ö. FONKSİYONEL DİSPEPSİLİ HASTALARDA HELICOBAKTER PYLORI ERADİKASYONUNUN EPİGASTRİK AĞRI SKORU İLE DEĞERLENDİRİLMESİ. Kırıkkale Üniversitesi Tıp Fakültesi Dergisi 2019. [DOI: 10.24938/kutfd.563210] [Reference Citation Analysis]
|
| 312 |
Rizvanov AA, Haertlé T, Bogomolnaya L, Talebi Bezmin Abadi A. Helicobacter pylori and Its Antibiotic Heteroresistance: A Neglected Issue in Published Guidelines. Front Microbiol 2019;10:1796. [PMID: 31456763 DOI: 10.3389/fmicb.2019.01796] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 313 |
Feng ZH, Fan L, Yang J, Huo XY, Guo Y, Zhang Y, Lan CH. Mutant selection window of clarithromycin for clinical isolates of Helicobacter pylori. BMC Microbiol 2019;19:176. [PMID: 31382897 DOI: 10.1186/s12866-019-1558-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 314 |
Attia TZ, Yamashita T, Tsujino H, Derayea SM, Tsutsumi Y, Uno T. Effect of Drug Combination on Omeprazole Metabolism by Cytochrome P450 2C19 in Helicobacter pylori Eradication Therapy. Chem Pharm Bull (Tokyo) 2019;67:810-5. [PMID: 31366830 DOI: 10.1248/cpb.c19-00084] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 315 |
Jha SK, Mishra MK, Saharawat K, Jha P, Purkayastha S, Ranjan R. Comparison of concomitant therapy versus standard triple-drug therapy for eradication of Helicobacter pylori infection: A prospective open-label randomized controlled trial. Indian J Gastroenterol 2019;38:325-31. [PMID: 31520370 DOI: 10.1007/s12664-019-00949-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 316 |
Kato M, Ota H, Okuda M, Kikuchi S, Satoh K, Shimoyama T, Suzuki H, Handa O, Furuta T, Mabe K, Murakami K, Sugiyama T, Uemura N, Takahashi S. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition. Helicobacter 2019;24:e12597. [PMID: 31111585 DOI: 10.1111/hel.12597] [Cited by in Crossref: 94] [Cited by in F6Publishing: 85] [Article Influence: 23.5] [Reference Citation Analysis]
|
| 317 |
Han C, Ni Z, Yuan T, Zhang J, Wang C, Wang X, Ning HB, Liu J, Sun N, Liu CF, Shi M, Lu WQ, Shi YQ. Influence of serum vitamin D level on Helicobacter pylori eradication: A multi-center, observational, prospective and cohort study. J Dig Dis 2019;20:421-6. [PMID: 31145549 DOI: 10.1111/1751-2980.12793] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 318 |
Zhi X, Liu Y, Lin L, Yang M, Zhang L, Zhang L, Liu Y, Alfranca G, Ma L, Zhang Q, Fu H, Conde J, Ding X, Chen D, Ni J, Song J, Cui D. Oral pH sensitive GNS@ab nanoprobes for targeted therapy of Helicobacter pylori without disturbance gut microbiome. Nanomedicine: Nanotechnology, Biology and Medicine 2019;20:102019. [DOI: 10.1016/j.nano.2019.102019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 319 |
McNicholl AG, Amador J, Ricote M, Cañones-Garzón PJ, Gene E, Calvet X, Gisbert JP; Spanish Primary Care Societies SEMFyC, SEMERGEN and SEMG, the Spanish Association of Gastroenterology, OPTICARE Long-Term Educational Project. Spanish primary care survey on the management of Helicobacter pylori infection and dyspepsia: Information, attitudes, and decisions. Helicobacter 2019;24:e12593. [PMID: 31111627 DOI: 10.1111/hel.12593] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 320 |
Koletzko L, Macke L, Schulz C, Malfertheiner P. Helicobacter pylori eradication in dyspepsia: New evidence for symptomatic benefit. Best Pract Res Clin Gastroenterol 2019;40-41:101637. [PMID: 31594649 DOI: 10.1016/j.bpg.2019.101637] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 321 |
Morilla AM, Álvarez-Argüelles ME, Duque JM, Armesto E, Villar H, Melón S. Primary antimicrobial resistance rates and prevalence of Helicobacter pylori infection in the north of Spain. A 13-year retrospective study. Gastroenterol Hepatol 2019;42:476-85. [PMID: 31324461 DOI: 10.1016/j.gastrohep.2019.05.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 322 |
Mukaisho KI, Kanai S, Kushima R, Nakayama T, Hattori T, Sugihara H. Barretts's carcinogenesis. Pathol Int 2019;69:319-30. [PMID: 31290583 DOI: 10.1111/pin.12804] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 323 |
Sahan AZ, Venkova T, Sayed IM, Beswick EJ, Reyes VE, Pinchuk I, Sahoo D, Ghosh P, Hazra TK, Das S. NEIL2 plays a critical role in limiting inflammation and preserving genomic integrity in H. pylori-infected gastric epithelial cells.. [DOI: 10.1101/687962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 324 |
Ladrón-de-guevara L, Bornstein-quevedo L, González-huezo S, Castañeda-romero B, Costa F, di Silvio-lópez M. Helicobacter pylori eradication in Mexico with a levofloxacin-based scheme versus standard triple therapy: Results from an open-label, randomized, noninferiority phase IIIb trial. Revista de Gastroenterología de México (English Edition) 2019;84:274-283. [DOI: 10.1016/j.rgmxen.2018.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 325 |
Hamid Dawood Alatbee A. High prevalence of helicobacter pylori in Basra city Southern of Iraq. J Phys : Conf Ser 2019;1279:012073. [DOI: 10.1088/1742-6596/1279/1/012073] [Reference Citation Analysis]
|
| 326 |
Delchier JC, Bastuji-Garin S, Raymond J, Megraud F, Amiot A, Cambau E, Burucoa C; HELICOSTIC Study Group. Efficacy of a tailored PCR-guided triple therapy in the treatment of Helicobacter pylori infection. Med Mal Infect. 2020;50:492-499. [PMID: 31257067 DOI: 10.1016/j.medmal.2019.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 327 |
Nezami BG, Jani M, Alouani D, Rhoads DD, Sadri N. Helicobacter pylori Mutations Detected by Next-Generation Sequencing in Formalin-Fixed, Paraffin-Embedded Gastric Biopsy Specimens Are Associated with Treatment Failure. J Clin Microbiol. 2019;57:pii: e01834-18. [PMID: 31068413 DOI: 10.1128/jcm.01834-18] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 328 |
Yin J, Yi J, Yang C, Xu B, Lin J, Hu H, Wu X, Shi H, Fei X. Weiqi Decoction Attenuated Chronic Atrophic Gastritis with Precancerous Lesion through Regulating Microcirculation Disturbance and HIF-1α Signaling Pathway. Evid Based Complement Alternat Med 2019;2019:2651037. [PMID: 31320912 DOI: 10.1155/2019/2651037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 329 |
Bordin DS, Voynovan IN, Kolbasnikov SV, Embutnieks YV. Diagnosis of Helicobacter pylori infection in clinical practice. Ter Arkh 2018;90:133-9. [PMID: 30701845 DOI: 10.26442/00403660.2018.12.000020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 330 |
Eed EM, Hawash YA, Khalifa AS, Alsharif KF, Alghamdi SA, Saber T, Ismail KA, Shehab-Eldeen SA. Molecular diagnosis of Helicobacter pylori antibiotic resistance in the Taif region, Saudi Arabia. Microbiol Immunol 2019;63:199-205. [PMID: 31045263 DOI: 10.1111/1348-0421.12686] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 331 |
Tuan VP, Narith D, Tshibangu-Kabamba E, Dung HDQ, Viet PT, Sokomoth S, Binh TT, Sokhem S, Tri TD, Ngov S, Tung PH, Thuan NPM, Truc TC, Phuc BH, Matsumoto T, Fauzia KA, Akada J, Trang TTH, Yamaoka Y. A Next-Generation Sequencing-Based Approach to Identify Genetic Determinants of Antibiotic Resistance in Cambodian Helicobacter pylori Clinical Isolates. J Clin Med 2019;8:E858. [PMID: 31208076 DOI: 10.3390/jcm8060858] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 332 |
Bordin DS, Embutnieks YV, Vologzhanina LG, Il'chishina TA, Voinovan IN, Sarsenbaeva AS, Alekseenko SA, Zaitsev OV, Abdulkhakov RA, Osipenko MF, Livzan MA, Tsukanov VV, Burkov SG, Bakulina NV, Dekhnich NN, Tarasova LV, Plotnikova EY, Maev IV, Kucheryavyi YA, Baryshnikova NV, Butov MA, Kolbasnikov SV, Pakhomova AL, Zhestkova TV, Baranovskii AY, Abdulkhakov SR, Ageeva EA, Lyalyukova EA, Vasyutin AV, Golubev NN, Savilova IV, Morkovkina LV, Kononova AG, Megraud F, O'Morain C, Ramas M, Nyssen OP, McNicholl AG, Gisbert JP. European Registry on the management of Helicobacter pylori infection (Hp-EuReg): analysis of 2360 patients receiving first-line therapy in Russia. Ter Arkh 2018;90:35-42. [PMID: 30701770 DOI: 10.26442/terarkh201890235-42] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 333 |
Salillas S, Alías M, Michel V, Mahía A, Lucía A, Rodrigues L, Bueno J, Galano-frutos JJ, De Reuse H, Velázquez-campoy A, Carrodeguas JA, Sostres C, Castillo J, Aínsa JA, Díaz-de-villegas MD, Lanas Á, Touati E, Sancho J. Design, Synthesis, and Efficacy Testing of Nitroethylene- and 7-Nitrobenzoxadiazol-Based Flavodoxin Inhibitors against Helicobacter pylori Drug-Resistant Clinical Strains and in Helicobacter pylori -Infected Mice. J Med Chem 2019;62:6102-15. [DOI: 10.1021/acs.jmedchem.9b00355] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 334 |
Gebeyehu E, Nigatu D, Engidawork E. Helicobacter pylori eradication rate of standard triple therapy and factors affecting eradication rate at Bahir Dar city administration, Northwest Ethiopia: A prospective follow up study. PLoS One 2019;14:e0217645. [PMID: 31163069 DOI: 10.1371/journal.pone.0217645] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 335 |
Baylina M, Muñoz N, Sánchez-Delgado J, López-Góngora S, Calvet X, Puig I. Systematic review: Would susceptibility-guided treatment achieve acceptable cure rates for second-line Helicobacter pylori therapy as currently practiced? Helicobacter 2019;24:e12584. [PMID: 30990575 DOI: 10.1111/hel.12584] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 336 |
Kowada A. Cost-effectiveness of Helicobacter pylori test and eradication versus upper gastrointestinal series versus endoscopy for gastric cancer mortality and outcomes in high prevalence countries. Scand J Gastroenterol 2019;54:685-9. [PMID: 31190581 DOI: 10.1080/00365521.2019.1627408] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 337 |
Lyu QJ, Pu QH, Zhong XF, Zhang J. Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials. Biomed Res Int 2019;2019:9781212. [PMID: 31211144 DOI: 10.1155/2019/9781212] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 338 |
Lopes-de-Campos D, Pinto RM, Lima SAC, Santos T, Sarmento B, Nunes C, Reis S. Delivering amoxicillin at the infection site - a rational design through lipid nanoparticles. Int J Nanomedicine 2019;14:2781-95. [PMID: 31114195 DOI: 10.2147/IJN.S193992] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 339 |
Chakravarty K, Gaur S. Role of Probiotics in Prophylaxis of Helicobacter pylori Infection. CPB 2019;20:137-45. [DOI: 10.2174/1389201020666190227203107] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 340 |
Abadi ATB, Ierardi E. Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon? Front Pharmacol. 2019;10:316. [PMID: 31024299 DOI: 10.3389/fphar.2019.00316] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 341 |
Hays C, Delerue T, Lamarque D, Burucoa C, Collobert G, Billöet A, Kalach N, Raymond J. Molecular diagnosis of Helicobacter pylori infection in gastric biopsies: Evaluation of the Amplidiag(®) H. pylori + ClariR assay. Helicobacter 2019;24:e12560. [PMID: 30548730 DOI: 10.1111/hel.12560] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 342 |
Sałagacka-kubiak A, Żebrowska-nawrocka M, Jeleń A, Mirowski M, Balcerczak E. CYP2C19*2 polymorphism in Polish peptic ulcer patients. Pharmacological Reports 2019;71:272-5. [DOI: 10.1016/j.pharep.2018.12.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 343 |
Shi X, Zhang J, Mo L, Shi J, Qin M, Huang X. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore) 2019;98:e15180. [PMID: 30985706 DOI: 10.1097/MD.0000000000015180] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 15.8] [Reference Citation Analysis]
|
| 344 |
Høgh MB, Kronborg C, Hansen JM, Schaffalitzky de Muckadell OB. The cost effectiveness of Helicobacter pylori population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up. Aliment Pharmacol Ther 2019;49:1013-25. [PMID: 30854700 DOI: 10.1111/apt.15193] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 345 |
Tran VH. EFFICACY OF MODIFIED BISMUTH QUADRUPLE THERAPY (RBMA) AS FIRST-LINE THERAPY FOR ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH CHRONIC GASTRITIS. JMP 2019. [DOI: 10.34071/jmp.2019.2.5] [Reference Citation Analysis]
|
| 346 |
Dore MP, Bibbò S, Pes GM, Francavilla R, Graham DY. Role of Probiotics in Helicobacter pylori Eradication: Lessons from a Study of Lactobacillus reuteri Strains DSM 17938 and ATCC PTA 6475 (Gastrus®) and a Proton-Pump Inhibitor. Can J Infect Dis Med Microbiol 2019;2019:3409820. [PMID: 31065301 DOI: 10.1155/2019/3409820] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 347 |
Zhang XY, Shen WX, Chen CF, Sheng HH, Cheng H, Li J, Hu F, Lu DR, Gao HJ. Detection of the clarithromycin resistance of Helicobacter pylori in gastric mucosa by the amplification refractory mutation system combined with quantitative real-time PCR. Cancer Med. 2019;8:1633-1640. [PMID: 30864275 DOI: 10.1002/cam4.1986] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 348 |
Lim H. Refractory Peptic Ulcer Disease. Korean J Helicobacter Up Gastrointest Res 2019;19:5-9. [DOI: 10.7704/kjhugr.2019.19.1.5] [Reference Citation Analysis]
|
| 349 |
Li P, Chen X, Shen Y, Li H, Zou Y, Yuan G, Hu P, Hu H. Mucus penetration enhanced lipid polymer nanoparticles improve the eradication rate of Helicobacter pylori biofilm. J Control Release 2019;300:52-63. [PMID: 30825476 DOI: 10.1016/j.jconrel.2019.02.039] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 350 |
Farid AS, Hegazy AM. Ameliorative effects of Moringa oleifera leaf extract on levofloxacin-induced hepatic toxicity in rats. Drug Chem Toxicol 2020;43:616-22. [PMID: 30782023 DOI: 10.1080/01480545.2019.1574811] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 351 |
Ge L, Moon RC, Nguyen H, de Quadros LG, Teixeira AF, Jawad MA. Pathologic findings of the removed stomach during sleeve gastrectomy. Surg Endosc 2019;33:4003-7. [PMID: 30771070 DOI: 10.1007/s00464-019-06689-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 352 |
Fontes LES, Martimbianco ALC, Zanin C, Riera R. N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev 2019;2:CD012357. [PMID: 30746681 DOI: 10.1002/14651858.CD012357.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 353 |
Sabbagh P, Javanian M, Koppolu V, Vasigala VR, Ebrahimpour S. Helicobacter pylori infection in children: an overview of diagnostic methods. Eur J Clin Microbiol Infect Dis 2019;38:1035-45. [PMID: 30734129 DOI: 10.1007/s10096-019-03502-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 354 |
Yoon H, Lee DH, Lee YH, Jeong JC, Lee ST, Choi MG, Jeon SW, Shim KN, Baik GH, Kim JG, Moon JS, Sung IK, Lee SK, Rhee PL, Jung HY, Lee BE, Kim HS, Kim SG, Lee KM, Seong JK, Jang JS, Park JJ. Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia: A Randomized, Controlled Trial. Gut Liver 2018;12:516-22. [PMID: 29938452 DOI: 10.5009/gnl17416] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 355 |
Graham DY, Lu H, Dore MP. Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI. Helicobacter 2019;24:e12554. [PMID: 30440097 DOI: 10.1111/hel.12554] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 356 |
Pittayanon R, Leelakusolvong S, Vilaichone RK, Rojborwonwitaya J, Treeprasertsuk S, Mairiang P, Chirnaksorn S, Chitapanarux T, Kaosombatwattana U, Sottisuporn J, Sansak I, Phisalprapa P, Bunchorntavakul C, Chuenrattanakul S, Chakkaphak S, Boonsirichan R, Wiwattanachang O, Maneerattanaporn M, Piyanirun W, Mahachai V. Thailand Dyspepsia Guidelines: 2018. J Neurogastroenterol Motil 2019;25:15-26. [PMID: 30504528 DOI: 10.5056/jnm18081] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 357 |
Shi Y, Wang P, Guo Y, Liang X, Li Y, Ding S. Helicobacter pylori-Induced DNA Damage Is a Potential Driver for Human Gastric Cancer AGS Cells. DNA Cell Biol 2019;38:272-80. [PMID: 30657337 DOI: 10.1089/dna.2018.4487] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 358 |
Urrutia-Baca VH, Escamilla-García E, de la Garza-Ramos MA, Tamez-Guerra P, Gomez-Flores R, Urbina-Ríos CS. In Vitro Antimicrobial Activity and Downregulation of Virulence Gene Expression on Helicobacter pylori by Reuterin. Probiotics Antimicrob Proteins 2018;10:168-75. [PMID: 29103130 DOI: 10.1007/s12602-017-9342-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 359 |
Chapman W, Siau K, Thomas F, Ernest S, Begum S, Iqbal T, Bhala N. Acute upper gastrointestinal bleeding: a guide for nurses. Br J Nurs 2019;28:53-9. [PMID: 30620657 DOI: 10.12968/bjon.2019.28.1.53] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 360 |
Kohler V, Vaishampayan A, Grohmann E. Problematic Groups of Multidrug-Resistant Bacteria and Their Resistance Mechanisms. Antibacterial Drug Discovery to Combat MDR 2019. [DOI: 10.1007/978-981-13-9871-1_2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 361 |
Samakar K, Dobrowolsky AB. Evaluation and Management: Recurrent Peptic Ulcer Disease. The SAGES Manual of Foregut Surgery 2019. [DOI: 10.1007/978-3-319-96122-4_62] [Reference Citation Analysis]
|
| 362 |
Mitchell HM. Helicobacter pylori in Sub-Saharan Africa. Digestive Diseases in Sub-Saharan Africa 2019. [DOI: 10.1016/b978-0-12-815677-3.00009-8] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 363 |
Maev IV, Drapkina ON, Lazebnik LB. Statements for an algorithm for the management of primary unexamined patients with symptoms of dyspepsia in primary health care. Profil med 2019;22:35. [DOI: 10.17116/profmed20192201135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 364 |
Zanotti G, Cendron L. Structural Aspects of Helicobacter pylori Antibiotic Resistance. Adv Exp Med Biol 2019;1149:227-41. [PMID: 31016632 DOI: 10.1007/5584_2019_368] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 365 |
Rugge M, Meggio A, Pravadelli C, Barbareschi M, Fassan M, Gentilini M, Zorzi M, Pretis G, Graham DY, Genta RM. Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut 2019;68:11-7. [PMID: 29306868 DOI: 10.1136/gutjnl-2017-314600] [Cited by in Crossref: 90] [Cited by in F6Publishing: 92] [Article Influence: 22.5] [Reference Citation Analysis]
|
| 366 |
Salar A. Gastric MALT lymphoma and Helicobacter pylori. Medicina Clínica (English Edition) 2019;152:65-71. [DOI: 10.1016/j.medcle.2018.09.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 367 |
Wu JY, Lee YC, Graham DY. The eradication of Helicobacter pylori to prevent gastric cancer: a critical appraisal. Expert Rev Gastroenterol Hepatol 2019;13:17-24. [PMID: 30791844 DOI: 10.1080/17474124.2019.1542299] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 368 |
Yucel O. Interactions between Helicobacter pylori and gastroesophageal reflux disease. Esophagus 2019;16:52-62. [PMID: 30151653 DOI: 10.1007/s10388-018-0637-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 369 |
Lohse AW, Mössner J. Magen-Darm-Mittel und Lebertherapeutika. Arzneiverordnungs-Report 2019 2019. [DOI: 10.1007/978-3-662-59046-1_34] [Reference Citation Analysis]
|
| 370 |
Matsumoto H, Shiotani A, Graham DY. Current and Future Treatment of Helicobacter pylori Infections. Adv Exp Med Biol 2019;1149:211-25. [PMID: 31016626 DOI: 10.1007/5584_2019_367] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 371 |
Bang Y, Oh D, Yang H, Kim SG, Kim W. Gastric Cancer. Textbook of Gastrointestinal Oncology 2019. [DOI: 10.1007/978-3-030-18890-0_5] [Reference Citation Analysis]
|
| 372 |
Hong SS, Lee HA, Kim JY, Jeong JW, Shim JJ, Lee JL, Sim JH, Chung Y, Kim O. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacilllus paracasei HP7. Lab Anim Res 2018;34:216-22. [PMID: 30671108 DOI: 10.5625/lar.2018.34.4.216] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 373 |
Valean S, Chira R, Dumitrascu D. Epidemiological trends in digestive cancers in Romania, 1955-2012, compared to alcohol consumption. Correlation or coincidence? Clujul Med 2018;91:376-86. [PMID: 30564012 DOI: 10.15386/cjmed-1067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 374 |
Bińkowska A, Biernat MM, Łaczmański Ł, Gościniak G. Molecular Patterns of Resistance Among Helicobacter pylori Strains in South-Western Poland. Front Microbiol 2018;9:3154. [PMID: 30619218 DOI: 10.3389/fmicb.2018.03154] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 375 |
Kayali S, Manfredi M, Gaiani F, Bianchi L, Bizzarri B, Leandro G, Di Mario F, De' Angelis GL. Helicobacter pylori, transmission routes and recurrence of infection: state of the art. Acta Biomed. 2018;89:72-76. [PMID: 30561421 DOI: 10.23750/abm.v89i8-s.7947] [Cited by in F6Publishing: 24] [Reference Citation Analysis]
|
| 376 |
Kayali S, Aloe R, Bonaguri C, Gaiani F, Manfredi M, Leandro G, Fornaroli F, Di Mario F, De' Angelis GL. Non-invasive tests for the diagnosis of helicobacter pylori: state of the art. Acta Biomed 2018;89:58-64. [PMID: 30561419 DOI: 10.23750/abm.v89i8-S.7910] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
|
| 377 |
Huang L, Wang ZY, Pan DD. Penicillin‑binding protein 1A mutation‑positive Helicobacter pylori promotes epithelial‑mesenchymal transition in gastric cancer via the suppression of microRNA‑134. Int J Oncol 2019;54:916-28. [PMID: 30569124 DOI: 10.3892/ijo.2018.4665] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 378 |
Cerqueira RM, Correia M, Vilar H, Manso MC. Cumulative Helicobacter Pylori Eradication Rates by Adopting First- and Second- Line Regimens Proposed by the Maastricht IV Consensus in Obese Patients Undergoing Gastric Bypass Surgery. Obes Surg 2018;28:743-7. [PMID: 29076008 DOI: 10.1007/s11695-017-2915-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 379 |
Kumar NS, Devi TR, Singh KG. PREVALENCE OF HELICOBACTER PYLORI INFECTION IN PATIENTS WITH ACUTE PEPTIC ULCER BLEEDING IN A TERTIARY CARE HOSPITAL IN MANIPUR. jemds 2018;7:5340-5342. [DOI: 10.14260/jemds/2018/1182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 380 |
Muñoz N, Sánchez-delgado J, Baylina M, López-góngora S, Calvet X. Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic review. Gastroenterología y Hepatología (English Edition) 2018;41:654-662. [DOI: 10.1016/j.gastre.2018.11.021] [Reference Citation Analysis]
|
| 381 |
White JR, Sami SS, Reddiar D, Mannath J, Ortiz-Fernández-Sordo J, Beg S, Scott R, Thiagarajan P, Ahmad S, Parra-Blanco A, Kasi M, Telakis E, Sultan AA, Davis J, Figgins A, Kaye P, Robinson K, Atherton JC, Ragunath K. Narrow band imaging and serology in the assessment of premalignant gastric pathology. Scand J Gastroenterol 2018;53:1611-8. [PMID: 30600732 DOI: 10.1080/00365521.2018.1542455] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 382 |
Dekhnich N, Ivanchik N, Kozlov R, Alimov A, Steshits A, Kirsov P, Pandav K. Dynamics of antimicrobial resistance of Helicobacter pylori isolates in the Smolensk region of Russian Federation. Helicobacter 2018;23:e12545. [PMID: 30324756 DOI: 10.1111/hel.12545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 383 |
Fann JC, Chiang TH, Yen AM, Lee YC, Wu MS, Chen HH. Personalized risk assessment for dynamic transition of gastric neoplasms. J Biomed Sci 2018;25:84. [PMID: 30453970 DOI: 10.1186/s12929-018-0485-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 384 |
Salar A. Gastric MALT lymphoma and Helicobacter pylori. Med Clin (Barc). 2019;152:65-71. [PMID: 30424932 DOI: 10.1016/j.medcli.2018.09.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 385 |
Sabbagh P, Mohammadnia-afrouzi M, Javanian M, Babazadeh A, Koppolu V, Vasigala VR, Nouri HR, Ebrahimpour S. Diagnostic methods for Helicobacter pylori infection: ideals, options, and limitations. Eur J Clin Microbiol Infect Dis 2019;38:55-66. [DOI: 10.1007/s10096-018-3414-4] [Cited by in Crossref: 51] [Cited by in F6Publishing: 59] [Article Influence: 10.2] [Reference Citation Analysis]
|
| 386 |
Khadka P, Chapagain G, Maharjan G, Paudyal P. A comparison of techniques to address the frequency of Helicobacter pylori positive dyspeptic patient. BMC Res Notes 2018;11:784. [PMID: 30390715 DOI: 10.1186/s13104-018-3897-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 387 |
Leow AH, Azmi AN, Loke MF, Vadivelu J, Graham DY, Goh KL. Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better? J Dig Dis 2018;19:674-7. [PMID: 30307122 DOI: 10.1111/1751-2980.12679] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 388 |
Sabry D, Abdelaleem OO, Hefzy EM, Ibrahim AA, Ahmed TI, Hassan EA, Abdel-hameed ND, Khalil MA. Interplay Between Helicobacter pylori Infection, Interleukin-11, and Leukemia Inhibitory Factor in Gastric Cancer Among Egyptian Patients. Journal of Interferon & Cytokine Research 2018;38:517-25. [DOI: 10.1089/jir.2018.0065] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 389 |
Ribaldone DG, Astegiano M, Saracco G, Pellicano R. Amoxycillin and Metronidazole Therapy for Helicobacter pylori Eradication: A 10-Year Trend in Turin, Italy. Balkan Med J 2017;34:290-1. [PMID: 28559221 DOI: 10.4274/balkanmedj.2015.1714] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 390 |
Lin TJ, Lee HC, Lin CL, Wang CK, Chen KY, Wu DC. CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication. World J Clin Cases 2018; 6(12): 514-520 [PMID: 30397607 DOI: 10.12998/wjcc.v6.i12.514] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 391 |
Luo PJ, Lin XH, Lin CC, Luo JC, Hu HY, Ting PH, Hou MC. Risk factors for upper gastrointestinal bleeding among aspirin users: An old issue with new findings from a population-based cohort study. J Formos Med Assoc. 2019;118:939-944. [PMID: 30366771 DOI: 10.1016/j.jfma.2018.10.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 392 |
Song HY, Zhou L, Liu DY, Yao XJ, Li Y. What Roles Do Probiotics Play in the Eradication of Helicobacter pylori? Current Knowledge and Ongoing Research. Gastroenterol Res Pract 2018;2018:9379480. [PMID: 30410538 DOI: 10.1155/2018/9379480] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 393 |
Liou JM, Chen PY, Kuo YT, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Toward population specific and personalized treatment of Helicobacter pylori infection. J Biomed Sci 2018;25:70. [PMID: 30285834 DOI: 10.1186/s12929-018-0471-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 394 |
McNicholl AG, Molina-Infante J, Lucendo AJ, Calleja JL, Pérez-Aisa Á, Modolell I, Aldeguer X, Calafat M, Comino L, Ramas M, Callejo Á, Badiola C, Serra J, Gisbert JP. Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: A randomized, double-blind, placebo-controlled trial. Helicobacter 2018;23:e12529. [PMID: 30141228 DOI: 10.1111/hel.12529] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 395 |
Hamza D, Elhelw R, Elhariri M, Ragab E. Genotyping and antimicrobial resistance patterns of Helicobacter pylori in human and dogs associated with A2142G and A2143G point mutations in clarithromycin resistance. Microbial Pathogenesis 2018;123:330-8. [DOI: 10.1016/j.micpath.2018.07.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 396 |
Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. Nichidai Igaku Zasshi 2018;77:333-334. [DOI: 10.4264/numa.77.5_333] [Reference Citation Analysis]
|
| 397 |
Silva GM, Silva HM, Nascimento J, Gonçalves JP, Pereira F, Lima R. Helicobacter pylori antimicrobial resistance in a pediatric population. Helicobacter 2018;23:e12528. [PMID: 30091503 DOI: 10.1111/hel.12528] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 398 |
Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, Pellegatta G, Coppo C, Savarino E. The appropriate use of proton-pump inhibitors. Minerva Med 2018;109. [DOI: 10.23736/s0026-4806.18.05705-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 399 |
Diab M, El-shenawy A, El-ghannam M, Salem D, Abdelnasser M, Shaheen M, Abdel-hady M, El-sherbini E, Saber M. Detection of antimicrobial resistance genes of Helicobacter pylori strains to clarithromycin, metronidazole, amoxicillin and tetracycline among Egyptian patients. Egyptian Journal of Medical Human Genetics 2018;19:417-23. [DOI: 10.1016/j.ejmhg.2018.01.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 400 |
Kesici U. Üst gastrointestinal sistem endoskopisi yapılan hastalarda intestinal metaplazi ve Helikobakter pylori skorlarının karşılaştırılması. Cukurova Medical Journal 2018;43:574-580. [DOI: 10.17826/cumj.338949] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 401 |
Talebi Bezmin Abadi A, Kusters JG. Future of Helicobacter pylori and its feasibility. Expert Review of Anti-infective Therapy 2018;16:733-5. [DOI: 10.1080/14787210.2018.1523715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 402 |
Ozaki H, Harada S, Takeuchi T, Kawaguchi S, Takahashi Y, Kojima Y, Ota K, Hongo Y, Ashida K, Sakaguchi M, Tokioka S, Sakamoto H, Furuta T, Tominaga K, Higuchi K. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy. Digestion 2018;97:212-8. [PMID: 29393194 DOI: 10.1159/000485097] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 403 |
Toscano EP, Madeira FF, Dutra-Rulli MP, Gonçalves LOM, Proença MA, Borghi VS, Cadamuro ACT, Mazzale GW, Acayaba R, Silva AE. Epidemiological and Clinical-Pathological Aspects of Helicobacter pylori Infection in Brazilian Children and Adults. Gastroenterol Res Pract 2018;2018:8454125. [PMID: 30254670 DOI: 10.1155/2018/8454125] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 404 |
Muñoz N, Sánchez-Delgado J, Baylina M, López-Góngora S, Calvet X. Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic review. Gastroenterol Hepatol 2018;41:654-62. [PMID: 30180998 DOI: 10.1016/j.gastrohep.2018.06.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 405 |
Talebi Bezmin Abadi A, Yamaoka Y. Helicobacter pylori therapy and clinical perspective. Journal of Global Antimicrobial Resistance 2018;14:111-7. [DOI: 10.1016/j.jgar.2018.03.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 406 |
Kabakambira JD, Hategeka C, Page C, Ntirenganya C, Dusabejambo V, Ndoli J, Ngabonziza F, Hale D, Bayingana C, Walker T. Efficacy of Helicobacter pylori eradication regimens in Rwanda: A randomized controlled trial. BMC Gastroenterol. 2018;18:134. [PMID: 30165823 DOI: 10.1186/s12876-018-0863-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 407 |
Zhang Y, Liu Y, Song R, Zhang L, Su Z, Li Y, Chen R, Shi N, Zhao X, Du S, Ding X. Validating traditional Chinese syndrome features in varied stages of chronic gastritis malignant transformation: study protocol for a cross-sectional study. BMJ Open 2018;8:e020939. [PMID: 30166291 DOI: 10.1136/bmjopen-2017-020939] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 408 |
Shiotani A, Katsumata R, Gouda K, Fukushima S, Nakato R, Murao T, Ishii M, Fujita M, Matsumoto H, Sakakibara T. Hypergastrinemia in Long-Term Use of Proton Pump Inhibitors. Digestion 2018;97:154-62. [PMID: 29310112 DOI: 10.1159/000484688] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 409 |
Tsay FW, Hsu PI. H. pylori infection and extra-gastroduodenal diseases. J Biomed Sci. 2018;25:65. [PMID: 30157866 DOI: 10.1186/s12929-018-0469-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 48] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 410 |
Okushin K, Tsutsumi T, Ikeuchi K, Kado A, Enooku K, Fujinaga H, Moriya K, Yotsuyanagi H, Koike K. Helicobacter pylori infection and liver diseases: Epidemiology and insights into pathogenesis. World J Gastroenterol 2018; 24(32): 3617-3625 [PMID: 30166857 DOI: 10.3748/wjg.v24.i32.3617] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 411 |
Afzali S, Mandegary A, Alimolaei M, Heidari M. Seroprevalence of Anti-Helicobacter pylori and Anti-CagA IgG Antibodies in Iranian Dyspeptic Patients. Int J Enteric Pathog 2018;6:56-9. [DOI: 10.15171/ijep.2018.16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 412 |
Graham DY, Dore MP, Lu H. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti Infect Ther. 2018;16:679-687. [PMID: 30102559 DOI: 10.1080/14787210.2018.1511427] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 413 |
Shiotani A, Lu H, Dore MP, Graham DY. Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. Cleve Clin J Med. 2017;84:310-318. [PMID: 28388387 DOI: 10.3949/ccjm.84a.14110] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 414 |
Westerik N, Reid G, Sybesma W, Kort R. The Probiotic Lactobacillus rhamnosus for Alleviation of Helicobacter pylori-Associated Gastric Pathology in East Africa. Front Microbiol 2018;9:1873. [PMID: 30154777 DOI: 10.3389/fmicb.2018.01873] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 415 |
An Y, Wang Y, Wu S, Wang YH, Qian X, Li Z, Fu YJ, Xie Y. Fourth-generation quinolones in the treatment of Helicobacter pylori infection: A meta-analysis. World J Gastroenterol 2018; 24(29): 3302-3312 [PMID: 30090010 DOI: 10.3748/wjg.v24.i29.3302] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 416 |
Coumes S, Froissart B, Wion N, Reche F, Arvieux C, Borel AL. Prevalence and Factors Associated with Helicobacter Pylori in Patients Undergoing Bariatric Surgery: the SOON Cohort. Obes Surg 2018;28:3958-64. [PMID: 30076561 DOI: 10.1007/s11695-018-3440-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 417 |
Blümel B, Goelz H, Kist M, Glocker EO. Retrospective study on outcome of salvage Helicobacter pylori eradication therapies based on molecular genetic susceptibility testing. Helicobacter 2018;23:e12494. [PMID: 29873430 DOI: 10.1111/hel.12494] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 418 |
Kotilea K, Kalach N, Homan M, Bontems P. Helicobacter pylori Infection in Pediatric Patients: Update on Diagnosis and Eradication Strategies. Paediatr Drugs 2018;20:337-51. [PMID: 29785564 DOI: 10.1007/s40272-018-0296-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 419 |
Rech TF, Mazzoleni LE, Mazzoleni F, Francesconi CFM, Sander GB, Michita RT, Nabinger DD, Milbradt TC, Torresini RJS, Simon D. Helicobacter pylori eradication: influence of interleukin-1beta -31 C/T polymorphism. Braz J Infect Dis 2018;22:311-6. [PMID: 30048609 DOI: 10.1016/j.bjid.2018.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 420 |
Ladrón-de-Guevara L, Bornstein-Quevedo L, González-Huezo S, Castañeda-Romero B, Costa FG, di Silvio-López M. Helicobacter pylori eradication in Mexico with a levofloxacin-based scheme versus standard triple therapy: Results from an open-label, randomized, noninferiority phase iiib trial. Rev Gastroenterol Mex (Engl Ed) 2019;84:274-83. [PMID: 30060902 DOI: 10.1016/j.rgmx.2018.04.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 421 |
Shao L, Li P, Ye J, Chen J, Han Y, Cai J, Lu X. Risk of gastric cancer among patients with gastric intestinal metaplasia. Int J Cancer. 2018;. [PMID: 29707766 DOI: 10.1002/ijc.31571] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 422 |
Chu MHK, Wu IXY, Ho RST, Wong CHL, Zhang AL, Zhang Y, Wu JCY, Chung VCH. Chinese herbal medicine for functional dyspepsia: systematic review of systematic reviews. Therap Adv Gastroenterol 2018;11:1756284818785573. [PMID: 30034530 DOI: 10.1177/1756284818785573] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 423 |
Fabricio Guaman J, Bayas-morejon IF, Arcos V, Tigre-leon A, Lucio-quintana A, Salazar S, Gaibor-chavez J, Ramon Curay R. Detection of Helicobacter pylori from Human Biological Samples (Feces) by Antigenic Screening and Culture. Jundishapur J Microbiol 2018;11. [DOI: 10.5812/jjm.66721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 424 |
Jiang J, Shen S, Dong N, Liu J, Xu Q, Sun L, Yuan Y. Correlation between negative expression of pepsinogen C and a series of phenotypic markers of gastric cancer in different gastric diseases. Cancer Med 2018;7:4068-76. [PMID: 29963765 DOI: 10.1002/cam4.1615] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 425 |
El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF, Crowe SE, Elfant A, Haas T, Hapke RJ, Graham DY. Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clin Gastroenterol Hepatol 2018;16:992-1002.e6. [PMID: 29559361 DOI: 10.1016/j.cgh.2018.03.013] [Cited by in Crossref: 134] [Cited by in F6Publishing: 139] [Article Influence: 26.8] [Reference Citation Analysis]
|
| 426 |
Zhu R, Gao C, Wang L, Zhang G, Zhang W, Zhang Z, Shen L, Wang S. Involvement of Aryl Hydrocarbon Receptor and Aryl Hydrocarbon Receptor Repressor in Helicobacter Pylori-related Gastric Pathogenesis. J Cancer 2018;9:2757-64. [PMID: 30087718 DOI: 10.7150/jca.26083] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 427 |
Caicedo Ochoa EY, Quintero Moreno CO, Méndez Fandiño YR, Sánchez Fonseca SC, Cortes Motta HF, Guio Guerra SA. Assessment of the use of vitamin C and E supplements concomitantly to antibiotic treatment against Helicobacter pylori : A systematic review and meta-analysis. Medicina Clínica (English Edition) 2018;151:45-52. [DOI: 10.1016/j.medcle.2018.05.016] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 428 |
Sierra JC, Asim M, Verriere TG, Piazuelo MB, Suarez G, Romero-Gallo J, Delgado AG, Wroblewski LE, Barry DP, Peek RM Jr, Gobert AP, Wilson KT. Epidermal growth factor receptor inhibition downregulates Helicobacter pylori-induced epithelial inflammatory responses, DNA damage and gastric carcinogenesis. Gut 2018;67:1247-60. [PMID: 28473630 DOI: 10.1136/gutjnl-2016-312888] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 9.4] [Reference Citation Analysis]
|
| 429 |
Tanabe H, Yoshino K, Ando K, Nomura Y, Ohta K, Satoh K, Ichiishi E, Ishizuka A, Otake T, Kohgo Y, Fujiya M, Okumura T. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Clin Microbiol Antimicrob 2018;17:29. [PMID: 29950163 DOI: 10.1186/s12941-018-0281-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 430 |
Alkim H, Koksal AR, Boga S, Sen I, Alkim C. Role of Bismuth in the Eradication of Helicobacter pylori. Am J Ther 2017;24:e751-7. [PMID: 26808355 DOI: 10.1097/MJT.0000000000000389] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 431 |
Valla K, Flowers CR, Koff JL. Targeting the B cell receptor pathway in non-Hodgkin lymphoma. Expert Opin Investig Drugs 2018;27:513-22. [PMID: 29855199 DOI: 10.1080/13543784.2018.1482273] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 432 |
Seid A, Demsiss W. Feco-prevalence and risk factors of Helicobacter pylori infection among symptomatic patients at Dessie Referral Hospital, Ethiopia. BMC Infect Dis. 2018;18:260. [PMID: 29879914 DOI: 10.1186/s12879-018-3179-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 433 |
Shu X, Yin G, Liu M, Peng K, Zhao H, Jiang M. Antibiotics resistance of Helicobacter pylori in children with upper gastrointestinal symptoms in Hangzhou, China. Helicobacter 2018;23:e12481. [PMID: 29528162 DOI: 10.1111/hel.12481] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 434 |
Venneman K, Huybrechts I, Gunter MJ, Vandendaele L, Herrero R, Van Herck K. The epidemiology of Helicobacter pylori infection in Europe and the impact of lifestyle on its natural evolution toward stomach cancer after infection: A systematic review. Helicobacter 2018;23:e12483. [PMID: 29635869 DOI: 10.1111/hel.12483] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 435 |
Park H, Park JJ, Park YM, Baik SJ, Lee HJ, Jung DH, Kim JH, Youn YH, Park H. The association between Helicobacter pylori infection and the risk of advanced colorectal neoplasia may differ according to age and cigarette smoking. Helicobacter 2018;23:e12477. [PMID: 29600573 DOI: 10.1111/hel.12477] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 436 |
Shim KN, Kim JI, Kim N, Kim SG, Jo YJ, Hong SJ, Shin JE, Kim GH, Park KS, Choi SC, Kwon JG, Kim JH, Kim HJ, Kim JW. The efficacy and safety of irsogladine maleate in nonsteroidal anti-inflammatory drug or aspirin-induced peptic ulcer and gastritis. Korean J Intern Med 2019;34:1008-21. [PMID: 29847892 DOI: 10.3904/kjim.2017.370] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 437 |
Muñoz N, Sánchez-Delgado J, Baylina M, Puig I, López-Góngora S, Suarez D, Calvet X. Systematic review, meta-analysis, and meta-regression: Successful second-line treatment for Helicobacter pylori. Helicobacter 2018;23:e12488. [PMID: 29663581 DOI: 10.1111/hel.12488] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 438 |
Lopes-de-Campos D, Nunes C, Sarmento B, Jakobtorweihen S, Reis S. Metronidazole within phosphatidylcholine lipid membranes: New insights to improve the design of imidazole derivatives. Eur J Pharm Biopharm 2018;129:204-14. [PMID: 29859282 DOI: 10.1016/j.ejpb.2018.05.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 439 |
Talebi Bezmin Abadi A. Diagnosis of Helicobacter pylori Using Invasive and Noninvasive Approaches. J Pathog 2018;2018:9064952. [PMID: 29951318 DOI: 10.1155/2018/9064952] [Cited by in Crossref: 28] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 440 |
Chung JW, Kim SY, Park HJ, Chung CS, Lee HW, Lee SM, Kim I, Pak JH, Lee GH, Jeong JY. In Vitro Activity of Diphenyleneiodonium toward Multidrug-Resistant Helicobacter pylori Strains. Gut Liver. 2017;11:648-654. [PMID: 28750485 DOI: 10.5009/gnl16503] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 441 |
Szadkowski A, Zemlak M, Muszyński J. Effectiveness of Helicobacter pylori eradication established on the basis of examination of antibiotic resistance of the bacteria. Prz Gastroenterol 2018;13:93-8. [PMID: 30002766 DOI: 10.5114/pg.2018.75821] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 442 |
Wang XY, Chen SH, Zhang YN, Xu CF. Olfactomedin-4 in digestive diseases: A mini-review. World J Gastroenterol 2018; 24(17): 1881-1887 [PMID: 29740203 DOI: 10.3748/wjg.v24.i17.1881] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 443 |
Shapla UM, Raihan J, Islam A, Alam F, Solayman N, Gan SH, Hossen S, Khalil I. Propolis: The future therapy against Helicobacter pylori-mediated gastrointestinal diseases. J Appl Biomed 2018;16:81-99. [DOI: 10.1016/j.jab.2017.10.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 444 |
Kwon S, Lee DH, Kang JB, Kim N, Park YS, Shin CM, Yoon H, Choi YJ. [The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication]. Korean J Gastroenterol 2018;71:196-203. [PMID: 29684968 DOI: 10.4166/kjg.2018.71.4.196] [Reference Citation Analysis]
|
| 445 |
Pintar T, Kaliterna N, Carli T. The need for a patient-tailored Helicobacter pylori eradication protocol prior to bariatric surgery. J Int Med Res 2018;46:2696-707. [PMID: 29690823 DOI: 10.1177/0300060518769543] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 446 |
D’silva M, Bhasker AG, Kantharia NS, Lakdawala M. High-Percentage Pathological Findings in Obese Patients Suggest that Esophago-gastro-duodenoscopy Should Be Made Mandatory Prior to Bariatric Surgery. OBES SURG 2018;28:2753-9. [DOI: 10.1007/s11695-018-3230-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 447 |
Tursi A, Franceschi M, Allegretta L, Savarino E, De Bastiani R, Elisei W, Baldassarre G, Ferronato A, Scida S, Miraglia C, Penna A, Licci C, Rizzo GL, Pranzo G, Cassieri C, Brandimarte G, Picchio M, Di Mario F. Effectiveness and Safety of Pylera® in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study. Dig Dis 2018;36:264-8. [PMID: 29669354 DOI: 10.1159/000487391] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 448 |
Lu C, Yu Y, Li L, Yu C, Xu P. Systematic review of the relationship of Helicobacter pylori infection with geographical latitude, average annual temperature and average daily sunshine. BMC Gastroenterol 2018;18:50. [PMID: 29665777 DOI: 10.1186/s12876-018-0779-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 449 |
Sahan AZ, Hazra TK, Das S. The Pivotal Role of DNA Repair in Infection Mediated-Inflammation and Cancer. Front Microbiol 2018;9:663. [PMID: 29696001 DOI: 10.3389/fmicb.2018.00663] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 450 |
De Witte C, Taminiau B, Flahou B, Hautekiet V, Daube G, Ducatelle R, Haesebrouck F. In-feed bambermycin medication induces anti-inflammatory effects and prevents parietal cell loss without influencing Helicobacter suis colonization in the stomach of mice. Vet Res 2018;49:35. [PMID: 29636083 DOI: 10.1186/s13567-018-0530-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 451 |
Sutton P, Boag JM. Status of vaccine research and development for Helicobacter pylori. Vaccine. 2018;pii:S0264-410X(18)30017-3. [PMID: 29627231 DOI: 10.1016/j.vaccine.2018.01.001] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 452 |
Talarico S, Korson AS, Leverich CK, Park S, Jalikis FG, Upton MP, Broussard E, Salama NR. High prevalence of Helicobacter pylori clarithromycin resistance mutations among Seattle patients measured by droplet digital PCR. Helicobacter 2018;23:e12472. [PMID: 29480566 DOI: 10.1111/hel.12472] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 453 |
Sánchez Delgado J, García-iglesias P, Titó L, Puig I, Planella M, Gené E, Saló J, Martínez-cerezo F, Molina-infante J, Gisbert JP, Calvet X. Update on the management of Helicobacter pylori infection. Position paper from the Catalan Society of Digestology. Gastroenterología y Hepatología (English Edition) 2018;41:272-280. [DOI: 10.1016/j.gastre.2018.04.018] [Reference Citation Analysis]
|
| 454 |
Sugizaki K, Tari A, Kitadai Y, Oda I, Nakamura S, Yoshino T, Sugiyama T. Anti-Helicobacter pylori therapy in localized gastric mucosa-associated lymphoid tissue lymphoma: A prospective, nationwide, multicenter study in Japan. Helicobacter 2018;23:e12474. [PMID: 29504247 DOI: 10.1111/hel.12474] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 455 |
Choe JW, Jung SW, Kim SY, Hyun JJ, Jung YK, Koo JS, Yim HJ, Lee SW. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea. Helicobacter 2018;23:e12466. [PMID: 29369454 DOI: 10.1111/hel.12466] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 456 |
Wang YH, Li Z, Wang L, Zhu-Ge LY, Zhao RL, Wu S, Wang Y, An Y, Xie Y. A systematic review and meta-analysis of genotypic methods for detecting antibiotic resistance in Helicobacter pylori. Helicobacter 2018;23:e12467. [PMID: 29405526 DOI: 10.1111/hel.12467] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 457 |
Sánchez Delgado J, García-iglesias P, Titó L, Puig I, Planella M, Gené E, Saló J, Martínez-cerezo F, Molina-infante J, Gisbert JP, Calvet X. Actualización en el manejo de la infección por Helicobacter pylori. Documento de posicionamiento de la Societat Catalana de Digestologia. Gastroenterología y Hepatología 2018;41:272-80. [DOI: 10.1016/j.gastrohep.2017.12.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 458 |
Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, Chen Y, Wang JB, Du YQ, Lu NH; Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and Peptic Ulcer. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter 2018;23:e12475. [PMID: 29512258 DOI: 10.1111/hel.12475] [Cited by in Crossref: 187] [Cited by in F6Publishing: 166] [Article Influence: 37.4] [Reference Citation Analysis]
|
| 459 |
Sebghatollahi V, Soheilipour M, Khodadoostan M, Shavakhi A, Shavakhi A. Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial. Adv Biomed Res 2018;7:55. [PMID: 29657940 DOI: 10.4103/abr.abr_133_17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 460 |
Xie Y, Pan X, Li Y, Wang H, Du Y, Xu J, Wang J, Zeng Z, Chen Y, Zhang G, Wu K, Liu D, Lv N. New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial. Journal of Antimicrobial Chemotherapy 2018;73:1681-7. [DOI: 10.1093/jac/dky056] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 461 |
Chen J, Ye L, Jin L, Xu X, Xu P, Wang X, Li H. Application of next-generation sequencing to characterize novel mutations in clarithromycin-susceptible Helicobacter pylori strains with A2143G of 23S rRNA gene. Ann Clin Microbiol Antimicrob. 2018;17:10. [PMID: 29562911 DOI: 10.1186/s12941-018-0259-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 462 |
Best LM, Takwoingi Y, Siddique S, Selladurai A, Gandhi A, Low B, Yaghoobi M, Gurusamy KS. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev. 2018;3:CD012080. [PMID: 29543326 DOI: 10.1002/14651858.cd012080.pub2] [Cited by in Crossref: 43] [Cited by in F6Publishing: 60] [Article Influence: 8.6] [Reference Citation Analysis]
|
| 463 |
Kashani N, Talebi Bezmin Abadi A. Optimised Helicobacter pylori antibiotic susceptibility profile using gold-standard method. Journal of Global Antimicrobial Resistance 2018;12:15-16. [DOI: 10.1016/j.jgar.2017.11.006] [Reference Citation Analysis]
|
| 464 |
Lee SM, Kim N, Kwon YH, Nam RH, Kim JM, Park JY, Lee YS, Lee DH. rdxA, frxA, and efflux pump in metronidazole-resistant Helicobacter pylori: Their relation to clinical outcomes. J Gastroenterol Hepatol 2018;33:681-8. [PMID: 28748532 DOI: 10.1111/jgh.13906] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 465 |
Mwafy SN, Afana WM. Hematological parameters, serum iron and vitamin B12 levels in hospitalized Palestinian adult patients infected with Helicobacter pylori: a case-control study. Hematol Transfus Cell Ther. 2018;40:160-165. [PMID: 30057990 DOI: 10.1016/j.htct.2017.11.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 466 |
Horemans T, Boulet G, van Kerckhoven M, Bogers J, Thys S, Vervaet C, Vervaeck A, Delputte P, Maes L, Cos P. In-vivo evaluation of apocynin for prevention of Helicobacter pylori-induced gastric carcinogenesis. Eur J Cancer Prev 2017;26:10-6. [PMID: 26938501 DOI: 10.1097/CEJ.0000000000000233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 467 |
Yu J, Ye H, Li J, Li N, Shi ZM, Zhang XZ. The Antibacterial Activity of Mass Galla Chinesis et Camelliae Fermentata on Helicobacter pylori Infection. Evid Based Complement Alternat Med 2018;2018:1491732. [PMID: 29670656 DOI: 10.1155/2018/1491732] [Reference Citation Analysis]
|
| 468 |
Zhang J, Zhong J, Ding J, Shi J, Tang T, Liu Q, Huang H, Dai L, Yang N. Simultaneous detection of human CYP2C19 polymorphisms and antibiotic resistance of Helicobacter pylori using a personalised diagnosis kit. J Glob Antimicrob Resist 2018;13:174-9. [PMID: 29444465 DOI: 10.1016/j.jgar.2017.12.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 469 |
Jin L, Li SY, Dai FL, Dai M, Xu WT. Efficacy and safety of Bifidobacterium combined with ilaprazole-containning quadruple therapy in rescue eradication of Helicobacter pylori. Shijie Huaren Xiaohua Zazhi 2018; 26(4): 256-262 [DOI: 10.11569/wcjd.v26.i4.256] [Reference Citation Analysis]
|
| 470 |
John S, Baltodano JD, Mehta N, Mark K, Murthy U. Unexplained iron deficiency anemia: does Helicobacter pylori have a role to play? Gastroenterol Rep (Oxf) 2018;6:215-20. [PMID: 30151206 DOI: 10.1093/gastro/goy001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 471 |
Knezevic P, Aleksic Sabo V, Simin N, Lesjak M, Mimica-Dukic N. A colorimetric broth microdilution method for assessment of Helicobacter pylori sensitivity to antimicrobial agents. J Pharm Biomed Anal 2018;152:271-8. [PMID: 29448222 DOI: 10.1016/j.jpba.2018.02.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 472 |
Ibrahim NH, Awaad AS, Alnafisah RA, Alqasoumi SI, El-Meligy RM, Mahmoud AZ. In - Vitro activity of Desmostachya bipinnata (L.) Stapf successive extracts against Helicobacter pylori clinical isolates. Saudi Pharm J 2018;26:535-40. [PMID: 29844726 DOI: 10.1016/j.jsps.2018.02.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 473 |
Mössner J. The Indications, Applications, and Risks of Proton Pump Inhibitors. Dtsch Arztebl Int 2016;113:477-83. [PMID: 27476707 DOI: 10.3238/arztebl.2016.0477] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 474 |
Mescoli C, Gallo Lopez A, Taxa Rojas L, Jove Oblitas W, Fassan M, Rugge M. Gastritis staging as a clinical priority. Eur J Gastroenterol Hepatol 2018;30:125-9. [PMID: 29215433 DOI: 10.1097/MEG.0000000000001015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 475 |
Hays C, Burucoa C, Lehours P, Tran CT, Leleu A, Raymond J. Molecular characterization of Helicobacter pylori resistance to rifamycins. Helicobacter 2018;23. [PMID: 29168600 DOI: 10.1111/hel.12451] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 476 |
Hwang YJ, Kim N, Lee HS, Lee JB, Choi YJ, Yoon H, Shin CM, Park YS, Lee DH. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years. Aliment Pharmacol Ther 2018;47:380-90. [PMID: 29193217 DOI: 10.1111/apt.14424] [Cited by in Crossref: 104] [Cited by in F6Publishing: 90] [Article Influence: 20.8] [Reference Citation Analysis]
|
| 477 |
Muñoz-Gómez P, Jordán-Castro JA, Abanades-Tercero M, Blanco-González JJ, Andrés Esteban EM, Valle-Muñoz J. Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens. Helicobacter 2018;23. [PMID: 29178562 DOI: 10.1111/hel.12452] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 478 |
Fiorini G, Zullo A, Vakil N, Saracino IM, Ricci C, Castelli V, Gatta L, Vaira D. Rifabutin Triple Therapy is Effective in Patients With Multidrug-resistant Strains of Helicobacter pylori. J Clin Gastroenterol 2018;52:137-40. [PMID: 27136964 DOI: 10.1097/MCG.0000000000000540] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 479 |
Šebunova N, Štšepetova J, Sillakivi T, Mändar R. The Prevalence of Helicobacter pylori in Estonian Bariatric Surgery Patients. Int J Mol Sci 2018;19:E338. [PMID: 29364158 DOI: 10.3390/ijms19020338] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 480 |
Luo M, Jia YY, Jing ZW, Li C, Zhou SY, Mei QB, Zhang BL. Construction and optimization of pH-sensitive nanoparticle delivery system containing PLGA and UCCs-2 for targeted treatment of Helicobacter pylori. Colloids Surf B Biointerfaces 2018;164:11-9. [PMID: 29367052 DOI: 10.1016/j.colsurfb.2018.01.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 481 |
. High-Risk Pregnancy. 2018. [DOI: 10.1017/9781108349185] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 482 |
Rodriguez-torres MDP, Acosta-torres LS, Diaz-torres LA. Heparin-Based Nanoparticles: An Overview of Their Applications. Journal of Nanomaterials 2018;2018:1-8. [DOI: 10.1155/2018/9780489] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 483 |
Ahn GY, Bae S. Strategies for the safe use of non-steroidal anti-inflammatory drugs. J Korean Med Assoc 2018;61:367. [DOI: 10.5124/jkma.2018.61.6.367] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 484 |
Yeo YH, Shiu SI, Ho HJ, Zou B, Lin JT, Wu MS, Liou JM, Wu CY; Taiwan Gastrointestinal Disease and Helicobacter Consortium. First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. Gut 2018;67:20-7. [PMID: 27670375 DOI: 10.1136/gutjnl-2016-311868] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 10.6] [Reference Citation Analysis]
|
| 485 |
Mahachai V, Vilaichone RK, Pittayanon R, Rojborwonwitaya J, Leelakusolvong S, Maneerattanaporn M, Chotivitayatarakorn P, Treeprasertsuk S, Kositchaiwat C, Pisespongsa P, Mairiang P, Rani A, Leow A, Mya SM, Lee YC, Vannarath S, Rasachak B, Chakravuth O, Aung MM, Ang TL, Sollano JD, Trong Quach D, Sansak I, Wiwattanachang O, Harnsomburana P, Syam AF, Yamaoka Y, Fock KM, Goh KL, Sugano K, Graham D. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol 2018;33:37-56. [PMID: 28762251 DOI: 10.1111/jgh.13911] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 13.8] [Reference Citation Analysis]
|
| 486 |
Rejchrt S, Koupil I, Kopáčová M, Škodová Fendrichová M, Seifert B, Voříšek V, Špirková J, Douda T, Tachecí I, Bureš J. The prevalence and sociodemographic determinants of uninvestigated dyspepsia in the Czech Republic: a multicentre prospective study accomplished 10 years after the first study from the same geographical areas. Eur J Gastroenterol Hepatol 2018;30:76-82. [PMID: 29135563 DOI: 10.1097/MEG.0000000000001007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 487 |
So S, Ahn JY, Na HK, Jung KW, Lee JH, Kim DH, Choi KD, Song HJ, Lee GH, Jung H. Helicobacter pylori Eradication in Patients with an Iatrogenic Ulcer after Endoscopic Resection and Peptic Ulcer. Korean J Helicobacter Up Gastrointest Res 2018;18:30. [DOI: 10.7704/kjhugr.2018.18.1.30] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 488 |
Yoon K, Kim N. Reversibility of Atrophic Gastritis and Intestinal Metaplasia by Eradication of Helicobacter pylori. Korean J Gastroenterol 2018;72:104. [DOI: 10.4166/kjg.2018.72.3.104] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 489 |
Dekhnich NN, Ivanchik NV, Kozlov RS, Alimov A, Steshits A, Kirsov P. Antimicrobial resistance of Helicobacter pylori in Smolensk. CMAC 2018;20:42-48. [DOI: 10.36488/cmac.2018.1.42-48] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 490 |
Mcknight G, Powell C. Peptic ulcer disease in the military setting. J R Nav Med Serv 2018;104:18-20. [DOI: 10.1136/jrnms-104-18] [Reference Citation Analysis]
|
| 491 |
Hwang Y, Kim N, Yun CY, Kwon MG, Baek SM, Kwon YJ, Lee HS, Lee JB, Choi YJ, Yoon H, Shin CM, Park YS, Lee DH. Predictive Factors for Improvement of Atrophic Gastritis and Intestinal Metaplasia: A Long-term Prospective Clinical Study. Korean J Helicobacter Up Gastrointest Res 2018;18:186. [DOI: 10.7704/kjhugr.2018.18.3.186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 492 |
Bakulin IG, Pirogov SS, Bakulina NV, Stadnik EA, Golubev NN. Prophylaxis and early diagnosis of stomach cancer. Dok gastroenterol 2018;7:44. [DOI: 10.17116/dokgastro201872244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 493 |
Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut 2018;67:28-35. [PMID: 29089382 DOI: 10.1136/gutjnl-2017-314605] [Cited by in Crossref: 266] [Cited by in F6Publishing: 272] [Article Influence: 53.2] [Reference Citation Analysis]
|
| 494 |
Ramírez FB, Núñez CG, Tejero Mas M, Rivera Jiménez N, Pérez Caballero FL. Criterios para la erradicación de Helicobacter pylori. FMC - Formación Médica Continuada en Atención Primaria 2018;25:43-53. [DOI: 10.1016/j.fmc.2017.03.009] [Reference Citation Analysis]
|
| 495 |
Vakil N. Helicobacter pylori and Other Gastritides. Gastrointestinal Motility Disorders 2018. [DOI: 10.1007/978-3-319-59352-4_27] [Reference Citation Analysis]
|
| 496 |
Chen L, Cui H, Fan S, Li Z, Han S, Ma X, Luo S, Song X, Lv Q. Detection of Helicobacter pylori in dental plaque using a DNA biosensor for noninvasive diagnosis. RSC Adv 2018;8:21075-83. [DOI: 10.1039/c8ra03134g] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 497 |
Zerbib F. Erosive Esophagitis. Gastrointestinal Motility Disorders 2018. [DOI: 10.1007/978-3-319-59352-4_8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 498 |
Mössner J. Magen-Darm-Mittel und Lebertherapeutika. Arzneiverordnungs-Report 2018 2018. [DOI: 10.1007/978-3-662-57386-0_33] [Reference Citation Analysis]
|
| 499 |
Dolak W, Bilgilier C, Stadlmann A, Leiner J, Püspök A, Plieschnegger W, Siebert F, Wewalka F, Schöfl R, Huber-Schönauer U, Datz C, Biowski-Frotz S, Högenauer C, Schrutka-Kölbl C, Makristathis A, Schöniger-Hekele M, Steininger C; Austrian Helicobacter Pylori Study Group. A multicenter prospective study on the diagnostic performance of a new liquid rapid urease test for the diagnosis of Helicobacter pylori infection. Gut Pathog 2017;9:78. [PMID: 29299067 DOI: 10.1186/s13099-017-0226-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 500 |
Jerzemowski M, Dąbrowiecki Z, Olszański R, Siermontowski P, Jerzemowski J. Selected Gastroenterologic Problems in the Tropics (Peacekeeping Missions, Work). Polish Hyperbaric Research 2017;61:55-66. [DOI: 10.1515/phr-2017-0023] [Reference Citation Analysis]
|
| 501 |
Simard EP, Jemal A. Microbial Carcinogens. The American Cancer Society's Principles of Oncology 2017. [DOI: 10.1002/9781119468868.ch7] [Reference Citation Analysis]
|
| 502 |
Toyoshima O, Tanikawa C, Yamamoto R, Watanabe H, Yamashita H, Sakitani K, Yoshida S, Kubo M, Matsuo K, Ito H, Koike K, Seto Y, Matsuda K. Decrease in PSCA expression caused by Helicobacter pylori infection may promote progression to severe gastritis. Oncotarget. 2018;9:3936-3945. [PMID: 29423095 DOI: 10.18632/oncotarget.23278] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 503 |
Yeung C, Lee H. Paediatric Helicobacter Pylori Infection in Taiwan: Current Status and Perspectives. EMJ Gastroenterol 2017. [DOI: 10.33590/emjgastroenterol/10312003] [Reference Citation Analysis]
|
| 504 |
Chen XZ, Schöttker B, Castro FA, Chen H, Zhang Y, Holleczek B, Brenner H. Association of helicobacter pylori infection and chronic atrophic gastritis with risk of colonic, pancreatic and gastric cancer: A ten-year follow-up of the ESTHER cohort study. Oncotarget. 2016;7:17182-17193. [PMID: 26958813 DOI: 10.18632/oncotarget.7946] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 505 |
Serajian A. PCR-RFLP Detection of Point Mutations in 23sr RNA Gene Responsible for Clarithromycin Resistance in Helicobacter pylori Isolates of Ahvaz, Iran. IJMBOA 2017;2. [DOI: 10.15406/ijmboa.2017.02.00038] [Reference Citation Analysis]
|
| 506 |
Tepes B, Kastelic M, Vujasinovic M, Lampic P, Seruga M, Jurecic NB, Nyssen OP, Donday MG, O'Morain C, Megraud F, McNicholl AG, Gisbert JP. Helicobacter Pylori Treatment Results in Slovenia in the Period 2013-2015 as a Part of European Registry on Helicobacter Pylori Management. Radiol Oncol 2018;52:1-6. [PMID: 29520199 DOI: 10.1515/raon-2017-0055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 507 |
Pellicano R. Similar Helicobacter pylori Eradication Rate in Obese Patients Undergoing Gastric Bypass Surgery and in General Population. Obes Surg 2018;28:553-4. [PMID: 29197049 DOI: 10.1007/s11695-017-3038-2] [Reference Citation Analysis]
|
| 508 |
Kwon YH, Kim JY, Kim N, Park JH, Nam RH, Lee SM, Kim JW, Kim JM, Park JY, Lee DH. Specific mutations of penicillin-binding protein 1A in 77 clinically acquired amoxicillin-resistant Helicobacter pylori strains in comparison with 77 amoxicillin-susceptible strains. Helicobacter 2017;22. [PMID: 28840971 DOI: 10.1111/hel.12437] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 509 |
Macías-García F, Llovo-Taboada J, Díaz-López M, Bastón-Rey I, Domínguez-Muñoz JE. High primary antibiotic resistance of Helicobacter Pylori strains isolated from dyspeptic patients: A prevalence cross-sectional study in Spain. Helicobacter 2017;22. [PMID: 28913872 DOI: 10.1111/hel.12440] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 510 |
Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol 2017;14:697-710. [PMID: 28930292 DOI: 10.1038/nrgastro.2017.117] [Cited by in Crossref: 144] [Cited by in F6Publishing: 136] [Article Influence: 24.0] [Reference Citation Analysis]
|
| 511 |
Rugge M, Genta RM, Di Mario F, El-Omar EM, El-Serag HB, Fassan M, Hunt RH, Kuipers EJ, Malfertheiner P, Sugano K, Graham DY. Gastric Cancer as Preventable Disease. Clin Gastroenterol Hepatol 2017;15:1833-43. [PMID: 28532700 DOI: 10.1016/j.cgh.2017.05.023] [Cited by in Crossref: 121] [Cited by in F6Publishing: 132] [Article Influence: 20.2] [Reference Citation Analysis]
|
| 512 |
Dong SQ, Singh TP, Wei X, Yao H, Wang HL. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion? Helicobacter 2017;22. [PMID: 28884937 DOI: 10.1111/hel.12438] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 513 |
Kim SY, Lee SW, Choe JW, Jung SW, Hyun JJ, Jung YK, Koo JS, Yim HJ. Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. Helicobacter 2017;22. [PMID: 28940815 DOI: 10.1111/hel.12441] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 514 |
Ye JF, Hong JB, Zhu Y, Xie Y, Shu X, Luo LY, Xie C, Zhu ZH, Lu NH. Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication. J Dig Dis 2017;18:704-8. [PMID: 29119724 DOI: 10.1111/1751-2980.12559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 515 |
Lin T, Lee H, Lin C, Wang C, Chen K, Wu D. CYP2C19 polymorphism has no influence on rabeprazole-based sequential therapy. Advances in Digestive Medicine 2017;4:134-139. [DOI: 10.1002/aid2.12134] [Reference Citation Analysis]
|
| 516 |
Prianichnikov NA, Malakhova MV, Babenko VV, Larin AK, Olekhnovich EI, Starikova EV, Chuvelev DI, Glushchenko OE, Samoilov AE, Manolov AI, Kovarsky BA, Tyakht AV, Pavlenko AV, Ilina EN, Kostryukova ES. Draft genomes of Enterococcus faecium strains isolated from human feces before and after eradication therapy against Helicobacter pylori. Data Brief 2018;16:511-4. [PMID: 29270449 DOI: 10.1016/j.dib.2017.11.069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 517 |
Barbosa AMC, Ribeiro RA, Silva CÍSM, Cruz FWS, Azevedo OGR, Pitombeira MHDS, Braga LLC. Platelet count response to Helicobacter pylori eradication for idiopathic thrombocytopenic purpura in northeastern Brazil. Rev Bras Hematol Hemoter 2018;40:12-7. [PMID: 29519366 DOI: 10.1016/j.bjhh.2017.09.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 518 |
. Gastrointestinal Infections. Clinical Microbiology for Diagnostic Laboratory Scientists 2017. [DOI: 10.1002/9781118745847.ch4] [Reference Citation Analysis]
|
| 519 |
Lee H, Kim BJ, Kim SG, Kim JI, Choi IJ, Lee YC, Kim JG, Kim JJ; Korean College of Helicobacter and Upper Gastrointestinal Research. Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial. Trials. 2017;18:549. [PMID: 29149904 DOI: 10.1186/s13063-017-2281-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 520 |
Liu DS, Wang YH, Zeng ZR, Zhang ZY, Lu H, Xu JM, Du YQ, Li Y, Wang JB, Xu SP, Chen Y, Lan CH, Cheng H, Jiang MD, Zhang LX, Huo LJ, Chen SY, Zhang GX, Wu KC, Zhu X, Chen YX, Zhu Y, Shu X, Xie Y, Lu NH. Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study. Clin Microbiol Infect 2018; 24: 780.e5-780. e8. [PMID: 29138101 DOI: 10.1016/j.cmi.2017.11.010] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 521 |
Caicedo Ochoa EY, Quintero Moreno CO, Méndez Fandiño YR, Sánchez Fonseca SC, Cortes Motta HF, Guio Guerra SA. Assessment of the use of vitamin C and E supplements concomitantly to antibiotic treatment against Helicobacter pylori: A systematic review and meta-analysis. Med Clin (Barc) 2018;151:45-52. [PMID: 29102269 DOI: 10.1016/j.medcli.2017.09.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 522 |
Tanabe H, Ando K, Sato K, Ito T, Goto M, Sato T, Fujinaga A, Kawamoto T, Utsumi T, Yanagawa N, Ichiishi E, Otake T, Kohgo Y, Nomura Y, Ueno N, Sugano H, Kashima S, Moriichi K, Fujiya M, Okumura T. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature. Dig Dis Sci 2017;62:3069-76. [PMID: 28664410 DOI: 10.1007/s10620-017-4664-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 523 |
Bomme M, Hansen JM, Wildner-Christensen M, Hallas J, Schaffalitzky de Muckadell OB. Effects of Community Screening for Helicobacter pylori: 13-Year Follow-Up Evaluation of a Randomized Controlled Trial. Clin Gastroenterol Hepatol 2017;15:1715-1723.e7. [PMID: 28606845 DOI: 10.1016/j.cgh.2017.06.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 524 |
Yang YJ, Wu CT, Ou HY, Lin CH, Cheng HC, Chang WL, Chen WY, Yang HB, Lu CC, Sheu BS. Male non-insulin users with type 2 diabetes mellitus are predisposed to gastric corpus-predominant inflammation after H. pylori infection. J Biomed Sci 2017;24:82. [PMID: 29082856 DOI: 10.1186/s12929-017-0389-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 525 |
Kuo SH, Yeh KH, Wu MS, Lin CW, Wei MF, Liou JM, Wang HP, Chen LT, Cheng AL. First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma. Sci Rep 2017;7:14333. [PMID: 29084984 DOI: 10.1038/s41598-017-14102-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 526 |
Chotivitayatarakorn P, Mahachai V, Vilaichone RK. Effectiveness of 7-Day and 14-Day Moxifloxacin-Dexlansoprazole Based Triple Therapy and Probiotic Supplement for Helicobacter Pylori Eradication in Thai Patients with Non-Ulcer Dyspepsia: A Double-Blind Randomized Placebo-Controlled Study. Asian Pac J Cancer Prev 2017;18:2839-43. [PMID: 29072432 DOI: 10.22034/APJCP.2017.18.10.2839] [Reference Citation Analysis]
|
| 527 |
Shindler-Itskovitch T, Ravona-Springer R, Leibovitz A, Muhsen K. A Systematic Review and Meta-Analysis of the Association between Helicobacterpylori Infection and Dementia. J Alzheimers Dis. 2016;52:1431-1442. [PMID: 27079725 DOI: 10.3233/jad-160132] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 528 |
Tsay FW, Wu DC, Yu HC, Kao SS, Lin KH, Cheng JS, Wang HM, Chen WC, Sun WC, Tsai KW, Hsu PI. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. Antimicrob Agents Chemother 2017;61:e00140-17. [PMID: 28807915 DOI: 10.1128/AAC.00140-17] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 529 |
Petra CV, Rus A, Dumitraşcu DL. Gastric microbiota: tracing the culprit. Clujul Med 2017;90:369-76. [PMID: 29151783 DOI: 10.15386/cjmed-854] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 530 |
Sue S, Suzuki N, Shibata W, Sasaki T, Yamada H, Kaneko H, Tamura T, Ishii T, Kondo M, Maeda S. First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin. Gastroenterol Res Pract 2017;2017:2019802. [PMID: 29181022 DOI: 10.1155/2017/2019802] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 531 |
Lim JH, Kim SG, Song JH, Hwang JJ, Lee DH, Han JP, Hong SJ, Kim JH, Jeon SW, Kim GH, Shim KN, Shin WG, Kim TH, Kim SM, Chung IK, Kim HS, Kim HU, Lee J, Kim JG. Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of Helicobacter pylori in Peptic Ulcer Disease. Gut Liver 2017;11:226-31. [PMID: 27609487 DOI: 10.5009/gnl16099] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 532 |
Wang Y, Zhao R, Wang B, Zhao Q, Li Z, Zhu-ge L, Yin W, Xie Y. Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: an updated systematic review and meta-analysis. Eur J Clin Pharmacol 2018;74:1-13. [DOI: 10.1007/s00228-017-2347-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 533 |
Rodríguez de Santiago E, Martín de Argila de Prados C, Marcos Prieto HM, Jorge Turrión MÃ, Barreiro Alonso E, Flores de Miguel A, de la Coba Ortiz C, Rodríguez Escaja C, Pérez Álvarez G, Ferre Aracil C, Aguilera Castro L, García García de Paredes A, Rodríguez Pérez A, Albillos Martínez A. Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera(®) ) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study. Helicobacter 2017;22. [PMID: 28771880 DOI: 10.1111/hel.12423] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 534 |
Parreira P, Soares BI, Freire CS, Silvestre AJ, Reis CA, Martins MCL, Duarte MF. Eucalyptus spp. outer bark extracts inhibit Helicobacter pylori growth: in vitro studies. Industrial Crops and Products 2017;105:207-14. [DOI: 10.1016/j.indcrop.2017.05.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 535 |
Thereza-Filho MA, Bansho ETO, Tonon D, I-Ching L, Dantas-Corrêa EB, Cunha VJL, Schiavon LL, Narciso-Schiavon JL. Recurrent anaemia in a patient with lymphocytic gastritis and vitamin B12 deficiency. Arab J Gastroenterol 2017;18:165-8. [PMID: 28943131 DOI: 10.1016/j.ajg.2017.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 536 |
Bjorkman DJ, Steenblik M. Best Practice Recommendations for Diagnosis and Management of Helicobacter pylori-Synthesizing the Guidelines. Curr Treat Options Gastroenterol 2017;15:648-59. [PMID: 28932965 DOI: 10.1007/s11938-017-0157-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 537 |
Abadi ATB. Resistance to clarithromycin and gastroenterologist’s persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization. World J Gastroenterol 2017; 23(35): 6379-6384 [PMID: 29085187 DOI: 10.3748/wjg.v23.i35.6379] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 538 |
Puig I, González-Santiago JM, Molina-Infante J, Barrio J, Herranz MT, Algaba A, Castro M, Gisbert JP, Calvet X. Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection. Int J Clin Pract 2017;71. [PMID: 28869699 DOI: 10.1111/ijcp.13004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 539 |
Yang YJ, Wu CT, Ou HY, Lin CH, Cheng HC, Chang WL, Chen WY, Yang HB, Lu CC, Sheu BS. Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes. Ann Med 2017;49:479-86. [PMID: 28266875 DOI: 10.1080/07853890.2017.1294761] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 540 |
Wu TS, Hsu PI, Kuo CH, Hu HM, Wu IC, Wang SSW, Chen YH, Wu DC, Su WW, Kuo FC. Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori. J Dig Dis 2017;18:537-42. [PMID: 28644575 DOI: 10.1111/1751-2980.12498] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 541 |
Pourlak T, Shokouhi B, Vahedi A. Role of Helicobacter Pylori stool antigen test in the diagnosis of Helicobacter Pylori infection. J Anal Res Clin Med 2017;5:86-90. [DOI: 10.15171/jarcm.2017.017] [Reference Citation Analysis]
|
| 542 |
Haj S, Chodick G, Refaeli R, Goren S, Shalev V, Muhsen K. Associations of Helicobacter pylori infection and peptic disease with diabetic mellitus: Results from a large population-based study. PLoS One 2017;12:e0183687. [PMID: 28850590 DOI: 10.1371/journal.pone.0183687] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 543 |
Tepeš B, Malfertheiner P, Labenz J, Aygen S. Modified Helicobacter test using a new test meal and a 13C-urea breath test in Helicobacter pylori positive and negative dyspepsia patients on proton pump inhibitors. World J Gastroenterol 2017; 23(32): 5954-5961 [PMID: 28932087 DOI: 10.3748/wjg.v23.i32.5954] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 544 |
Kwon S, Lee DH, Kang JB, Kim N, Park YS, Shin CM, Yoon H, Choi YJ. [The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure in Helicobacter pylori Eradication]. Korean J Gastroenterol 2017;70:72-80. [PMID: 28830132 DOI: 10.4166/kjg.2017.70.2.72] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 545 |
Kazakova MA, Pozdeev OK, Valeeva YV, Morozova LG, Fayzullina RA. Species spectrum of microflora of upper digestive tract mucosa and its effect on the development of pathology in children. Kazan Med J 2017;98:557-563. [DOI: 10.17750/kmj2017-557] [Reference Citation Analysis]
|
| 546 |
Kim TH, Cheung DY. Helicobacter pylori Eradication, a Gordian Knot for Idiopathic Thrombocytopenic Purpura? Gut Liver 2016;10:323-4. [PMID: 27114429 DOI: 10.5009/gnl16095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 547 |
Tosetti C, Nanni I. Use of proton pump inhibitors in general practice. World J Gastrointest Pharmacol Ther 2017; 8(3): 180-185 [PMID: 28828196 DOI: 10.4292/wjgpt.v8.i3.180] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 548 |
Lanas A, Chan FKL. Peptic ulcer disease. Lancet 2017;390:613-24. [PMID: 28242110 DOI: 10.1016/S0140-6736(16)32404-7] [Cited by in Crossref: 394] [Cited by in F6Publishing: 263] [Article Influence: 65.7] [Reference Citation Analysis]
|
| 549 |
Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2017;11:27-37. [PMID: 27840364 DOI: 10.5009/gnl15502] [Cited by in Crossref: 219] [Cited by in F6Publishing: 227] [Article Influence: 36.5] [Reference Citation Analysis]
|
| 550 |
Cheng HC, Tsai YC, Yang HB, Yeh YC, Chang WL, Kuo HY, Lu CC, Sheu BS. The corpus-predominant gastritis index can be an early and reversible marker to identify the gastric cancer risk of Helicobacter pylori-infected nonulcer dyspepsia. Helicobacter 2017;22. [PMID: 28326664 DOI: 10.1111/hel.12385] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 551 |
Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter 2017;22. [PMID: 28464347 DOI: 10.1111/hel.12392] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 552 |
Wang X, Lu B, Meng L, Fan Y, Zhang S, Li M. The correlation between histological gastritis staging- 'OLGA/OLGIM' and serum pepsinogen test in assessment of gastric atrophy/intestinal metaplasia in China. Scand J Gastroenterol 2017;52:822-7. [PMID: 28436254 DOI: 10.1080/00365521.2017.1315739] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 553 |
Kotilea K, Mekhael J, Salame A, Mahler T, Miendje-Deyi VY, Cadranel S, Bontems P. Eradication rate of Helicobacter Pylori infection is directly influenced by adherence to therapy in children. Helicobacter 2017;22. [PMID: 28303625 DOI: 10.1111/hel.12383] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 554 |
Mohammadi M, Attaran B, Malekzadeh R, Graham DY. Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran. Dig Dis Sci 2017;62:1890-6. [PMID: 28577244 DOI: 10.1007/s10620-017-4628-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 555 |
Xu Z, Li J, Wang H, Xu G. Helicobacter pylori infection and atherosclerosis: is there a causal relationship? Eur J Clin Microbiol Infect Dis 2017;36:2293-301. [DOI: 10.1007/s10096-017-3054-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 556 |
Cheung DY. Helicobacter pylori Eradication Therapy, the Reasonable First Line Therapy for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Irrespective of Infection Status and Disease Stages. Gut Liver 2016;10:659-60. [PMID: 27563015 DOI: 10.5009/gnl16359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 557 |
Abeer Mohammed A, Al-saman MA, Tayel AA. Antibacterial activity of fusion from biosynthesized acidocin/silver nanoparticles and its application for eggshell decontamination. J Basic Microbiol 2017;57:744-51. [DOI: 10.1002/jobm.201700192] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 558 |
Yoon H, Lee DH, Jang ES, Kim J, Shin CM, Park YS, Hwang JH, Kim JW, Jeong SH, Kim N. Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial. Gut Liver 2016;10:520-5. [PMID: 26347514 DOI: 10.5009/gnl15048] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 559 |
Kim JS, Kim BW, Hong SJ, Kim JI, Shim KN, Kim JH, Baik GH, Kim SW, Song HJ, Kim JH. Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial. Gut Liver. 2016; Apr 28. [Epub ahead of print]. [PMID: 27114421 DOI: 10.5009/gnl15470] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 560 |
Link A, Langner C, Schirrmeister W, Habendorf W, Weigt J, Venerito M, Tammer I, Schlüter D, Schlaermann P, Meyer TF, Wex T, Malfertheiner P. Helicobacter pylori vacA genotype is a predominant determinant of immune response to Helicobacter pylori CagA. World J Gastroenterol 2017; 23(26): 4712-4723 [PMID: 28765692 DOI: 10.3748/wjg.v23.i26.4712] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 561 |
Wang R, Chen LL, Wang DZ, Chen BX. Association Between Helicobacter Pylori Infection and Long-term Outcome in Patients with Drug-eluting Stent Implantation. Sci Rep 2017;7:44954. [PMID: 28703181 DOI: 10.1038/srep44954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 562 |
Katelaris PH, Katelaris AL. A prospective evaluation of levofloxacin-based triple therapy for refractory Helicobacter pylori infection in Australia: Levofloxacin triple therapy for refractory H. pylori. Intern Med J 2017;47:761-6. [DOI: 10.1111/imj.13432] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 563 |
Shimoyama T, Chinda D, Sawada Y, Komai K, Chiba H, Saito Y, Sasaki Y, Matsuzaka M, Fukuda S. Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens. Intern Med 2017;56:1621-7. [PMID: 28674348 DOI: 10.2169/internalmedicine.56.7823] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 564 |
Jeon J, Kim JK, Kim G. Detection of Clarithromycin-Resistant Helicobacter pylori by Polymerase Chain Reaction Using Residual Samples from Rapid Urease Test. Indian Journal of Medical Microbiology 2017;35:406-409. [DOI: 10.4103/ijmm.ijmm_17_246] [Reference Citation Analysis]
|
| 565 |
Hunt R, Armstrong D, Katelaris P, Afihene M, Bane A, Bhatia S, Chen MH, Choi MG, Melo AC, Fock KM, Ford A, Hongo M, Khan A, Lazebnik L, Lindberg G, Lizarzabal M, Myint T, Moraes-Filho JP, Salis G, Lin JT, Vaidya R, Abdo A, LeMair A; Review Team:. World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease. J Clin Gastroenterol 2017;51:467-78. [PMID: 28591069 DOI: 10.1097/MCG.0000000000000854] [Cited by in Crossref: 103] [Cited by in F6Publishing: 105] [Article Influence: 17.2] [Reference Citation Analysis]
|
| 566 |
Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, Bazzoli F. Proton pump inhibitors: Risks of long-term use. J Gastroenterol Hepatol 2017;32:1295-302. [PMID: 28092694 DOI: 10.1111/jgh.13737] [Cited by in Crossref: 101] [Cited by in F6Publishing: 104] [Article Influence: 16.8] [Reference Citation Analysis]
|
| 567 |
Itskoviz D, Boltin D, Leibovitzh H, Tsadok Perets T, Comaneshter D, Cohen A, Niv Y, Levi Z. Smoking increases the likelihood of Helicobacter pylori treatment failure. Dig Liver Dis 2017;49:764-8. [PMID: 28427781 DOI: 10.1016/j.dld.2017.03.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 568 |
Sapmaz F, Kalkan IH, Atasoy P, Basyigit S, Guliter S. A Non-Inferiority Study: Modified Dual Therapy Consisting Higher Doses of Rabeprazole Is as Successful as Standard Quadruple Therapy in Eradication of Helicobacter pylori. American Journal of Therapeutics 2017;24:e393-8. [DOI: 10.1097/mjt.0000000000000316] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 569 |
Murakami TT, Scranton RA, Brown HE, Harris RB, Chen Z, Musuku S, Oren E. Management of Helicobacter Pylori in the United States: Results from a national survey of gastroenterology physicians. Prev Med 2017;100:216-22. [PMID: 28457713 DOI: 10.1016/j.ypmed.2017.04.021] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 570 |
Shiota S, Thrift AP, Green L, Shah R, Verstovsek G, Rugge M, Graham DY, El-Serag HB. Clinical Manifestations of Helicobacter pylori-Negative Gastritis. Clin Gastroenterol Hepatol 2017;15:1037-1046.e3. [PMID: 28110098 DOI: 10.1016/j.cgh.2017.01.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 571 |
Robinson K, Letley DP, Kaneko K. The Human Stomach in Health and Disease: Infection Strategies by Helicobacter pylori. Curr Top Microbiol Immunol. 2017;400:1-26. [PMID: 28124147 DOI: 10.1007/978-3-319-50520-6_1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 572 |
Hwang JJ, Lee DH, Yoon H, Shin CM, Park YS, Kim N. The Effects of Helicobacter pylori Eradication Therapy for Chronic IdiopathicThrombocytopenic Purpura. Gut Liver 2016;10:356-61. [PMID: 26347517 DOI: 10.5009/gnl14483] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 573 |
Manzouri L, Zarei F, Niazi N, Sedaghattalab M. Comparison of the Success Rate of Quadruple and Triple Antibiotic Therapy in Eradicating Helicobacter pylori Infection in Southwest of Iran: A Randomized Clinical Trial. Int J Infect 2017;4. [DOI: 10.5812/iji.15610] [Reference Citation Analysis]
|
| 574 |
Rhodes LA PharmD. Practical considerations for managing Helicobacter pylori in college health. J Am Coll Health 2017;65:361-2. [PMID: 28622096 DOI: 10.1080/07448481.2017.1341901] [Reference Citation Analysis]
|
| 575 |
Fadilah N, Hanafiah A, Razlan H, Wong ZQ, Mohamed Rose I, Rahman MM. Multiplex PCR for detection of Helicobacter pylori infection in gastric biopsies with lower inflammatory score. Br J Biomed Sci 2016;73:180-7. [PMID: 27922429 DOI: 10.1080/09674845.2016.1220705] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 576 |
Ibrahimi M, Alaei M, Gholampour M, Mohammdoo-khorasani M. Helicobacter pylori Treatment: Potential for Gastric Cancer Prevention. Int J Infect 2017;5. [DOI: 10.5812/iji.14138] [Reference Citation Analysis]
|
| 577 |
Morilla A, Melón S, Álvarez-Argüelles ME, Armesto E, Villar H, de Oña M. Utility of normalized genome quantification of Helicobacter pylori in gastric mucosa using an in-house real-time polymerase chain reaction. PLoS One 2017;12:e0178674. [PMID: 28575047 DOI: 10.1371/journal.pone.0178674] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 578 |
Sheu BS, Wu MS, Chiu CT, Lo JC, Wu DC, Liou JM, Wu CY, Cheng HC, Lee YC, Hsu PI, Chang CC, Chang WL, Lin JT. Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale. Helicobacter 2017;22. [PMID: 28066960 DOI: 10.1111/hel.12368] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 579 |
Acosta CP, Quiroga AJ, Sierra CH, Trespalacios AA. [Frequency of Helicobacter pylori nitroreductase RdxA mutations for metronidazole activation in a population in the Cauca Department, Colombia]. Biomedica 2017;37:191-9. [PMID: 28527283 DOI: 10.7705/biomedica.v37i2.3007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 580 |
Sue S, Kuwashima H, Iwata Y, Oka H, Arima I, Fukuchi T, Sanga K, Inokuchi Y, Ishii Y, Kanno M, Terada M, Amano H, Naito M, Iwase S, Okazaki H, Komatsu K, Kokawa A, Kawana I, Morimoto M, Saito T, Kunishi Y, Ikeda A, Takahashi D, Miwa H, Sasaki T, Tamura T, Kondo M, Shibata W, Maeda S. The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication. Intern Med 2017;56:1277-85. [PMID: 28566587 DOI: 10.2169/internalmedicine.56.7833] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 581 |
Ozturk O, Doganay L, Colak Y, Yilmaz Enc F, Ulasoglu C, Ozdil K, Tuncer I. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication. Arab Journal of Gastroenterology 2017;18:62-7. [DOI: 10.1016/j.ajg.2017.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 582 |
Tursi A, Di Mario F, Franceschi M, De Bastiani R, Elisei W, Baldassarre G, Ferronato A, Grillo S, Landi S, Zamparella M, De Polo M, Boscariolo L, Picchio M. New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice. Helicobacter 2017;22. [PMID: 28125857 DOI: 10.1111/hel.12371] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 583 |
Wang L, Lin Z, Chen S, Li J, Chen C, Huang Z, Ye B, Ding J, Li W, Wu L, Jiang Y, Meng L, Du Q, Si J. Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori –related chronic gastritis: a prospective randomized study in China. Clinical Microbiology and Infection 2017;23:391-5. [DOI: 10.1016/j.cmi.2016.12.032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 584 |
Akpinar Z, Akay S, Unsal B. Improving the standard sequential treatment of Helicobacter pylori with either extended treatment or by adding bismuth. Arab Journal of Gastroenterology 2017;18:58-61. [DOI: 10.1016/j.ajg.2017.05.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 585 |
Fu W, Song Z, Zhou L, Xue Y, Ding Y, Suo B, Tian X, Wang L. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection. Dig Dis Sci 2017;62:1580-9. [PMID: 28391418 DOI: 10.1007/s10620-017-4564-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 586 |
Negovan A, Iancu M, Moldovan V, Sàrkàny K, Bataga S, Mocan S, Țilea I, Banescu C. The contribution of clinical and pathological predisposing factors to severe gastro-duodenal lesions in patients with long-term low-dose aspirin and proton pump inhibitor therapy. Eur J Intern Med 2017;44:62-6. [PMID: 28576397 DOI: 10.1016/j.ejim.2017.05.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 587 |
Radovanović Spurnić A, Brmbolić B, Stojšić Z, Pekmezović T, Bukumirić Z, Korać M, Salemović D, Pešić-Pavlović I, Stevanović G, Milošević I, Jevtović D. The increasing prevalence of HIV/Helicobacter pylori co-infection over time, along with the evolution of antiretroviral therapy (ART). PeerJ 2017;5:e3392. [PMID: 28584718 DOI: 10.7717/peerj.3392] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 588 |
Formichella L, Romberg L, Meyer H, Bolz C, Vieth M, Geppert M, Göttner G, Nölting C, Schepp W, Schneider A, Ulm K, Wolf P, Holster IL, Kuipers EJ, Birkner B, Soutschek E, Gerhard M. Validation of a Novel Immunoline Assay for Patient Stratification according to Virulence of the Infecting Helicobacter pylori Strain and Eradication Status. J Immunol Res 2017;2017:8394593. [PMID: 28638837 DOI: 10.1155/2017/8394593] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 589 |
Ra SW, Sze MA, Lee EC, Tam S, Oh Y, Fishbane N, Criner GJ, Woodruff PG, Lazarus SC, Albert R, Connett JE, Han MK, Martinez FJ, Aaron SD, Reed RM, Man SFP, Sin DD; Canadian Respiratory Research Network. Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori. Respir Res 2017;18:109. [PMID: 28558695 DOI: 10.1186/s12931-017-0594-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 590 |
周林, 赵阳鹏, 张伟. 幽门螺杆菌根除治疗在胃癌预防中的现状及前景. 世界华人消化杂志 2017; 25(15): 1327-1337 [DOI: 10.11569/wcjd.v25.i15.1327] [Reference Citation Analysis]
|
| 591 |
Abu-Sini M, Mayyas A, Al-Karablieh N, Darwish R, Al-Hiari Y, Aburjai T, Arabiyat S, Abu-Qatouseh L. Synthesis of 1,2,3-Triazolo[4,5-h]quinolone Derivatives with Novel Anti-Microbial Properties against Metronidazole Resistant Helicobacter pylori. Molecules 2017;22:E841. [PMID: 28531095 DOI: 10.3390/molecules22050841] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 592 |
Li ZX, Huang LL, Liu C, Formichella L, Zhang Y, Wang YM, Zhang L, Ma JL, Liu WD, Ulm K. Cut-off optimization for 13 C-urea breath test in a community-based trial by mathematic, histology and serology approach. Sci Rep. 2017;7:2072. [PMID: 28522798 DOI: 10.1038/s41598-017-02180-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 593 |
Angol DC, Ocama P, Ayazika Kirabo T, Okeng A, Najjingo I, Bwanga F. Helicobacter pylori from Peptic Ulcer Patients in Uganda Is Highly Resistant to Clarithromycin and Fluoroquinolones: Results of the GenoType HelicoDR Test Directly Applied on Stool. Biomed Res Int. 2017;2017:5430723. [PMID: 28555193 DOI: 10.1155/2017/5430723] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 594 |
Ozbey G, Hanafiah A. Epidemiology, Diagnosis, and Risk Factors of Helicobacter pylori Infection in Children. Euroasian J Hepatogastroenterol 2017;7:34-9. [PMID: 29201769 DOI: 10.5005/jp-journals-10018-1208] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 595 |
N Şirvan B, K Usta M, U Kizilkan N, Urganci N. Are Synbiotics added to the Standard Therapy to eradicate Helicobacter pylori in Children Beneficial? A Randomized Controlled Study. Euroasian J Hepatogastroenterol 2017;7:17-22. [PMID: 29201766 DOI: 10.5005/jp-journals-10018-1205] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 596 |
Miftahussurur M, Nusi IA, Akil F, Syam AF, Wibawa IDN, Rezkitha YAA, Maimunah U, Subsomwong P, Parewangi ML, Mariadi IK, Adi P, Uchida T, Purbayu H, Sugihartono T, Waskito LA, Hidayati HB, Lusida MI, Yamaoka Y. Gastric mucosal status in populations with a low prevalence of Helicobacter pylori in Indonesia. PLoS One 2017;12:e0176203. [PMID: 28463979 DOI: 10.1371/journal.pone.0176203] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 597 |
Grooten IJ, Den Hollander WJ, Roseboom TJ, Kuipers EJ, Jaddoe VW, Gaillard R, Painter RC. Helicobacter pylori infection: a predictor of vomiting severity in pregnancy and adverse birth outcome. Am J Obstet Gynecol 2017;216:512.e1-9. [PMID: 28188774 DOI: 10.1016/j.ajog.2017.01.042] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 598 |
Smith S, Boyle B, Brennan D, Buckley M, Crotty P, Doyle M, Farrell R, Hussey M, Kevans D, Malfertheiner P, Megraud F, Nugent S, O'Connor A, O'Morain C, Weston S, McNamara D. The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. Eur J Gastroenterol Hepatol 2017;29:552-9. [PMID: 28350745 DOI: 10.1097/MEG.0000000000000822] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 599 |
García-iglesias P, Botargues J, Feu Caballé F, Villanueva Sánchez C, Calvet Calvo X, Brullet Benedi E, Cánovas Moreno G, Fort Martorell E, Gallach Montero M, Gené Tous E, Hidalgo Rosas J, Lago Macía A, Nieto Rodríguez A, Papo Berger M, Planella de Rubinat M, Saló Rich J, Campo Fernández de los Ríos R. Management of non variceal upper gastrointestinal bleeding: Position paper statement of the Catalan Society of Gastroenterology. Gastroenterología y Hepatología (English Edition) 2017;40:363-374. [DOI: 10.1016/j.gastre.2016.11.011] [Reference Citation Analysis]
|
| 600 |
Lopes D, Nunes C, Fontaine P, Sarmento B, Reis S. Proof of pore formation and biophysical perturbations through a 2D amoxicillin-lipid membrane interaction approach. Biochimica et Biophysica Acta (BBA) - Biomembranes 2017;1859:803-12. [DOI: 10.1016/j.bbamem.2017.01.031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 601 |
Tu H, Sun L, Dong X, Gong Y, Xu Q, Jing J, Bostick RM, Wu X, Yuan Y. A Serological Biopsy Using Five Stomach-Specific Circulating Biomarkers for Gastric Cancer Risk Assessment: A Multi-Phase Study. Am J Gastroenterol 2017;112:704-15. [PMID: 28323271 DOI: 10.1038/ajg.2017.55] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 602 |
Arslan N, Yılmaz Ö, Demiray-Gürbüz E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol 2017; 23(16): 2854-2869 [PMID: 28522904 DOI: 10.3748/wjg.v23.i16.2854] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 55] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 603 |
Abadi ATB. Strategies used by helicobacter pylori to establish persistent infection. World J Gastroenterol 2017; 23(16): 2870-2882 [PMID: 28522905 DOI: 10.3748/wjg.v23.i16.2870] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 58] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 604 |
Ahn HJ, Kim DP, Chu MS, Yun HJ, Kim SH, Lee SW, Lee DS. Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections. Gastroenterol Res Pract 2017;2017:1654907. [PMID: 28539935 DOI: 10.1155/2017/1654907] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 605 |
Gong Y, Li Q, Yuan Y. Accuracy of testing for anti-Helicobacter pylori IgG in urine for H. pylori infection diagnosis: A systematic review and meta-analysis. BMJ Open. 2017;7:e013248. [PMID: 28455424 DOI: 10.1136/bmjopen-2016-013248] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 606 |
Tsimmerman YS, Zakharova YA. Kyoto consensus - the new etiological classification of chronic gastritis and its discussion. Klin med 2017;95:181-188. [DOI: 10.18821/0023-2149-2017-95-2-181-188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 607 |
Xu MY, Liu L, Yuan BS, Yin J, Lu QB. Association of obesity with Helicobacter pylori infection: A retrospective study. World J Gastroenterol 2017; 23(15): 2750-2756 [PMID: 28487612 DOI: 10.3748/wjg.v23.i15.2750] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 608 |
Long Parma D, Muñoz E, Ogden SM, Westin GF, Leach RJ, Thompson IM, Ramirez AG. Helicobacter Pylori Infection in Texas Hispanic and Non-Hispanic White Men: Implications for Gastric Cancer Risk Disparities. Am J Mens Health 2017;11:1039-45. [PMID: 28413904 DOI: 10.1177/1557988317702038] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 609 |
Floch P, Mégraud F, Lehours P. Helicobacter pylori Strains and Gastric MALT Lymphoma. Toxins (Basel) 2017;9:E132. [PMID: 28397767 DOI: 10.3390/toxins9040132] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 610 |
Rokkas T, Rokka A, Portincasa P. A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Ann Gastroenterol 2017;30:414-23. [PMID: 28655977 DOI: 10.20524/aog.2017.0144] [Cited by in Crossref: 29] [Cited by in F6Publishing: 45] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 611 |
Mackie AR, Goycoolea FM, Menchicchi B, Caramella CM, Saporito F, Lee S, Stephansen K, Chronakis IS, Hiorth M, Adamczak M, Waldner M, Nielsen HM, Marcelloni L. Innovative Methods and Applications in Mucoadhesion Research. Macromol Biosci 2017;17:1600534. [DOI: 10.1002/mabi.201600534] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 612 |
Ferenc S, Gnus J, Kościelna M, Kinda M, Yarka A, Stewart L, Witkiewicz W. High antibiotic resistance of Helicobacter pylori and its effect on tailored and empiric eradication of the organism in Lower Silesia, Poland. Helicobacter 2017;22. [PMID: 27879042 DOI: 10.1111/hel.12365] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 613 |
Valdovinos M, Montijo E, Abreu A, Heller S, González-garay A, Bacarreza D, Bielsa-fernández M, Bojórquez-ramos M, Bosques-padilla F, Burguete-garcía A, Carmona-sánchez R, Consuelo-sánchez A, Coss-adame E, Chávez-barrera J, de Ariño M, Flores-calderón J, Gómez-escudero O, González-huezo M, Icaza-chávez M, Larrosa-haro A, Morales-arámbula M, Murata C, Ramírez-mayans J, Remes-troche J, Rizo-robles T, Peláez-luna M, Toro-monjaraz E, Torre A, Urquidi-rivera M, Vázquez R, Yamamoto-furusho J, Guarner F. The Mexican consensus on probiotics in gastroenterology. Revista de Gastroenterología de México (English Edition) 2017;82:156-178. [DOI: 10.1016/j.rgmxen.2017.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 614 |
Harmati M, Gyukity-Sebestyen E, Dobra G, Terhes G, Urban E, Decsi G, Mimica-Dukić N, Lesjak M, Simin N, Pap B, Nemeth IB, Buzas K. Binary mixture of Satureja hortensis and Origanum vulgare subsp. hirtum essential oils: in vivo therapeutic efficiency against Helicobacter pylori infection. Helicobacter 2017;22. [PMID: 27578489 DOI: 10.1111/hel.12350] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 615 |
Delgado-garcía G, Mandujano-cruz I, González-padilla K, Hernández-velázquez B, Martínez-cabriales S, Ocampo-candiani J, Villarreal-alarcón MÁ, Galarza-delgado D. Severe gastrointestinal involvement in adult-onset Henoch–Schönlein purpura associated with clarithromycin-resistant Helicobacter pylori infection. The Egyptian Rheumatologist 2017;39:121-125. [DOI: 10.1016/j.ejr.2016.05.003] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 616 |
O'Connor A, O'Morain CA, Ford AC. Population screening and treatment of Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol 2017;14:230-40. [PMID: 28053340 DOI: 10.1038/nrgastro.2016.195] [Cited by in Crossref: 102] [Cited by in F6Publishing: 103] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 617 |
Pereyra LDV, Gorordo Ipiña RC, Berruezo FA, Amieva CA, García ME, Bottiglieri MT. Sensibilidad a los antimicrobianos de aislamientos de Helicobacter pylori aislados de lesiones gástricas. Revista Argentina de Microbiología 2017;49:153-157. [DOI: 10.1016/j.ram.2016.11.001] [Reference Citation Analysis]
|
| 618 |
Chunlertlith K, Limpapanasit U, Mairiang P, Vannaprasaht S, Tassaneeyakul W, Sangchan A, Sawadpanich K, Suttichaimongkol T, Pongpit J, Pattarapongsin M. Outcomes of a Randomized Controlled Trial Comparing Modified High Dose Omeprazole and Amoxicillin Triple Therapy with Standard Triple Therapy for Helicobacter Pylori Eradication. Asian Pac J Cancer Prev 2017;18:927-32. [PMID: 28545189 DOI: 10.22034/APJCP.2017.18.4.927] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 619 |
Schmocker RK, Lidor AO. Management of Non-neoplastic Gastric Lesions. Surgical Clinics of North America 2017;97:387-403. [DOI: 10.1016/j.suc.2016.11.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 620 |
Zhu XY, Liu F. Probiotics as an adjuvant treatment in Helicobacter pylori eradication therapy. J Dig Dis 2017;18:195-202. [PMID: 28294543 DOI: 10.1111/1751-2980.12466] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 621 |
Marin AC, Nyssen OP, Mcnicholl AG, Gisbert JP. Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. Drugs 2017;77:765-76. [DOI: 10.1007/s40265-017-0730-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 622 |
Tamayo E, Montes M, Fernández-Reyes M, Lizasoain J, Ibarra B, Mendarte U, Zapata E, Mendiola J, Pérez-Trallero E. Clarithromycin resistance in Helicobacter pylori and its molecular determinants in Northern Spain, 2013-2015. J Glob Antimicrob Resist 2017;9:43-6. [PMID: 28343971 DOI: 10.1016/j.jgar.2016.12.019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 623 |
Bustamante-Rengifo JA, Matta AJ, Pazos AJ, Bravo LE. Effect of treatment failure on the CagA EPIYA motif in Helicobacter pylori strains from Colombian subjects. World J Gastroenterol 2017; 23(11): 1980-1989 [PMID: 28373764 DOI: 10.3748/wjg.v23.i11.1980] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 624 |
Siupsinskiene N, Katutiene I, Jonikiene V, Janciauskas D, Vaitkus S. Helicobacter pylori in the tonsillar tissue: a possible association with chronic tonsillitis and laryngopharyngeal reflux. J Laryngol Otol 2017;131:549-56. [DOI: 10.1017/s0022215117000597] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 625 |
Mitchell H, Katelaris P. Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. Med J Aust. 2016;204:376-380. [PMID: 27256648 DOI: 10.5694/mja16.00104] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 626 |
Alekberzade AV, Krylov NN, Rustamov EA, Badalov DA, Popovtsev MA. [Perforated peptic ulcer closure: laparoscopic or open?]. Khirurgiia (Mosk) 2017;:45-50. [PMID: 28303872 DOI: 10.17116/hirurgia2017245-50] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 627 |
Sugimoto M, Ban H, Ichikawa H, Sahara S, Otsuka T, Inatomi O, Bamba S, Furuta T, Andoh A. Efficacy of the Kyoto Classification of Gastritis in Identifying Patients at High Risk for Gastric Cancer. Intern Med. 2017;56:579-586. [PMID: 28321054 DOI: 10.2169/internalmedicine.56.7775] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 628 |
Mansour-Ghanaei F, Pedarpour Z, Shafaghi A, Joukar F. Clarithromycin versus Gemifloxacin in Quadruple Therapeutic Regimens for Helicobacter Pylori Infection Eradication. Middle East J Dig Dis. 2017;9:100-106. [PMID: 28638586 DOI: 10.15171/mejdd.2017.58] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 629 |
Fontes LES, Martimbianco ALC, Mochdece CC, Riera R. Proton pump inhibitor- and fluoroquinolone-based triple therapies forHelicobacter pylorieradication. Cochrane Database of Systematic Reviews 2017. [DOI: 10.1002/14651858.cd012588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 630 |
Navarro-Jarabo JM, Fernández-Sánchez F, Fernández-Moreno N, Hervas-Molina AJ, Casado-Caballero F, Puente-Gutierrez JJ, Pallares-Manrique H, Rodríguez-Ramos C, Fernández-Gutierrez C, Pérez-Aisa A, Rivas-Ruiz F, Montiel Quezel-Guerraz N. Prevalence of Primary Resistance of Helicobacter pylori to Clarithromycin and Levofloxacin in Southern Spain. Digestion 2015;92:78-82. [PMID: 26227669 DOI: 10.1159/000435949] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 631 |
Boltin D, Ben-Zvi H, Perets TT, Gingold-Belfer R, Dickman R, Niv Y. Appropriateness of Repeating Helicobacter pylori Culture and Susceptibility Testing Following Failure of Individualized Antibiotic Therapy. Digestion 2015;92:66-72. [PMID: 27355208 DOI: 10.1159/000435950] [Reference Citation Analysis]
|
| 632 |
Gungor G, Baglıcakoglu M, Kayacetin E, Biyik M, Ucar R, Goktepe H, Ataseven H, Demir A. Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey. Digestion 2015;92:55-9. [PMID: 26183105 DOI: 10.1159/000434627] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 633 |
Park SM, Kim JS, Kim BW, Ji JS, Choi H. Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. J Gastroenterol Hepatol 2017;32:589-94. [PMID: 27505301 DOI: 10.1111/jgh.13510] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 634 |
Talebi Bezmin Abadi A. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 2017;8:123-30. [DOI: 10.1016/j.jgar.2016.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 635 |
Seabra CL, Nunes C, Gomez-lazaro M, Correia M, Machado JC, Gonçalves IC, Reis CA, Reis S, Martins MCL. Docosahexaenoic acid loaded lipid nanoparticles with bactericidal activity against Helicobacter pylori. International Journal of Pharmaceutics 2017;519:128-37. [DOI: 10.1016/j.ijpharm.2017.01.014] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 636 |
Serrano CA, Leon MA, Palma C, Vera M, Hernandez C, Harris PR. Helicobacter pylori-Clarithromycin Resistance in Symptomatic Pediatric Patients in a High Prevalence Country. J Pediatr Gastroenterol Nutr 2017;64:e56-60. [PMID: 27159208 DOI: 10.1097/MPG.0000000000001257] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 637 |
He XM, Huang X. Clinical efficacy of Weifuchun combined with quadruple therapy in treatment of chronic non-atrophic gastritis. Shijie Huaren Xiaohua Zazhi 2017; 25(6): 521-525 [DOI: 10.11569/wcjd.v25.i6.521] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 638 |
Yeo SH, Yang CH. [Peptic Ulcer Disease Associated with Helicobacter pylori Infection]. Korean J Gastroenterol 2016;67:289-99. [PMID: 27312829 DOI: 10.4166/kjg.2016.67.6.289] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 639 |
Branquinho D, Almeida N, Gregório C, Cabral JE, Casela A, Donato MM, Tomé L. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics? BMC Gastroenterol 2017;17:31. [PMID: 28202013 DOI: 10.1186/s12876-017-0589-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 640 |
Kim SE, Park MI, Park SJ, Moon W, Kim JH, Jung K, Kim HK, Lee YD. Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes. World J Gastroenterol 2017; 23(6): 1059-1066 [PMID: 28246480 DOI: 10.3748/wjg.v23.i6.1059] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 641 |
Miftahussurur M, Cruz M, Subsomwong P, Jiménez Abreu JA, Hosking C, Nagashima H, Akada J, Yamaoka Y. Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Helicobacter pylori Infection in the Dominican Republic. Am J Trop Med Hyg 2017;96:1050-9. [PMID: 28193745 DOI: 10.4269/ajtmh.16-0729] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 642 |
Feng L, Wen MY, Zhu YJ, Men RT, Yang L. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. Am J Ther. 2016;23:e880-e893. [PMID: 25569598 DOI: 10.1097/mjt.0000000000000191] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 643 |
Martins GM, Sanches BS, Moretzsohn LD, Lima KS, Cota BD, Coelho LG. Molecular detection of clarithromycin and fluoroquinolones resistance in Helicobacter pylori infection, directly applied to gastric biopsies, in an urban brazilian population. Arq Gastroenterol. 2016;53:113-117. [PMID: 27305419 DOI: 10.1590/s0004-28032016000200012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 644 |
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017;112:212-39. [PMID: 28071659 DOI: 10.1038/ajg.2016.563] [Cited by in Crossref: 744] [Cited by in F6Publishing: 743] [Article Influence: 124.0] [Reference Citation Analysis]
|
| 645 |
Sugimoto M, Sahara S, Ichikawa H, Kagami T, Ban H, Otsuka T, Andoh A, Furuta T. Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan. Helicobacter 2017;22. [PMID: 27213463 DOI: 10.1111/hel.12319] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 646 |
Su J, Zhou X, Chen H, Hao B, Zhang W, Zhang G. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. Medicine (Baltimore) 2017;96:e5859. [PMID: 28207505 DOI: 10.1097/MD.0000000000005859] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 647 |
Hudak L, Jaraisy A, Haj S, Muhsen K. An updated systematic review and meta-analysis on the association between Helicobacter pylori infection and iron deficiency anemia. Helicobacter 2017;22. [PMID: 27411077 DOI: 10.1111/hel.12330] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 13.7] [Reference Citation Analysis]
|
| 648 |
Wang YH, Lv ZF, Zhong Y, Liu DS, Chen SP, Xie Y. The internalization of Helicobacter pylori plays a role in the failure of H. pylori eradication. Helicobacter 2017;22. [PMID: 27282442 DOI: 10.1111/hel.12324] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 649 |
Song ZQ, Liu J, Zhou LY. Hybrid Therapy Regimen for Helicobacter Pylori Eradication. Chin Med J (Engl). 2016;129:992-999. [PMID: 27064046 DOI: 10.4103/0366-6999.179803] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 650 |
Dovjak P. [Duodenal ulcers, gastric ulcers and Helicobacter pylori]. Z Gerontol Geriatr 2017;50:159-69. [PMID: 28150170 DOI: 10.1007/s00391-017-1190-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 651 |
Quach DT, Luu MN, Hiyama T, To TH, Bui QN, Tran TA, Tran BD, Vo MH, Tanaka S, Uemura N. Early Diagnosis of Helicobacter pylori Infection in Vietnamese Patients with Acute Peptic Ulcer Bleeding: A Prospective Study. Gastroenterol Res Pract 2017;2017:3845067. [PMID: 28133477 DOI: 10.1155/2017/3845067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 652 |
Mori J, Tanikawa C, Ohnishi N, Funauchi Y, Toyoshima O, Ueda K, Matsuda K. EPSIN 3, A Novel p53 Target, Regulates the Apoptotic Pathway and Gastric Carcinogenesis. Neoplasia 2017;19:185-95. [PMID: 28152424 DOI: 10.1016/j.neo.2016.12.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 653 |
Sakurai K, Suda H, Ido Y, Takeichi T, Okuda A, Hasuda K, Hattori M. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol 2017; 23(4): 668-675 [PMID: 28216974 DOI: 10.3748/wjg.v23.i4.668] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 654 |
Marcus EA, Sachs G, Scott DR. Eradication of Helicobacter pylori Infection. Curr Gastroenterol Rep 2016;18:33. [PMID: 27177639 DOI: 10.1007/s11894-016-0509-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 655 |
García-Iglesias P, Botargues JM, Feu Caballé F, Villanueva Sánchez C, Calvet Calvo X, Brullet Benedi E, Cánovas Moreno G, Fort Martorell E, Gallach Montero M, Gené Tous E, Hidalgo Rosas JM, Lago Macía A, Nieto Rodríguez A, Papo Berger M, Planella de Rubinat M, Saló Rich J, Campo Fernández de Los Ríos R. Management of non variceal upper gastrointestinal bleeding: position statement of the Catalan Society of Gastroenterology. Gastroenterol Hepatol 2017;40:363-74. [PMID: 28109636 DOI: 10.1016/j.gastrohep.2016.11.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 656 |
Bor S, Kitapcioglu G, Kasap E. Prevalence of gastroesophageal reflux disease in a country with a high occurrence of Helicobacter pylori. World J Gastroenterol 2017; 23(3): 525-532 [PMID: 28210089 DOI: 10.3748/wjg.v23.i3.525] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 657 |
Chang JY, Shim KN, Tae CH, Lee KE, Lee J, Lee KH, Moon CM, Kim SE, Jung HK, Jung SA. Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication. BMC Gastroenterol 2017;17:16. [PMID: 28109257 DOI: 10.1186/s12876-017-0579-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 658 |
Valdovinos MA, Montijo E, Abreu AT, Heller S, González-Garay A, Bacarreza D, Bielsa-Fernández M, Bojórquez-Ramos MC, Bosques-Padilla F, Burguete-García AI, Carmona-Sánchez R, Consuelo-Sánchez A, Coss-Adame E, Chávez-Barrera JA, de Ariño M, Flores-Calderón J, Gómez-Escudero O, González-Huezo MS, Icaza-Chávez ME, Larrosa-Haro A, Morales-Arámbula M, Murata C, Ramírez-Mayans JA, Remes-Troche JM, Rizo-Robles T, Peláez-Luna M, Toro-Monjaraz EM, Torre A, Urquidi-Rivera ME, Vázquez R, Yamamoto-Furusho JK, Guarner F. The Mexican consensus on probiotics in gastroenterology. Rev Gastroenterol Mex 2017;82:156-78. [PMID: 28104319 DOI: 10.1016/j.rgmx.2016.08.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 659 |
Kim SB, Lee SH, Kim KO, Jang BI, Kim TN. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection]. Korean J Gastroenterol 2015;66:261-7. [PMID: 26586348 DOI: 10.4166/kjg.2015.66.5.261] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 660 |
Abu-Qatouseh L, Abu-Sini M, Mayyas A, Al-Hiari Y, Darwish R, Aburjai T. Synthesis of New Nitrofluoroquinolone Derivatives with Novel Anti-Microbial Properties against Metronidazole Resistant H. pylori. Molecules 2017;22:E71. [PMID: 28054994 DOI: 10.3390/molecules22010071] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 661 |
Bassi V, Fattoruso O, Santinelli C. Autoimmune Thyroid Diseases and Helicobacter Pylori. Open J Thyroid Res 2017;1:001-006. [DOI: 10.17352/ojtr.000001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 662 |
Miwa H, Uedo N, Watari J, Mori Y, Sakurai Y, Takanami Y, Nishimura A, Tatsumi T, Sakaki N. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials. Aliment Pharmacol Ther 2017;45:240-52. [PMID: 27891632 DOI: 10.1111/apt.13876] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 663 |
Pimentel-nunes P, Marcos-pinto R, Dinis-ribeiro M. Peptic Ulcer. Encyclopedia of Pathology 2017. [DOI: 10.1007/978-3-319-40560-5_1665] [Reference Citation Analysis]
|
| 664 |
Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:6-30. [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288] [Cited by in Crossref: 1710] [Cited by in F6Publishing: 1774] [Article Influence: 285.0] [Reference Citation Analysis]
|
| 665 |
Thiel A, Ristimäki A. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Encyclopedia of Pathology 2017. [DOI: 10.1007/978-3-319-40560-5_1574] [Reference Citation Analysis]
|
| 666 |
Nohemann L, Almeida MPD, Ferrari PC. Floating ability and drug release evaluation of gastroretentive microparticles system containing metronidazole obtained by spray drying. Braz J Pharm Sci 2017;53. [DOI: 10.1590/s2175-97902017000115218] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 667 |
Leiß O. Ulcera duodeni et ventriculi. Uexküll, Psychosomatische Medizin 2017. [DOI: 10.1016/b978-3-437-21833-0.00081-4] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 668 |
Okuda M, Kikuchi S, Mabe K, Osaki T, Kamiya S, Fukuda Y, Kato M. Nationwide survey of Helicobacter pylori treatment for children and adolescents in Japan. Pediatr Int 2017;59:57-61. [PMID: 27223686 DOI: 10.1111/ped.13038] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 669 |
Peng X, Song Z, He L, Lin S, Gong Y, Sun L, Zhao F, Gu Y, You Y, Zhou L, Zhang J. Gastric Juice-Based Real-Time PCR for Tailored Helicobacter Pylori Treatment: A Practical Approach. Int J Med Sci 2017;14:595-601. [PMID: 28638276 DOI: 10.7150/ijms.18996] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 670 |
Benson J, Rahim RA, Agrawal R. Newly arrived refugee children with Helicobacter pylori are thinner than their non-infected counterparts. Aust J Prim Health 2017;23:92. [DOI: 10.1071/py15187] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 671 |
Figueiredo C. Helicobacter pylori Infection. Encyclopedia of Pathology 2017. [DOI: 10.1007/978-3-319-40560-5_1631] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 672 |
Mosińska P, Sałaga M. Diagnostic Criteria in Peptic Ulcer Disease. Introduction to Gastrointestinal Diseases Vol. 2 2017. [DOI: 10.1007/978-3-319-59885-7_4] [Reference Citation Analysis]
|
| 673 |
Enroth H, Engstrand L. Helicobacter pylori. International Encyclopedia of Public Health 2017. [DOI: 10.1016/b978-0-12-803678-5.00200-9] [Reference Citation Analysis]
|
| 674 |
Mégraud F, Musso D, Drancourt M, Lehours P. Curved and Spiral Bacilli. Infectious Diseases 2017. [DOI: 10.1016/b978-0-7020-6285-8.00182-9] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 675 |
Gesamtliteraturverzeichnis. Uexküll, Psychosomatische Medizin 2017. [DOI: 10.1016/b978-3-437-21833-0.16001-2] [Reference Citation Analysis]
|
| 676 |
Hakimi AM, Lashgari N, Mahernia S, Ziarani GM, Amanlou M. Facile one-pot four-component synthesis of 3,4-dihydro-2-pyridone derivatives: novel urease inhibitor scaffold. Res Pharm Sci 2017;12:353-63. [PMID: 28974973 DOI: 10.4103/1735-5362.213980] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 677 |
Yoshioka T, Takeshita E, Sakata Y, Hara M, Akutagawa K, Sakata N, Endo H, Ohyama T, Matsunaga K, Tanaka Y, Shirai S, Ito Y, Tsuruoka N, Iwakiri R, Kusano M, Fujimoto K. Helicobacter pylori infection status had no influence on upper gastrointestinal symptoms: a cross-sectional analysis of 3,005 Japanese subjects without upper gastrointestinal lesions undergoing medical health checkups. Esophagus 2017;14:249-53. [PMID: 28725170 DOI: 10.1007/s10388-017-0573-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 678 |
Takafuta T, Fujimura K. Helicobacter pylori (H. pylori) Eradication. Autoimmune Thrombocytopenia 2017. [DOI: 10.1007/978-981-10-4142-6_12] [Reference Citation Analysis]
|
| 679 |
White JR, Ingram RJ, Atherton JC. Gastritis, Peptic Ulceration and Related Conditions. Infectious Diseases 2017. [DOI: 10.1016/b978-0-7020-6285-8.00036-8] [Reference Citation Analysis]
|
| 680 |
Carabotti M, Severi C. Upper Gastrointestinal Diseases Before and After Bariatric Surgery. Metabolism and Pathophysiology of Bariatric Surgery 2017. [DOI: 10.1016/b978-0-12-804011-9.00045-5] [Reference Citation Analysis]
|
| 681 |
Maruyama M, Tanaka N, Kubota D, Miyajima M, Kimura T, Tokutake K, Imai R, Fujisawa T, Mori H, Matsuda Y, Wada S, Horiuchi A, Kiyosawa K. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial. Can J Gastroenterol Hepatol 2017;2017:4385161. [PMID: 28349044 DOI: 10.1155/2017/4385161] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 682 |
Mcdermott PF, Mégraud F. Antimicrobial Resistance in Helicobacter and Campylobacter. Antimicrobial Drug Resistance 2017. [DOI: 10.1007/978-3-319-47266-9_14] [Reference Citation Analysis]
|
| 683 |
Wasilewski A, Mosińska P. Patient’s Guide: Helicobacter pylori in Peptic Ulcer Disease. Introduction to Gastrointestinal Diseases Vol. 2 2017. [DOI: 10.1007/978-3-319-59885-7_8] [Reference Citation Analysis]
|
| 684 |
Mössner J. Magen-Darm-Mittel und Lebertherapeutika. Arzneiverordnungs-Report 2017 2017. [DOI: 10.1007/978-3-662-54630-7_33] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 685 |
Neufeld NH, Mohamed NS, Grujich N, Shulman K. Acute Neuropsychiatric Symptoms Associated With Antibiotic Treatment of Helicobacter Pylori Infections: A Review. J Psychiatr Pract 2017;23:25-35. [PMID: 28072642 DOI: 10.1097/PRA.0000000000000205] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 686 |
Zhou LY, Song ZQ, Xue Y, Li X, Li YQ, Qian JM. Recurrence of Helicobacter pylori infection and the affecting factors: A follow-up study. J Dig Dis 2017;18:47-55. [PMID: 28026906 DOI: 10.1111/1751-2980.12440] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 687 |
Shin WG. Management ofHelicobacter pyloriInfection in Europe: Focusing on the Maastricht V/Florence Consensus. Korean J Helicobacter Up Gastrointest Res 2017;17:11. [DOI: 10.7704/kjhugr.2017.17.1.11] [Reference Citation Analysis]
|
| 688 |
Liou JM, Lin JT, Wu MS. Bismuth and Non-bismuth Quadruple Therapy for Helicobacter pylori Eradication: Time to Make the Switch in Clinical Practice? Gastroenterology 2017;152:301-2. [PMID: 27899016 DOI: 10.1053/j.gastro.2016.06.058] [Reference Citation Analysis]
|
| 689 |
Sung J, Kim N, Park YH, Hwang YJ, Kwon S, Na G, Choi JY, Kang JB, Kim HR, Kim J, Lee DH. Rifabutin-based Fourth and Fifth-line Rescue Therapy in Patients with for Helicobacter pylori Eradication Failure. Korean J Gastroenterol 2017;69:109. [DOI: 10.4166/kjg.2017.69.2.109] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 690 |
Kim GH. Status ofHelicobacter pyloriEradication in Japan. Korean J Helicobacter Up Gastrointest Res 2017;17:4. [DOI: 10.7704/kjhugr.2017.17.1.4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 691 |
García A, Navarro K, Sanhueza E, Pineda S, Pastene E, Quezada M, Henríquez K, Karlyshev A, Villena J, González C. Characterization of Lactobacillus fermentum UCO-979C, a probiotic strain with a potent anti-Helicobacter pylori activity. Electronic Journal of Biotechnology 2017;25:75-83. [DOI: 10.1016/j.ejbt.2016.11.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 692 |
Adams CA, Cioffi WG, Valdez C, Diaz JJ. Complicated Acute Gastric Emergencies. Complications in Acute Care Surgery 2017. [DOI: 10.1007/978-3-319-42376-0_8] [Reference Citation Analysis]
|
| 693 |
Ustundag GH, Altuntas H, Soysal YD, Kokturk F. The Effects of Synbiotic "Bifidobacterium lactis B94 plus Inulin" Addition on Standard Triple Therapy of Helicobacter pylori Eradication in Children. Can J Gastroenterol Hepatol 2017;2017:8130596. [PMID: 28656129 DOI: 10.1155/2017/8130596] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 694 |
Mulder KE, Ahmed S, Davies JD, Doll CM, Dowden S, Gill S, Gordon V, Hebbard P, Lim H, McFadden A, McGhie JP, Park J, Wong R. Report from the 17th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Edmonton, Alberta; 11-12 September 2015. Curr Oncol. 2016;23:425-434. [PMID: 28050139 DOI: 10.3747/co.23.3384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 695 |
Venerito M, Goni E, Malfertheiner P. Helicobacter pylori screening: options and challenges. Expert Rev Gastroenterol Hepatol 2016;10:497-503. [PMID: 26619972 DOI: 10.1586/17474124.2016.1126507] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 696 |
Franchini M, Veneri D, Lippi G. Thrombocytopenia and infections. Expert Rev Hematol 2017;10:99-106. [PMID: 27936979 DOI: 10.1080/17474086.2017.1271319] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 697 |
Bouihat N, Burucoa C, Benkirane A, Seddik H, Sentissi S, Al Bouzidi A, Elouennas M, Benouda A. Helicobacter pylori Primary Antibiotic Resistance in 2015 in Morocco: A Phenotypic and Genotypic Prospective and Multicenter Study. Microb Drug Resist. 2017;23:727-732. [PMID: 27996373 DOI: 10.1089/mdr.2016.0264] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 698 |
Peña J, Rojas H, Reyes N, Fernández-Delgado M, García-Amado MA, Michelangeli F, Contreras M. Multiple cag genotypes of Helicobacter pylori isolates colonize the oesophagus in individual hosts in a Venezuelan population. J Med Microbiol 2017;66:226-35. [PMID: 27983473 DOI: 10.1099/jmm.0.000409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 699 |
Song ZQ, Zhou LY. Helicobacter Pylori and Gastric Cancer: Clinical Aspects. Chin Med J (Engl) 2015;128:3101-5. [PMID: 26608993 DOI: 10.4103/0366-6999.169107] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 700 |
Lee JY, Park KS. Optimal First-Line Treatment for Helicobacter pylori Infection: Recent Strategies. Gastroenterol Res Pract 2016;2016:9086581. [PMID: 28070184 DOI: 10.1155/2016/9086581] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 701 |
Schwarzwalder GM, Scott DR, Vanderwal CD. A Synthesis of Exiguaquinol Dessulfate. Chemistry 2016;22:17953-7. [PMID: 27673578 DOI: 10.1002/chem.201604506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 702 |
Barati B. Egg Yolk Antibodies for Disease Prevention. JBMOA 2016;3. [DOI: 10.15406/jbmoa.2016.03.00058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 703 |
Chen Q, Zhang W, Fu Q, Liang X, Liu W, Xiao S, Lu H. Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy. Am J Gastroenterol 2016;111:1736-42. [PMID: 27670603 DOI: 10.1038/ajg.2016.443] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 704 |
Gao CP, Zhou Z, Wang JZ, Han SX, Li LP, Lu H. Efficacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy: A systematic review and meta-analysis. J Dig Dis 2016;17:811-9. [PMID: 27977071 DOI: 10.1111/1751-2980.12432] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 705 |
Liou JM, Wu MS, Lin JT. Treatment of Helicobacter pylori infection: Where are we now? J Gastroenterol Hepatol 2016;31:1918-26. [PMID: 27088632 DOI: 10.1111/jgh.13418] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 706 |
Miftahussurur M, Syam AF, Nusi IA, Makmun D, Waskito LA, Zein LH, Akil F, Uwan WB, Simanjuntak D, Wibawa ID, Waleleng JB, Saudale AM, Yusuf F, Mustika S, Adi P, Maimunah U, Maulahela H, Rezkitha YA, Subsomwong P, Nasronudin, Rahardjo D, Suzuki R, Akada J, Yamaoka Y. Surveillance of Helicobacter pylori Antibiotic Susceptibility in Indonesia: Different Resistance Types among Regions and with Novel Genetic Mutations. PLoS One. 2016;11:e0166199. [PMID: 27906990 DOI: 10.1371/journal.pone.0166199] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 707 |
Raymond J, Kalach N. Tratamiento de la infección por Helicobacter pylori en el niño y bases epidemiológicas de las indicaciones. EMC - Pediatría 2016;51:1-5. [DOI: 10.1016/s1245-1789(16)80716-7] [Reference Citation Analysis]
|
| 708 |
Sokpon M, Salihoun M, Lahlou L, Acharki M, Razine R, Kabbaj N. Facteurs prédictifs de l’infection à Helicobacter pylori (Hp) au cours de la gastrite chronique : à propos d’une étude marocaine. J Afr Hepato Gastroenterol 2016;10:203-207. [DOI: 10.1007/s12157-016-0687-z] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 709 |
Song Z, Suo B, Zhang L, Zhou L. Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication. Helicobacter 2016;21:462-70. [PMID: 27060292 DOI: 10.1111/hel.12313] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 710 |
Gisbert JP, Molina-infante J, Amador J, Bermejo F, Bujanda L, Calvet X, Castro-fernández M, Cuadrado-lavín A, Elizalde JI, Gene E, Gomollón F, Lanas Á, Martín de Argila C, Mearin F, Montoro M, Pérez-aisa Á, Pérez-trallero E, Mcnicholl AG. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterología y Hepatología (English Edition) 2016;39:697-721. [DOI: 10.1016/j.gastre.2016.11.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 711 |
Sawant P, Poddar P. Helicobacter pylori: past, present and future. Journal of Gastrointestinal Infections 2016;6:12-15. [DOI: 10.5005/jp-jogi-6-1-12] [Reference Citation Analysis]
|
| 712 |
Qi XJ, Shi BX, Jiang Y. Furazolidone-based first-line therapy for Helicobacter pylori infection in China: A meta-analysis. Shijie Huaren Xiaohua Zazhi 2016; 24(33): 4484-4490 [DOI: 10.11569/wcjd.v24.i33.4484] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 713 |
Demiray-Gürbüz E, Yılmaz Ö, Olivares AZ, Gönen C, Sarıoğlu S, Soytürk M, Tümer S, Altungöz O, Şimşek İ, Perez Perez GI. Rapid identification of Helicobacter pylori and assessment of clarithromycin susceptibility from clinical specimens using FISH. J Pathol Clin Res 2017;3:29-37. [PMID: 28138399 DOI: 10.1002/cjp2.57] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 714 |
Liu AR, Du YQ. Current status of Helicobacter pylori infection and evolution of treatment strategy in China. Shijie Huaren Xiaohua Zazhi 2016; 24(32): 4396-4403 [DOI: 10.11569/wcjd.v24.i32.4396] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 715 |
Takeoka A, Tayama J, Yamasaki H, Kobayashi M, Ogawa S, Saigo T, Hayashida M, Shirabe S. Impact of Helicobacter pylori Immunoglobulin G Levels and Atrophic Gastritis Status on Risk of Metabolic Syndrome. PLoS One 2016;11:e0166588. [PMID: 27851820 DOI: 10.1371/journal.pone.0166588] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 716 |
Rhee YH, Ku HJ, Noh HJ, Cho HH, Kim HK, Ahn JC. Anti-Helicobacter pylori effect of CaG-NANA, a new sialic acid derivative. World J Gastrointest Pathophysiol 2016; 7(4): 300-306 [PMID: 27895975 DOI: 10.4291/wjgp.v7.i4.300] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 717 |
Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Chen CC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2016;388:2355-65. [PMID: 27769562 DOI: 10.1016/S0140-6736(16)31409-X] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 13.1] [Reference Citation Analysis]
|
| 718 |
Salas-jara MJ, Sanhueza EA, Retamal-díaz A, González C, Urrutia H, García A. Probiotic Lactobacillus fermentum UCO-979C biofilm formation on AGS and Caco-2 cells and Helicobacter pylori inhibition. Biofouling 2016;32:1245-57. [DOI: 10.1080/08927014.2016.1249367] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 719 |
Raymond J, Thiberge JM, Dauga C. Diagnosis of Helicobacter pylori recurrence: relapse or reinfection? Usefulness of molecular tools. Scand J Gastroenterol 2016;51:672-8. [PMID: 26784882 DOI: 10.3109/00365521.2015.1132338] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 720 |
Hassan ST, Šudomová M. Probiotics as Dietary Supplements for Eradication of Helicobacter pylori Infection in Children: A Role Beyond Infection. Children (Basel) 2016;3:E27. [PMID: 27834907 DOI: 10.3390/children3040027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 721 |
Brennan DE, Omorogbe J, Hussey M, Tighe D, Holleran G, O’Morain C, Smith SM, McNamara D. Molecular detection of Helicobacter pylori antibiotic resistance in stool vs biopsy samples. World J Gastroenterol 2016; 22(41): 9214-9221 [PMID: 27895408 DOI: 10.3748/wjg.v22.i41.9214] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 722 |
Miftahussurur M, Shrestha PK, Subsomwong P, Sharma RP, Yamaoka Y. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. BMC Microbiol. 2016;16:256. [PMID: 27809767 DOI: 10.1186/s12866-016-0873-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 723 |
Liou JM, Chen CC, Chang CY, Chen MJ, Chen CC, Fang YJ, Lee JY, Yang TH, Luo JC, Wu JY, Liou TC, Chang WH, Hsu YC, Tseng CH, Chang CC, Bair MJ, Liu TY, Hsieh CF, Tsao FY, Shun CT, Lin JT, Lee YC, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial. Gut 2016;65:1784-92. [PMID: 26338825 DOI: 10.1136/gutjnl-2015-310142] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 8.1] [Reference Citation Analysis]
|
| 724 |
Campillo A, Amorena E, Ostiz M, Kutz M, Laiglesia M. Triple terapia 10 días con esomeprazol 40 mg/12 h vs. cuádruple concomitante sin bismuto como tratamiento de primera línea de la infección por Helicobacter pylori. Gastroenterología y Hepatología 2016;39:584-9. [DOI: 10.1016/j.gastrohep.2016.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 725 |
Yang X, Tan P, Song L, Lu Z. Comparison Between Sequential Therapy and Modified Bismuth-Included Quadruple Therapy for Helicobacter pylori Eradication in Chinese Patients. American Journal of Therapeutics 2016;23:e1436-41. [DOI: 10.1097/mjt.0000000000000261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 726 |
Pellicano R. The appropriate age to study the incidence of Helicobacter pylori infection. Revista Chilena de Pediatría 2016;87:513. [DOI: 10.1016/j.rchipe.2016.07.013] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 727 |
Campillo A, Amorena E, Ostiz M, Kutz M, Laiglesia M. 10-day triple therapy with esomeprazole 40mg/12h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection. Gastroenterología y Hepatología (English Edition) 2016;39:584-589. [DOI: 10.1016/j.gastre.2016.10.007] [Reference Citation Analysis]
|
| 728 |
Zhang X, Jiang A, Yu H, Xiong Y, Zhou G, Qin M, Dou J, Wang J. Human Lysozyme Synergistically Enhances Bactericidal Dynamics and Lowers the Resistant Mutant Prevention Concentration for Metronidazole to Helicobacter pylori by Increasing Cell Permeability. Molecules 2016;21:E1435. [PMID: 27801837 DOI: 10.3390/molecules21111435] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 729 |
Paroni Sterbini F, Palladini A, Masucci L, Cannistraci CV, Pastorino R, Ianiro G, Bugli F, Martini C, Ricciardi W, Gasbarrini A, Sanguinetti M, Cammarota G, Posteraro B. Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients. Appl Environ Microbiol. 2016;82:6633-6644. [PMID: 27590821 DOI: 10.1128/aem.01437-16] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 730 |
Chimed T, Sandagdorj T, Znaor A, Laversanne M, Tseveen B, Genden P, Bray F. Cancer incidence and cancer control in Mongolia: Results from the National Cancer Registry 2008-12. Int J Cancer. 2017;140:302-309. [PMID: 27716912 DOI: 10.1002/ijc.30463] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 731 |
Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. Eur J Intern Med 2017;37:19-24. [PMID: 27784575 DOI: 10.1016/j.ejim.2016.10.007] [Cited by in Crossref: 122] [Cited by in F6Publishing: 133] [Article Influence: 17.4] [Reference Citation Analysis]
|
| 732 |
Allison R, Lecky DM, Bull M, Turner K, Godbole G, McNulty CA. Audit of Helicobacter pylori Testing in Microbiology Laboratories in England: To Inform Compliance with NICE Guidance and the Feasibility of Routine Antimicrobial Resistance Surveillance. Int J Microbiol 2016;2016:8540904. [PMID: 27829836 DOI: 10.1155/2016/8540904] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 733 |
Wang D, Gong YH, Yuan Y. Bacterial factors associated with Helicobacter pylori antibiotic resistance. Shijie Huaren Xiaohua Zazhi 2016; 24(29): 4102-4109 [DOI: 10.11569/wcjd.v24.i29.4102] [Reference Citation Analysis]
|
| 734 |
Panpetch W, Spinler JK, Versalovic J, Tumwasorn S. Characterization of Lactobacillus salivarius strains B37 and B60 capable of inhibiting IL-8 production in Helicobacter pylori-stimulated gastric epithelial cells. BMC Microbiol 2016;16:242. [PMID: 27756217 DOI: 10.1186/s12866-016-0861-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 735 |
Arias Á, Lucendo AJ, Martínez-Fernández P, González-Castro AM, Fortea M, González-Cervera J, Yagüe-Compadre JL, Mota-Huertas T, Vicario M. Dietary treatment modulates mast cell phenotype, density, and activity in adult eosinophilic oesophagitis. Clin Exp Allergy 2016;46:78-91. [PMID: 25640519 DOI: 10.1111/cea.12504] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 736 |
Biranjia-Hurdoyal SD, Seetulsingh-Goorah SP. Performances of Four Helicobacter pylori Serological Detection Kits Using Stool Antigen Test as Gold Standard. PLoS One 2016;11:e0163834. [PMID: 27736910 DOI: 10.1371/journal.pone.0163834] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 737 |
Lü M, Yu S, Deng J, Yan Q, Yang C, Xia G, Zhou X. Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials. PLoS One 2016;11:e0163743. [PMID: 27723762 DOI: 10.1371/journal.pone.0163743] [Cited by in Crossref: 70] [Cited by in F6Publishing: 76] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 738 |
Wang YK, Kuo FC, Liu CJ, Wu MC, Shih HY, Wang SS, Wu JY, Kuo CH, Huang YK, Wu DC. Diagnosis of Helicobacter pylori infection: Current options and developments. World J Gastroenterol. 2015;21:11221-11235. [PMID: 26523098 DOI: 10.3748/wjg.v21.i40.11221.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 739 |
Mahmoudi L, Farshad S, Seddigh M, Mahmoudi P, Ejtehadi F, Niknam R. High efficacy of gemifloxacin-containing therapy in Helicobacter Pylori eradication: A pilot empirical second-line rescue therapy. Medicine (Baltimore) 2016;95:e4410. [PMID: 27759625 DOI: 10.1097/MD.0000000000004410] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 740 |
Hu Y, Liu JP, Zhu Y, Lu NH. The Importance of Toll-like Receptors in NF-κB Signaling Pathway Activation by Helicobacter pylori Infection and the Regulators of this Response. Helicobacter 2016;21:428-40. [PMID: 26763943 DOI: 10.1111/hel.12292] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 741 |
Ho MC, Hasegawa K, Chen XP, Nagano H, Lee YJ, Chau GY, Zhou J, Wang CC, Choi YR, Poon RT, Kokudo N. Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer 2016;5:245-56. [PMID: 27781197 DOI: 10.1159/000449336] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 742 |
Zemali N, Guillemot G, Jaubert J, Picot S, Thomas E, Becquart J, Camuset G, Gérardin P, Michault A, Kwiatek S. Helicobacter pylori resistance to clarithromycin in Reunion Island. Médecine et Maladies Infectieuses 2016;46:385-9. [DOI: 10.1016/j.medmal.2016.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 743 |
Song Z, Zhou L, Zhang J, He L, Bai P, Xue Y. Hybrid Therapy as First-Line Regimen for Helicobacter pylori Eradication in Populations with High Antibiotic Resistance Rates. Helicobacter 2016;21:382-8. [PMID: 26809022 DOI: 10.1111/hel.12294] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 744 |
Ciccaglione AF, Tavani R, Grossi L, Cellini L, Manzoli L, Marzio L. Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third-Line Treatment of Helicobacter pylori Infection: Two Pilot Studies. Helicobacter 2016;21:375-81. [PMID: 26807668 DOI: 10.1111/hel.12296] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 745 |
UEG Week 2016 Poster Presentations. United European Gastroenterology Journal 2016;4:A157-A720. [DOI: 10.1177/2050640616663689] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 746 |
Hu Y, Zhang M, Lu B, Dai J. Helicobacter pylori and Antibiotic Resistance, A Continuing and Intractable Problem. Helicobacter 2016;21:349-63. [PMID: 26822340 DOI: 10.1111/hel.12299] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 747 |
Lee YC, Chiang TH, Liou JM, Chen HH, Wu MS, Graham DY. Mass Eradication of Helicobacter pylorito Prevent Gastric Cancer: Theoretical and Practical Considerations. Gut Liver 2016;10:12-26. [PMID: 26696028 DOI: 10.5009/gnl15091] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 748 |
Gobert AP, Wilson KT. Polyamine- and NADPH-dependent generation of ROS during Helicobacter pylori infection: A blessing in disguise. Free Radic Biol Med 2017;105:16-27. [PMID: 27682363 DOI: 10.1016/j.freeradbiomed.2016.09.024] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 749 |
Stenström B, Windsor HM, Fulurija A, Benghezal M, Kumarasinghe MP, Kimura K, Tay CY, Viiala CH, Ee HC, Lu W, Schoep TD, Webberley KM, Marshall BJ. Helicobacter pylori overcomes natural immunity in repeated infections. Clin Case Rep 2016;4:1026-33. [PMID: 27830066 DOI: 10.1002/ccr3.687] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 750 |
Stein J, Connor S, Virgin G, Ong DEH, Pereyra L. Anemia and iron deficiency in gastrointestinal and liver conditions. World J Gastroenterol 2016; 22(35): 7908-7925 [PMID: 27672287 DOI: 10.3748/wjg.v22.i35.7908] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 79] [Article Influence: 10.6] [Reference Citation Analysis]
|
| 751 |
Ribaldone DG, Saracco G, Pellicano R. Response to: Comment on "Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients". Gastroenterol Res Pract 2016;2016:4760378. [PMID: 27641900 DOI: 10.1155/2016/4760378] [Reference Citation Analysis]
|
| 752 |
Fontes LES, Batista CS, Martimbianco ALC, Zanin CG, Riera R. N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication. Cochrane Database of Systematic Reviews 2016. [DOI: 10.1002/14651858.cd012357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 753 |
Tsimmerman YS, Vologzhanina LG. Gastroesophageal reflux disease: current views and prospects. Klin med 2016;94:485-96. [DOI: 10.18821/0023-2149-2016-94-7-485-496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 754 |
Zhang Y, Zhao F, Kong M, Wang S, Nan L, Hu B, Olszewski MA, Miao Y, Ji D, Jiang W, Fang Y, Zhang J, Chen F, Xiang P, Wu Y, Zhao H. Validation of a High-Throughput Multiplex Genetic Detection System for Helicobacter pylori Identification, Quantification, Virulence, and Resistance Analysis. Front Microbiol 2016;7:1401. [PMID: 27656172 DOI: 10.3389/fmicb.2016.01401] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 755 |
Sanches BS, Martins GM, Lima K, Cota B, Moretzsohn LD, Ribeiro LT, Breyer HP, Maguilnik I, Maia AB, Rezende-Filho J, Meira AC, Pinto H, Alves E, Mascarenhas R, Passos R, de Souza JD, Trindade OR, Coelho LG. Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. World J Gastroenterol 2016; 22(33): 7587-7594 [PMID: 27672279 DOI: 10.3748/wjg.v22.i33.7587] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 756 |
Sakurai Y, Shiino M, Okamoto H, Nishimura A, Nakamura K, Hasegawa S. Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study. Adv Ther 2016;33:1519-35. [PMID: 27432383 DOI: 10.1007/s12325-016-0374-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 757 |
Mcnicholl AG, Pena AS, Gisbert JP. Ensuring the highest eradication rates in H. pylori: the case of non-bismuth quadruple concomitant therapy. European Journal of Internal Medicine 2016;33:1-2. [DOI: 10.1016/j.ejim.2016.06.002] [Reference Citation Analysis]
|
| 758 |
Campillo A, Ostiz M, Amorena E, Kutz M, La Iglesia M. Quadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection. Medicina Clínica (English Edition) 2016;147:199-201. [DOI: 10.1016/j.medcle.2016.05.051] [Reference Citation Analysis]
|
| 759 |
Goli YD, Moniri R. Efficacy of probiotics as an adjuvant agent in eradication of Helicobacter pylori infection and associated side effects. Beneficial Microbes 2016;7:519-27. [DOI: 10.3920/bm2015.0130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 760 |
Boltin D, Kimchi N, Dickman R, Gingold-Belfer R, Niv Y, Birkenfeld S. Attitudes and practice related to Helicobacter pylori infection among primary care physicians. Eur J Gastroenterol Hepatol 2016;28:1035-40. [PMID: 27167452 DOI: 10.1097/MEG.0000000000000659] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 761 |
Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016;65:1439-46. [PMID: 26935876 DOI: 10.1136/gutjnl-2015-311304] [Cited by in Crossref: 223] [Cited by in F6Publishing: 228] [Article Influence: 31.9] [Reference Citation Analysis]
|
| 762 |
Vasapolli R, Malfertheiner P, Kandulski A. Helicobacter pylori and non-malignant upper gastrointestinal diseases. Helicobacter 2016;21 Suppl 1:30-3. [PMID: 27531536 DOI: 10.1111/hel.12337] [Cited by in Crossref: 12] [Cited by in F6Publishing: 42] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 763 |
Chen PY, Wu MS, Chen CY, Bair MJ, Chou CK, Lin JT, Liou JM; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment Pharmacol Ther 2016;44:427-37. [PMID: 27363687 DOI: 10.1111/apt.13712] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 7.1] [Reference Citation Analysis]
|
| 764 |
Yamamoto T, Matsui H, Yamaji K, Takahashi T, Øverby A, Nakamura M, Matsumoto A, Nonaka K, Sunazuka T, Ōmura S, Nakano H. Narrow-spectrum inhibitors targeting an alternative menaquinone biosynthetic pathway of Helicobacter pylori. Journal of Infection and Chemotherapy 2016;22:587-92. [DOI: 10.1016/j.jiac.2016.05.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 765 |
Leja M, Axon A, Brenner H. Epidemiology of Helicobacter pylori infection. Helicobacter 2016;21 Suppl 1:3-7. [PMID: 27531531 DOI: 10.1111/hel.12332] [Cited by in Crossref: 64] [Cited by in F6Publishing: 90] [Article Influence: 9.1] [Reference Citation Analysis]
|
| 766 |
Assef MS, Melo TT, Araki O, Marioni F. EVALUATION OF UPPER GASTROINTESTINAL ENDOSCOPY IN PATIENTS UNDERGOING BARIATRIC SURGERY. Arq Bras Cir Dig 2015;28 Suppl 1:39-42. [PMID: 26537272 DOI: 10.1590/S0102-6720201500S100012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [ |
